

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

OMEGA HEALTHCARE INVESTORS, INC.

(Exact name of registrant as specified in its charter)

Maryland
(State or other jurisdiction of incorporation or organization)

1-11316
(Commission file number)

38-3041398
(IRS Employer Identification No.)

303 International Circle, Suite 200, Hunt Valley, MD 21030
(Address of principal executive offices)

(410) 427-1700
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$.10 par value	OHI	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of July 31, 2023, there were 244,872,475 shares of common stock outstanding.

OMEGA HEALTHCARE INVESTORS, INC.
FORM 10-Q
June 30, 2023

TABLE OF CONTENTS

	<u>Page No.</u>
<u>PART I</u>	
<u>Financial Information</u>	
<u>Item 1.</u>	
<u>Financial Statements of Omega Healthcare Investors, Inc. (Unaudited):</u>	
<u>Consolidated Balance Sheets</u>	2
<u>June 30, 2023 and December 31, 2022</u>	
<u>Consolidated Statements of Operations</u>	3
<u>Three and six months ended June 30, 2023 and 2022</u>	
<u>Consolidated Statements of Comprehensive Income</u>	4
<u>Three and six months ended June 30, 2023 and 2022</u>	
<u>Consolidated Statements of Equity</u>	5
<u>Three and six months ended June 30, 2023 and 2022</u>	
<u>Consolidated Statements of Cash Flows</u>	7
<u>Six months ended June 30, 2023 and 2022</u>	
<u>Notes to Consolidated Financial Statements</u>	8
<u>June 30, 2023</u>	
<u>Item 2.</u>	
<u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	37
<u>Item 3.</u>	
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	55
<u>Item 4.</u>	
<u>Controls and Procedures</u>	55
<u>PART II</u>	
<u>Other Information</u>	
<u>Item 1.</u>	
<u>Legal Proceedings</u>	56
<u>Item 1A.</u>	
<u>Risk Factors</u>	56
<u>Item 2.</u>	
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	56
<u>Item 6.</u>	
<u>Exhibits</u>	57

PART I – FINANCIAL INFORMATION

Item 1 - Financial Statements

**OMEGA HEALTHCARE INVESTORS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)**

	June 30, 2023 (Unaudited)	December 31, 2022
ASSETS		
Real estate assets		
Buildings and improvements	\$ 7,398,122	\$ 7,347,853
Land	928,318	923,605
Furniture and equipment	499,102	499,902
Construction in progress	107,983	88,904
Total real estate assets	8,933,525	8,860,264
Less accumulated depreciation	(2,444,149)	(2,322,773)
Real estate assets – net	6,489,376	6,537,491
Investments in direct financing leases – net	8,995	8,503
Real estate loans receivable – net	1,096,806	1,042,731
Investments in unconsolidated joint ventures	191,667	178,920
Assets held for sale	1,400	9,456
Total real estate investments	7,788,244	7,777,101
Non-real estate loans receivable – net	227,916	225,281
Total investments	8,016,160	8,002,382
Cash and cash equivalents	350,691	297,103
Restricted cash	5,820	3,541
Contractual receivables – net	8,837	8,228
Other receivables and lease inducements	200,650	177,798
Goodwill	643,862	643,151
Other assets	178,013	272,960
Total assets	<u>\$ 9,404,033</u>	<u>\$ 9,405,163</u>
LIABILITIES AND EQUITY		
Revolving credit facility	\$ 20,342	\$ 19,246
Secured borrowings	360,775	366,596
Senior notes and other unsecured borrowings – net	4,905,761	4,900,992
Accrued expenses and other liabilities	304,563	315,047
Total liabilities	<u>5,591,441</u>	<u>5,601,881</u>
Equity:		
Preferred stock \$1.00 par value authorized – 20,000 shares, issued and outstanding – none	—	—
Common stock \$0.10 par value authorized – 350,000 shares, issued and outstanding – 240,991 shares as of June 30, 2023 and 234,252 shares as of December 31, 2022	24,099	23,425
Additional paid-in capital	6,526,367	6,314,203
Cumulative net earnings	3,534,199	3,438,401
Cumulative dividends paid	(6,501,899)	(6,186,986)
Accumulated other comprehensive income	41,353	20,325
Total stockholders' equity	3,624,119	3,609,368
Noncontrolling interest	188,473	193,914
Total equity	<u>3,812,592</u>	<u>3,803,282</u>
Total liabilities and equity	<u>\$ 9,404,033</u>	<u>\$ 9,405,163</u>

See notes to consolidated financial statements.

OMEGA HEALTHCARE INVESTORS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Unaudited
(in thousands, except per share amounts)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2023	2022	2023	2022
Revenues				
Rental income	\$ 219,101	\$ 211,428	\$ 408,178	\$ 428,311
Income from direct financing leases	254	256	508	512
Interest income	29,232	31,374	57,652	62,517
Miscellaneous income	1,600	1,591	2,051	2,624
Total revenues	<u>250,187</u>	<u>244,649</u>	<u>468,389</u>	<u>493,964</u>
Expenses				
Depreciation and amortization	82,018	83,207	163,210	165,959
General and administrative	22,158	18,775	42,684	35,160
Real estate taxes	3,925	3,717	7,922	7,320
Acquisition, merger and transition related costs	423	3,960	1,062	5,473
Impairment on real estate properties	21,114	7,695	60,102	11,206
Provision (recovery) for credit losses	12,967	(1,563)	8,910	261
Interest expense	58,776	58,372	117,322	116,517
Total expenses	<u>201,381</u>	<u>174,163</u>	<u>401,212</u>	<u>341,896</u>
Other income (expense)				
Other income (expense) – net	1,029	(4,407)	3,749	(4,862)
Loss on debt extinguishment	—	(7)	(6)	(13)
Gain on assets sold – net	12,243	25,180	25,880	138,817
Total other income	<u>13,272</u>	<u>20,766</u>	<u>29,623</u>	<u>133,942</u>
Income before income tax expense and income from unconsolidated joint ventures				
	62,078	91,252	96,800	286,010
Income tax expense	(1,626)	(1,119)	(334)	(2,344)
Income from unconsolidated joint ventures	1,069	1,782	1,900	3,405
Net income	61,521	91,915	98,366	287,071
Net income attributable to noncontrolling interest	(1,665)	(2,448)	(2,568)	(7,997)
Net income available to common stockholders	<u>\$ 59,856</u>	<u>\$ 89,467</u>	<u>\$ 95,798</u>	<u>\$ 279,074</u>
Earnings per common share available to common stockholders:				
Basic:				
Net income available to common stockholders	<u>\$ 0.25</u>	<u>\$ 0.38</u>	<u>\$ 0.41</u>	<u>\$ 1.17</u>
Diluted:				
Net income available to common stockholders	<u>\$ 0.25</u>	<u>\$ 0.38</u>	<u>\$ 0.40</u>	<u>\$ 1.17</u>

See notes to consolidated financial statements.

OMEGA HEALTHCARE INVESTORS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Unaudited
(in thousands)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
Net income	\$ 61,521	\$ 91,915	\$ 98,366	\$ 287,071
Other comprehensive income (loss)				
Foreign currency translation	13,207	(22,341)	24,000	(33,150)
Cash flow hedges	7,199	19,444	(2,351)	39,022
Total other comprehensive income (loss)	20,406	(2,897)	21,649	5,872
Comprehensive income	81,927	89,018	120,015	292,943
Comprehensive income attributable to noncontrolling interest	(2,251)	(2,368)	(3,189)	(8,168)
Comprehensive income attributable to common stockholders	\$ 79,676	\$ 86,650	\$ 116,826	\$ 284,775

See notes to consolidated financial statements.

OMEGA HEALTHCARE INVESTORS, INC.
CONSOLIDATED STATEMENTS OF EQUITY
Three Months Ended June 30, 2023 and 2022
Unaudited
(in thousands, except per share amounts)

	Common Stock Par Value	Additional Paid-in Capital	Cumulative Net Earnings	Cumulative Dividends Paid	Accumulated Other Comprehensive Income	Total Stockholders' Equity	Noncontrolling Interest	Total Equity
Balance at March 31, 2023	\$ 23,434	\$6,322,160	\$3,474,343	\$(6,344,413)	\$ 21,533	\$ 3,497,057	\$ 188,554	\$3,685,611
Stock related compensation	—	8,855	—	—	—	8,855	—	8,855
Issuance of common stock	663	198,963	—	—	—	199,626	—	199,626
Common dividends declared (\$0.67 per share)	—	—	—	(157,486)	—	(157,486)	—	(157,486)
Vesting/exercising of Omega OP Units	—	(4,118)	—	—	—	(4,118)	4,118	—
Conversion and redemption of Omega OP Units to common stock	2	542	—	—	—	544	(621)	(77)
Omega OP Units distributions	—	—	—	—	—	—	(5,636)	(5,636)
Net change in noncontrolling interest holder in consolidated JV	—	(35)	—	—	—	(35)	(193)	(228)
Other comprehensive income	—	—	—	—	19,820	19,820	586	20,406
Net income	—	—	59,856	—	—	59,856	1,665	61,521
Balance at June 30, 2023	<u>\$ 24,099</u>	<u>\$6,526,367</u>	<u>\$3,534,199</u>	<u>\$(6,501,899)</u>	<u>\$ 41,353</u>	<u>\$ 3,624,119</u>	<u>\$ 188,473</u>	<u>\$3,812,592</u>
Balance at March 31, 2022	\$ 23,820	\$6,401,207	\$3,201,081	\$(5,714,595)	\$ 6,318	\$ 3,917,831	\$ 212,013	\$4,129,844
Stock related compensation	—	6,892	—	—	—	6,892	—	6,892
Issuance of common stock	13	2,331	—	—	—	2,344	—	2,344
Repurchase of common stock	(423)	(114,523)	—	—	—	(114,946)	—	(114,946)
Common dividends declared (\$0.67 per share)	—	—	—	(157,674)	—	(157,674)	—	(157,674)
Conversion and redemption of Omega OP Units to common stock	—	—	—	—	—	—	(9,704)	(9,704)
Omega OP Units distributions	—	—	—	—	—	—	(5,062)	(5,062)
Other comprehensive loss	—	—	—	—	(2,817)	(2,817)	(80)	(2,897)
Net income	—	—	89,467	—	—	89,467	2,448	91,915
Balance at June 30, 2022	<u>\$ 23,410</u>	<u>\$6,295,907</u>	<u>\$3,290,548</u>	<u>\$(5,872,269)</u>	<u>\$ 3,501</u>	<u>\$ 3,741,097</u>	<u>\$ 199,615</u>	<u>\$3,940,712</u>

See notes to consolidated financial statements.

OMEGA HEALTHCARE INVESTORS, INC.
CONSOLIDATED STATEMENTS OF EQUITY
Six Months Ended June 30, 2023 and 2022
Unaudited
(in thousands, except per share amounts)

	Common Stock Par Value	Additional Paid-in Capital	Cumulative Net Earnings	Cumulative Dividends Paid	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity	Noncontrolling Interest	Total Equity
Balance at December 31, 2022	\$ 23,425	\$6,314,203	\$3,438,401	\$(6,186,986)	\$ 20,325	\$ 3,609,368	\$ 193,914	\$3,803,282
Stock related compensation	—	17,647	—	—	—	17,647	—	17,647
Issuance of common stock	672	200,939	—	—	—	201,611	—	201,611
Common dividends declared (\$1.34 per share)	—	—	—	(314,913)	—	(314,913)	—	(314,913)
Vesting/exercising of Omega OP Units	—	(6,929)	—	—	—	(6,929)	6,929	—
Conversion and redemption of Omega OP Units to common stock	2	542	—	—	—	544	(621)	(77)
Omega OP Units distributions	—	—	—	—	—	—	(14,767)	(14,767)
Net change in noncontrolling interest holder in consolidated JV	—	(35)	—	—	—	(35)	(171)	(206)
Other comprehensive income	—	—	—	—	21,028	21,028	621	21,649
Net income	—	—	95,798	—	—	95,798	2,568	98,366
Balance at June 30, 2023	<u>\$ 24,099</u>	<u>\$6,526,367</u>	<u>\$3,534,199</u>	<u>\$(6,501,899)</u>	<u>\$ 41,353</u>	<u>\$ 3,624,119</u>	<u>\$ 188,473</u>	<u>\$3,812,592</u>
Balance at December 31, 2021	\$ 23,906	\$6,427,566	\$3,011,474	\$(5,553,908)	\$ (2,200)	\$ 3,906,838	\$ 201,388	\$4,108,226
Stock related compensation	—	13,797	—	—	—	13,797	—	13,797
Issuance of common stock	25	3,466	—	—	—	3,491	—	3,491
Repurchase of common stock	(521)	(141,746)	—	—	—	(142,267)	—	(142,267)
Common dividends declared (\$1.34 per share)	—	—	—	(318,361)	—	(318,361)	—	(318,361)
Vesting/exercising of Omega OP Units	—	(7,176)	—	—	—	(7,176)	7,176	—
Conversion and redemption of Omega OP Units to common stock	—	—	—	—	—	—	(9,704)	(9,704)
Omega OP Units distributions	—	—	—	—	—	—	(10,338)	(10,338)
Capital contribution from noncontrolling interest holder in consolidated JV	—	—	—	—	—	—	2,925	2,925
Other comprehensive income	—	—	—	—	5,701	5,701	171	5,872
Net income	—	—	279,074	—	—	279,074	7,997	287,071
Balance at June 30, 2022	<u>\$ 23,410</u>	<u>\$6,295,907</u>	<u>\$3,290,548</u>	<u>\$(5,872,269)</u>	<u>\$ 3,501</u>	<u>\$ 3,741,097</u>	<u>\$ 199,615</u>	<u>\$3,940,712</u>

See notes to consolidated financial statements.

OMEGA HEALTHCARE INVESTORS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Unaudited (in thousands)

	Six Months Ended June 30,	
	2023	2022
Cash flows from operating activities		
Net income	\$ 98,366	\$ 287,071
Adjustment to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	163,210	165,959
Impairment on real estate properties	60,102	11,206
Provision for rental income	13,401	14,805
Provision for credit losses	8,910	261
Amortization of deferred financing costs and loss on debt extinguishment	6,510	6,457
Accretion of direct financing leases	53	38
Stock-based compensation expense	17,550	13,706
Gain on assets sold – net	(25,880)	(138,817)
Amortization of acquired in-place leases – net	(6,775)	(2,584)
Straight-line rent and effective interest receivables	(23,257)	(39,082)
Interest paid-in-kind	(5,221)	(4,511)
Loss (income) from unconsolidated joint ventures	37	(1,503)
Change in operating assets and liabilities – net:		
Contractual receivables	(610)	902
Lease inducements	(12,146)	3,865
Other operating assets and liabilities	(12,514)	(12,577)
Net cash provided by operating activities	<u>281,736</u>	<u>305,196</u>
Cash flows from investing activities		
Acquisition of real estate	(154,927)	(113,168)
Net proceeds from sale of real estate investments	62,284	386,861
Investments in construction in progress	(14,681)	(7,978)
Placement of loan principal	(182,728)	(203,720)
Collection of loan principal	121,918	239,803
Investments in unconsolidated joint ventures	(8,195)	(113)
Distributions from unconsolidated joint ventures in excess of earnings	1,134	1,176
Capital improvements to real estate investments	(13,191)	(26,260)
Receipts from insurance proceeds	3,717	565
Net cash (used in) provided by investing activities	<u>(184,669)</u>	<u>277,166</u>
Cash flows from financing activities		
Proceeds from long-term borrowings	80,000	515,208
Payments of long-term borrowings	(86,001)	(474,886)
Payments of financing related costs	(6)	(13)
Net proceeds from issuance of common stock	201,611	3,491
Repurchase of common stock	—	(142,267)
Dividends paid	(314,816)	(318,269)
Net payments to noncontrolling members of consolidated joint venture	(206)	22
Proceeds from derivative instruments	92,577	—
Redemption of Omega OP Units	(77)	(9,704)
Distributions to Omega OP Unit Holders	(14,767)	(10,338)
Net cash used in financing activities	<u>(41,685)</u>	<u>(436,756)</u>
Effect of foreign currency translation on cash, cash equivalents and restricted cash	485	(1,553)
Increase in cash, cash equivalents and restricted cash	55,867	144,053
Cash, cash equivalents and restricted cash at beginning of period	300,644	24,411
Cash, cash equivalents and restricted cash at end of period	<u>\$ 356,511</u>	<u>\$ 168,464</u>

See notes to consolidated financial statements.

OMEGA HEALTHCARE INVESTORS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Unaudited
June 30, 2023

NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Business Overview and Organization

Omega Healthcare Investors, Inc. (“Parent”) is a Maryland corporation that, together with its consolidated subsidiaries (collectively, “Omega,” the “Company,” “we,” “our,” or “us”) invests in healthcare-related real estate properties located in the United States (“U.S.”) and the United Kingdom (“U.K.”). Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (“SNFs”), assisted living facilities (“ALFs”), and to a lesser extent, independent living facilities (“ILFs”), rehabilitation and acute care facilities (“specialty facilities”) and medical office buildings. Our core portfolio consists of long-term “triple net” leases and real estate loans with healthcare operating companies and affiliates (collectively, our “operators”). In addition to our core investments, we make loans to operators and/or their principals. From time to time, we also acquire equity interests in joint ventures or entities that support the long-term healthcare industry and our operators.

Omega has elected to be taxed as a real estate investment trust (“REIT”) for federal income tax purposes and is structured as an umbrella partnership REIT (“UPREIT”) under which all of Omega’s assets are owned directly or indirectly by, and all of Omega’s operations are conducted directly or indirectly through, its operating partnership subsidiary, OHI Healthcare Properties Limited Partnership (collectively with its subsidiaries, “Omega OP”). Omega has exclusive control over Omega OP’s day-to-day management pursuant to the partnership agreement governing Omega OP. As of June 30, 2023, Parent owned approximately 97% of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 3% of the outstanding Omega OP Units.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our Annual Report on [Form 10-K](#) for the year ended December 31, 2022.

Omega’s consolidated financial statements include the accounts of (i) Parent, (ii) all direct and indirect wholly owned subsidiaries of Omega, including Omega OP, (iii) other entities in which Omega or Omega OP has a majority voting interest and control and (iv) variable interest entities (“VIEs”) of which Omega is the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation, and Omega’s net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.

Segments

We conduct our operations and report financial results as one business segment. The presentation of financial results as one reportable segment is consistent with the way we operate our business and is consistent with the manner in which our Chief Operating Decision Maker (CODM), our Chief Executive Officer, evaluates performance and makes resource and operating decisions for the business.

Reclassification

Certain line items on our Consolidated Statements of Operations and Consolidated Statements of Cash Flows have been reclassified to conform to the current period presentation.

Risks and Uncertainties including COVID-19

The Company is subject to certain risks and uncertainties affecting the healthcare industry, including those that arose from the novel coronavirus (“COVID-19”) global pandemic, which disproportionately impacted the senior care sector, as well as those stemming from healthcare legislation and changing regulation by federal, state and local governments. Additionally, we are subject to risks and uncertainties as a result of changes affecting operators of nursing home facilities due to the actions of governmental agencies and insurers to limit the rising cost of healthcare services.

Recent Accounting Pronouncements

ASU – 2020-04, Financial Instruments – Reference Rate Reform (Topic 848)

On March 12, 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, which contains optional practical expedients for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). The guidance may be elected over time until December 31, 2022, as reference rate reform activities occur. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the practical expedients under ASU 2020-04 to December 31, 2024. The Company had several derivative instruments that referenced LIBOR which were terminated during the second quarter of 2023 (see Note 16 – Derivatives and Hedging). The Company also had a \$1.45 billion senior unsecured multicurrency revolving credit facility and a \$50.0 million senior unsecured term loan facility (see Note 15 – Borrowing Activities and Arrangements) that referenced LIBOR. During the second quarter of 2023, the Company amended its \$1.45 billion senior unsecured multicurrency revolving credit facility and \$50.0 million senior unsecured term loan facility to adjust the interest on each loan from a LIBOR based interest rate to a Secured Overnight Financing Rate (“SOFR”) based interest rate. For both loans we have elected to apply the optional expedient pursuant to Topic 848. As such we will account for the amendments as if the modifications were not substantial and thus a continuation of the existing contract resulting in no change to the current loan carrying values or the related deferred financing costs.

NOTE 2 – REAL ESTATE ASSETS

At June 30, 2023, our leased real estate properties included 660 SNFs, 175 ALFs, 19 ILFs, 17 specialty facilities and one medical office building. The following table summarizes the Company’s rental income from operating leases:

	<u>Three Months Ended June 30,</u>		<u>Six Months Ended June 30,</u>	
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
	(in thousands)		(in thousands)	
Rental income – operating leases	\$ 215,307	\$ 207,791	\$ 400,634	\$ 421,388
Variable lease income – operating leases	3,794	3,637	7,544	6,923
Total rental income	\$ 219,101	\$ 211,428	\$ 408,178	\$ 428,311

Our variable lease income primarily represents the reimbursement of real estate taxes and ground lease expenses by operators that Omega pays directly.

Asset Acquisitions

The following table summarizes the asset acquisitions that occurred during the six months ended June 30, 2023:

Period	Number of Facilities		Country/State	Total Real Estate Assets Acquired (in millions)	Initial Annual Cash Yield ⁽¹⁾
	SNF	ALF			
Q1	—	6	U.K.	\$ 26.4 ⁽²⁾	8.0 %
Q2	4	—	WV	114.8 ⁽³⁾	9.5 %
Q2	1	—	WV	13.7	10.0 %
Total	5	6		\$ 154.9	

(1) Initial annual cash yield reflects the initial annual contractual cash rent divided by the purchase price.

(2) In connection with this acquisition, the Company recorded \$9.9 million of right-of-use assets and lease liabilities associated with ground leases assumed in the acquisition.

(3) In connection with this acquisition, the Company also provided \$104.6 million of mezzanine financing discussed further in Note 5 – Real Estate Loans Receivable and Note 6 – Non-Real Estate Loans Receivable.

Construction in Progress and Capital Expenditure Investments

We invested \$17.8 million and \$27.9 million under our construction in progress and capital improvement programs during the three and six months ended June 30, 2023, respectively. We invested \$16.0 million and \$34.2 million under our construction in progress and capital improvement programs during the three and six months ended June 30, 2022, respectively. During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately \$0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of \$15.2 million for the development of the land.

NOTE 3 – ASSETS HELD FOR SALE, DISPOSITIONS AND IMPAIRMENTS

Periodically we sell facilities to reduce our exposure to certain operators, geographies and non-strategic assets or due to the exercise of a tenant purchase option.

The following is a summary of our assets held for sale:

	June 30,	December 31,
	2023	2022
Number of facilities held for sale	1	2
Amount of assets held for sale (in thousands)	\$ 1,400	\$ 9,456

Asset Sales

During the three and six months ended June 30, 2023, we sold ten facilities (nine SNFs and one ILF) and 12 facilities (ten SNFs, one ILF and one medical office building) subject to operating leases, for approximately \$44.7 million and \$62.3 million in net cash proceeds, respectively. As a result of these sales, we recognized net gains of approximately \$12.2 million and \$25.9 million, respectively. The proceeds for the three and six months ended June 30, 2023 primarily relate to the sale of five facilities in the second quarter of 2023 that were previously leased to Guardian Healthcare (“Guardian”) and were included in assets held for sale as of March 31, 2023. The net cash proceeds from the sale were \$23.8 million, and we did not recognize any gain or loss on the sale because we had already impaired the facilities down to the estimated fair value less costs to sell during the first quarter of 2023. Additionally, we sold one facility, also previously leased to Guardian, for a sales price of \$12.0 million, which was fully financed by Omega through a \$12.0 million first lien mortgage on the facility. The one facility sale and related seller financing did not meet the contract criteria to be recognized under ASC 610-20. During the three months ended June 30, 2023, we received interest of \$0.2 million related to the seller financing, which was deferred and recorded as a contract liability within accrued expenses and other liabilities on our Consolidated Balance Sheets.

[Table of Contents](#)

During the three and six months ended June 30, 2022, we sold 13 and 40 facilities, subject to operating leases, for approximately \$54.3 million and \$386.9 million in net cash proceeds, respectively. As a result of these sales, we recognized net gains of approximately \$25.2 million and \$138.8 million during the three and six months ended June 30, 2022, respectively. Our 2022 sales were primarily driven by restructuring transactions and negotiations related to our lease agreements with Gulf Coast Health Care LLC (together with certain affiliates "Gulf Coast") and Guardian. In the first quarter of 2022, we sold 22 facilities that were previously leased and operated by Gulf Coast. The net cash proceeds from the sale, including previously accrued for related costs, were \$304.0 million, and we recognized a net gain of \$113.5 million. During the first and second quarter of 2022, we sold nine total facilities that were leased to Guardian for \$39.5 million in net proceeds, which resulted in a net gain of \$13.7 million.

In December 2022, in connection with restructuring negotiations with LaVie Care Centers, LLC ("LaVie," f/k/a Consulate Health Care), we sold 11 facilities previously leased to LaVie to a third party for a sales price of \$129.8 million. Omega provided \$104.8 million in senior seller financing, collateralized by first lien mortgages on the 11 facilities, to fund a portion of the purchase price. The 11-facility sale does not meet the contract criteria to be recognized under ASC 610-20. During the three and six months ended June 30, 2023, we received interest of \$2.1 million and \$4.2 million, respectively, related to the \$104.8 million in senior seller financing, which was deferred and recorded as a contract liability within accrued expenses and other liabilities on our Consolidated Balance Sheets.

Real Estate Impairments

During the three and six months ended June 30, 2023, we recorded impairments on four and six facilities of approximately \$21.1 million and \$60.1 million, respectively. Of the \$60.1 million, \$57.5 million related to four held-for-use facilities (of which \$48.0 million relates to three facilities that were closed during the year) for which the carrying value exceeded the fair value and \$2.6 million related to two facilities that were classified as held for sale for which the carrying value exceeded the estimated fair value less costs to sell.

During the three and six months ended June 30, 2022, we recorded impairments on four and six facilities of approximately \$7.7 million and \$11.2 million, respectively. Of the \$11.2 million, \$3.5 million related to two facilities that were classified as held for sale for which the carrying values exceeded the estimated fair values less costs to sell, and \$7.7 million related to four held-for-use facilities for which the carrying value exceeded the fair value.

To estimate the fair value of the facilities for the impairments noted above, we utilized a market approach that considered binding sale agreements (a Level 1 input) or non-binding offers from unrelated third parties and/or broker quotes (a Level 3 input).

NOTE 4 – CONTRACTUAL RECEIVABLES AND OTHER RECEIVABLES AND LEASE INDUCEMENTS

Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception, modification or renewal of the lease, and are amortized as a reduction of rental income over the non-cancellable lease term.

[Table of Contents](#)

A summary of our net receivables and lease inducements by type is as follows:

	June 30, 2023	December 31, 2022
	(in thousands)	
Contractual receivables – net	\$ 8,837	\$ 8,228
Effective yield interest receivables	\$ 4,603	\$ 5,696
Straight-line rent receivables	190,360	166,061
Lease inducements	5,687	6,041
Other receivables and lease inducements	\$ 200,650	\$ 177,798

Cash Basis Operators and Straight-Line Receivable Write-Offs

We review our collectibility assumptions related to our operator leases on an ongoing basis. During the three and six months ended June 30, 2023, we placed two new operators, which Omega has not previously had relationships with prior to the second quarter of 2023, on a cash basis of revenue recognition as collection of substantially all contractual lease payments due from them was not deemed probable. The new lease agreements with each of these operators were executed in the second quarter of 2023 as part of transitions of facilities from other operators, and we placed them on a cash basis concurrent with the respective lease commencement dates, so there were no straight-line rent write-offs associated with moving these operators to a cash basis.

During the three and six months ended June 30, 2022, we placed two and four operators, respectively, on a cash basis of revenue recognition as collection of substantially all contractual lease payments due from such operators was not deemed probable. In connection with moving these operators to a cash basis, we recognized \$10.4 million in total straight-line accounts receivable write-offs through rental income during the three and six months ended June 30, 2022.

During the six months ended June 30, 2023, we transitioned the portfolios of four cash basis operators with an aggregate of 48 facilities, including 14 facilities related to the operator referred to as the “1.2% Operator” in our Annual Report on [Form 10-K](#) for the year ended December 31, 2022 and 20 facilities related to the operator referred to as the “2.0% Operator” in our Annual Report on [Form 10-K](#) for the year ended December 31, 2022, to new or amended leases with five operators. We are recognizing revenue on a straight-line basis for the leases associated with these five operators. The aggregate initial contractual rent related to the 48 facilities following the transition to other operators is \$48.0 million per annum. In connection with the transition of the 14 facilities, Omega made or agreed to make termination payments of \$15.5 million in aggregate that were recorded as initial direct costs related to the lease with the new operator of the 14 transitioned facilities in the first quarter of 2023. These termination payments are deferred and recognized within depreciation and amortization expense on a straight-line basis over the term of the master lease.

During the six months ended June 30, 2023 and 2022, we also wrote-off \$0.9 million and \$3.2 million, respectively, of straight-line rent receivable balances through rental income as a result of transitioning facilities between existing operators.

As of June 30, 2023, we had 18 operators on a cash basis for revenue recognition, which represent 25.8% and 32.3% of our total revenues (excluding the impact of write-offs) for the six months ended June 30, 2023 and 2022, respectively.

Rent Deferrals and Application of Collateral

During the six months ended June 30, 2023 and 2022, we allowed nine operators and seven operators, respectively, to defer \$33.6 million and \$24.0 million, respectively, of contractual rent and interest. The deferrals during the six months ended June 30, 2023 primarily related to the following operators: LaVie (\$19.0 million), Healthcare Homes Limited (“Healthcare Homes”) (\$8.2 million), Agemo Holdings, LLC (“Agemo”) (\$1.9 million) and Maplewood Senior Living (along with affiliates, “Maplewood”) (\$0.7 million).

[Table of Contents](#)

Additionally, we allowed four operators and five operators to apply collateral, such as security deposits or letters of credit, to contractual rent and interest during the six months ended June 30, 2023 and 2022, respectively. The total collateral applied to contractual rent and interest was \$5.5 million and \$4.7 million for the six months ended June 30, 2023 and 2022, respectively.

Operator Collectibility Updates

Agemo

In the first quarter of 2023, Omega and Agemo entered into a restructuring agreement, an amended and restated master lease and a new loan agreement for two replacement loans. As part of the restructuring agreement and related agreements, Omega agreed to, among other things:

- Forgive and release Agemo from previously written off past due rent and interest obligations related to certain periods prior to the 2018 Agemo restructuring and from August 2021 through January 2023, with contractual rent under the lease agreement and contractual interest under the loan agreements scheduled to resume on April 1, 2023;
- reduce monthly contractual base rent from \$4.8 million to \$1.9 million following the sales of 22 facilities, previously leased and operated by Agemo, that occurred in the third and fourth quarters of 2022;
- extend the initial Agemo lease term from December 31, 2030, to December 31, 2036 with three consecutive tenant 10-year extension options; and
- refinance and restructure the \$25.0 million secured working capital loan (the “Agemo WC Loan”), the \$32.0 million term loan (the “Agemo Term Loan”) and the aggregate deferred rent balance of \$25.2 million into two replacement loans to Agemo that mature on December 31, 2036, with aggregate principal of \$82.2 million and an annual interest rate of 5.63% through October 2024, which increases to 5.71% until maturity.

Agemo resumed making contractual rent payments during the second quarter of 2023 in accordance with the restructuring terms discussed above. Agemo is on a cash basis of revenue recognition for lease purposes, and we recorded rental income of \$5.8 million for the three and six months ended June 30, 2023 for the contractual rent payments that were received. Additionally, no interest income was recognized during the three and six months ended June 30, 2023 and 2022 on the two loans with Agemo because these loans are on non-accrual status and we are utilizing the cost recovery method, under which any payments, if received, are applied against the principal amount. See Note 6 – Non-Real Estate Loans Receivable for further discussion on the impact of the restructuring on the loans.

LaVie

In the first quarter of 2023, Omega continued the process of restructuring our portfolio with LaVie and entered into lease amendments that allow for a partial rent deferral for the first four months of 2023. In doing so, we agreed to allow LaVie to defer up to \$19.1 million of contractual rent from January 2023 through April 2023 under our lease agreements. During the three and six months ended June 30, 2023, LaVie elected to defer \$4.7 million and \$19.0 million, respectively, of contractual rent. Since LaVie was placed on a cash basis of revenue recognition for lease purposes in the fourth quarter of 2022, the \$16.9 million and \$24.3 million of contractual rent payments that we received from LaVie to satisfy the remaining contractual obligations after utilizing the deferral were recorded as rental income during the three and six months ended June 30, 2023, respectively. During the second quarter of 2023, we transitioned two facilities, previously subject to the master lease with LaVie, to another operator. In July 2023, LaVie paid \$2.5 million of contractual rent, a short pay of \$4.7 million of the \$7.2 million due under its lease agreement. Revenue from LaVie represents approximately 5.1% and 11.3% of our total revenues (excluding the impact of write-offs) for the six months ended June 30, 2023 and 2022, respectively.

Maplewood

In the first quarter of 2023, we agreed to a formal restructuring agreement, master lease amendments and loan amendments with Maplewood. As part of the restructuring agreement and related agreements, Omega agreed to, among other things:

- Extend the maturity date of the master lease from December 2033 to December 2037 with two consecutive 5-year tenant extension options;
- fix contractual rent at \$69.3 million per annum (December 2022 rent annualized) and defer the 2.5% annual escalators under our lease agreement through December 31, 2025, with mandatory repayments to be made subject to certain metrics and due in full by the maturity date;
- fund \$22.5 million of capital expenditures through December 31, 2025;
- extend the maturity date of the secured revolving credit facility from June 2030 to June 2035 with one borrower 2-year extension option;
- increase the capacity of the secured revolving credit facility from \$250.5 million to \$320.0 million, inclusive of payment-in-kind (“PIK”) interest applied to principal;
- convert the 7% per annum cash interest due on the secured revolving credit facility to all PIK interest in 2023, 1% cash interest and 6% PIK interest in 2024, 4% cash interest and 3% PIK interest in 2025 and through the maturity date;
- pay a one-time option termination fee of \$12.5 million to Maplewood; and
- reduce Maplewood’s share of any future potential sales proceeds (in excess of our gross investment) by the unpaid deferred rent balance, the \$22.5 million of capital expenditures and the \$12.5 million option termination fee payment.

Maplewood short-paid the contractual rent amount due under its lease agreement in each of June 2023 and July 2023 by \$1.0 million each. During the third quarter of 2023, we applied \$2.0 million of Maplewood’s security deposit toward the unpaid portion of June 2023 rent and July 2023 rent. Following the application of the security deposit, we have a \$2.8 million security deposit remaining. We are taking actions to preserve our rights and are in discussions with Maplewood to address the deficiency. Maplewood is on a cash basis of revenue recognition for lease purposes, and we recorded rental income of \$16.3 million and \$33.6 million for the three and six months ended June 30, 2023, respectively, for the contractual rent payments that were received. The \$12.5 million option termination fee payment made in the first quarter of 2023 was accounted for as a lease inducement and recorded as a reduction to rental income since Maplewood is on a cash basis of revenue recognition. Additionally, as discussed further in Note 5 – Real Estate Loans Receivable, we recorded interest income of \$1.5 million on the secured revolving credit facility during the three months ended March 31, 2023 for the contractual interest payment received related to December 2022, as the loan was placed on non-accrual status for interest recognition during the fourth quarter of 2022. Revenue from Maplewood represents approximately 7.3% and 9.0% of our total revenues (excluding the impact of write-offs) for the six months ended June 30, 2023 and 2022, respectively.

Healthcare Homes

In December 2022, we agreed to allow Healthcare Homes, a U.K.-based operator representing 3.1% and 2.9% of our total revenues (excluding the impact of write-offs) for the six months ended June 30, 2023 and 2022, respectively, the ability to defer up to £6.7 million of contractual rent from January 2023 through April 2023 with regular payments required to resume in May 2023. The deferred rent balance accrues interest monthly at a rate of 8% per annum and must be fully repaid by December 31, 2024. During the three and six months ended June 30, 2023, Healthcare Homes elected to defer £1.7 million (\$2.1 million in USD) and £6.7 million (\$8.2 million in USD), respectively, of contractual rent in accordance with the December 2022 agreement. Healthcare Homes is on a straight-line basis of revenue recognition. In May 2023, Healthcare Homes resumed making full contractual rent payments.

NOTE 5 – REAL ESTATE LOANS RECEIVABLE

Real estate loans consist of mortgage notes and other real estate loans which are primarily collateralized by a first, second or third mortgage lien or a leasehold mortgage on, or an assignment of the partnership interest in the related properties. As of June 30, 2023, our real estate loans receivable consists of eight fixed rate mortgage notes on 49 long-term care facilities and 12 other real estate loans. The mortgage notes relate to facilities located in six states that are operated by seven independent healthcare operating companies. We monitor compliance with our real estate loans and, when necessary, have initiated collection, foreclosure and other proceedings with respect to certain outstanding real estate loans.

The principal amounts outstanding of real estate loans receivable, net of allowances, were as follows:

	<u>June 30,</u> <u>2023</u>	<u>December 31,</u> <u>2022</u>
	(in thousands)	
Mortgage notes due 2030; interest at 11.01% ⁽¹⁾	\$ 509,475	\$ 506,321
Mortgage note due 2031; interest at 11.27%	—	76,049
Mortgage note due 2037; interest at 10.50% ⁽²⁾	72,420	72,420
Mortgage note due 2025; interest at 7.85%	62,921	63,811
Other mortgage notes outstanding ⁽³⁾	25,622	12,922
Mortgage notes receivable – gross	670,438	731,523
Allowance for credit losses on mortgage notes receivable	(40,226)	(83,393)
Mortgage notes receivable – net	630,212	648,130
Other real estate loan due 2035; interest at 7.00%	263,520	250,500
Other real estate loans due 2024; interest at 13.19% ⁽¹⁾	102,535	98,440
Other real estate loans due 2023-2029; interest at 11.75% ⁽¹⁾	103,307	43,628
Other real estate loan outstanding ⁽⁴⁾	20,000	20,000
Other real estate loans – gross	489,362	412,568
Allowance for credit losses on other real estate loans	(22,768)	(17,967)
Other real estate loans – net	466,594	394,601
Total real estate loans receivable – net	<u>\$ 1,096,806</u>	<u>\$ 1,042,731</u>

(1) Approximates the weighted average interest rate on facilities as of June 30, 2023.

(2) During the second quarter of 2023, this mortgage note was extended from December 31, 2032 to December 31, 2037.

(3) Other mortgage notes outstanding have a weighted average interest rate of 8.6% as of June 30, 2023, with maturity dates ranging from 2023 through 2026. Two of the mortgage notes with an aggregate principal balance of \$12.9 million are past due and have been written down, through our allowance for credit losses, to the estimated fair value of the underlying collateral of \$1.5 million.

(4) As of June 30, 2023 and December 31, 2022, includes one other real estate loan that bears interest at a rate of 12% and matures on December 2, 2027.

[Table of Contents](#)

Interest revenue on real estate loans is included within interest income on the Consolidated Statements of Operations and is summarized as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
	(in thousands)		(in thousands)	
Mortgage notes – interest income	\$ 16,998	\$ 19,597	\$ 33,546	\$ 40,146
Other real estate loans – interest income	6,981	9,042	13,830	17,421
Total real estate loans interest income	<u>\$ 23,979</u>	<u>\$ 28,639</u>	<u>\$ 47,376</u>	<u>\$ 57,567</u>

Mortgage note due 2031

In the second quarter of 2022, we agreed to a formal restructuring agreement and amended the mortgage loan with Guardian, which among other adjustments, extended the loan's maturity date and allowed for the deferral of certain contractual interest. The loan amendment was treated as a loan modification provided to a borrower experiencing financial difficulty. Following the execution of the restructuring agreement, Guardian resumed paying contractual rent and interest during the second quarter of 2022 and continued such payments throughout the remainder of 2022 and the first and second quarters of 2023, in accordance with the restructuring terms. The mortgage loan is on non-accrual status and is being accounted for under the cost recovery method, under which any payments, if received, are applied against the principal amount. During the three and six months ended June 30, 2023, we received \$1.6 million and \$3.9 million, respectively, of interest payments from Guardian that we applied against the outstanding principal of the loan and recognized a recovery for credit loss equal to the amount of payments applied against principal.

In the second quarter of 2023, Guardian completed the sale of the four remaining facilities subject to the mortgage note with Omega. Guardian used \$35.2 million of proceeds from the sale of the facilities to make a principal repayment to Omega, in the same amount, against the mortgage note. Following the repayment, Omega agreed to release the mortgage liens on these facilities and forgive the remaining \$46.8 million of outstanding principal due under the mortgage note. We had previously established an allowance for credit loss to reserve this loan down to \$35.2 million in anticipation of this settlement.

Other real estate loan due 2035

As discussed in Note 4 – Contractual Receivables and Other Receivables and Lease Inducements, in the first quarter of 2023, Omega entered into a restructuring agreement and a loan amendment with Maplewood that modified Maplewood's secured revolving credit facility. As part of the restructuring agreement and loan amendment, Omega agreed to extend the maturity date of the facility to June 2035, increase the capacity of the secured revolving credit facility from \$250.5 million to \$320.0 million, including PIK interest applied to the principal, and to convert the 7% cash interest due on the secured revolving credit facility to all PIK interest in 2023, 1% cash interest and 6% PIK interest in 2024, 4% cash interest and 3% PIK interest in 2025 and through the maturity date. The maximum PIK interest allowable under credit facility, as amended, is \$52.2 million. This amendment was treated as a loan modification provided to a borrower experiencing financial difficulty.

During the three months ended March 31, 2023, we recorded interest income of \$1.5 million on the secured revolving credit facility for the contractual interest payment received related to December 2022, as the loan was placed on non-accrual status for interest recognition during the fourth quarter of 2022. We did not record any interest income related to the PIK interest during the three and six months ended June 30, 2023. As of June 30, 2023, the amortized cost basis of this loan was \$263.5 million, which represents 22.7% of the total amortized cost basis of all real estate loan receivables. As of June 30, 2023, the remaining commitment under the secured revolving credit facility, including the unrecognized PIK interest, was \$48.8 million.

Other real estate loans due 2023-2029

On April 14, 2023, we entered into two mezzanine loans, with principal balances of \$68.0 million and \$6.6 million, respectively, with an existing operator and its affiliates in connection with the operator's acquisition of 13 SNFs in West Virginia. The \$68.0 million loan matures on April 13, 2029 and bears interest at a variable rate that results in a blended interest rate of 12% per annum across this loan and three other loans, including the \$6.6 million mezzanine loan and both \$15.0 million mezzanine loans discussed under Notes due 2023-2029 in Note 6 – Non-Real Estate Loans Receivable. The \$68.0 million loan requires quarterly principal payments of \$1.0 million commencing on July 1, 2023 and additional payments contingent on certain metrics. The \$68.0 million loan is secured by a leasehold mortgage and a pledge of the operator's equity interest in subsidiaries of the operator. The \$6.6 million mezzanine loan matures on April 14, 2029 and bears interest at a rate of 8% per annum. The \$6.6 million mezzanine loan was made to a new real estate joint venture, RCA NH Holdings RE Co., LLC, that we formed in April 2023 with the acquiring operator (see Note 9 – Investments in Joint Ventures for additional information on this joint venture).

NOTE 6 – NON-REAL ESTATE LOANS RECEIVABLE

Our non-real estate loans consist of fixed and variable rate loans to operators and/or principals. These loans may be either unsecured or secured by the collateral of the borrower, which may include the working capital of the borrower. As of June 30, 2023, we had 39 loans with 22 different borrowers. A summary of our non-real estate loans is as follows:

	<u>June 30,</u> <u>2023</u>	<u>December 31,</u> <u>2022</u>
	(in thousands)	
Notes due 2023-2029; interest at 11.30% ⁽¹⁾	\$ 86,763	\$ 55,981
Notes due 2036; interest at 5.63%	80,207	55,791
Notes due 2036; interest at 2.00%	32,308	32,539
Note due 2024; interest at 7.50%	50,999	47,999
Note due 2027; interest at 12.00% ⁽²⁾	—	39,653
Other notes outstanding ⁽³⁾	93,318	77,186
Non-real estate loans receivable – gross	343,595	309,149
Allowance for credit losses on non-real estate loans receivable	(115,679)	(83,868)
Total non-real estate loans receivable – net	<u>\$ 227,916</u>	<u>\$ 225,281</u>

(1) Approximates the weighted average interest rate as of June 30, 2023.

(2) During the first quarter of 2023, this loan was fully repaid.

(3) Other notes outstanding have a weighted average interest rate of 7.39% as of June 30, 2023, with maturity dates ranging from 2023 through 2030 (with \$19.6 million maturing in 2023). We have one loan within other notes outstanding with principal of \$4.1 million that matured in 2022 but remained outstanding as of June 30, 2023. We wrote the \$4.1 million loan down to the fair value of its collateral of \$1.0 million during the first quarter of 2023.

For the three months ended June 30, 2023 and 2022, non-real estate loans generated interest income of \$5.3 million and \$2.8 million, respectively. For the six months ended June 30, 2023 and 2022, non-real estate loans generated interest income of \$10.3 million and \$5.0 million, respectively. Interest income on non-real estate loans is included within interest income on the Consolidated Statements of Operations.

Notes due 2036; interest at 5.63%

As discussed in Note 4 – Contractual Receivables and Other Receivables and Lease Inducements, in the first quarter of 2023, Omega entered into a restructuring agreement and a replacement loan agreement that modified the existing Agemo loans. Under the restructuring agreement, previously written off contractual unpaid interest related to the Agemo WC Loan and the Agemo Term Loan was forgiven. The outstanding principal of the Agemo Term Loan was refinanced into a new \$32.0 million loan (“Agemo Replacement Loan A”). The outstanding principal of the Agemo WC Loan and the aggregate rent deferred and outstanding under the Agemo lease agreement was combined and refinanced into a new \$50.2 million loan (“Agemo Replacement Loan B” and with Agemo Replacement Loan A, the “Agemo Replacement Loans”). The Agemo Replacement Loans bear interest at 5.63% per annum through October 2024, which increases to 5.71% per annum until maturity. The Agemo Replacement Loans mature on December 31, 2036. Interest payments were scheduled to resume on April 1, 2023, contingent upon Agemo’s compliance with certain conditions of the restructuring agreement; however, Agemo had the option to defer the interest payment due on April 1, 2023. Beginning in January 2025, Agemo will be required to make principal payments on the Agemo Replacement Loans dependent on certain metrics. These amendments were treated as loan modifications provided to a borrower experiencing financial difficulty. Both of these loans are on non-accrual status, and we are utilizing the cost recovery method, under which any payments, if received, are applied against the principal amount.

Prior to the restructuring, the principal of the Agemo WC Loan and the Agemo Term Loan were written down to \$5.9 million and zero, respectively, the fair value of the underlying collateral of these loans. No changes to the collateral supporting the loans were made because of the refinancing of these loans into the Agemo Replacement Loans. Additional principal of \$25.2 million related to deferred rent due under the master lease was combined with the principal of the Agemo WC Loan under Agemo Replacement Loan B. This deferred rent balance was previously written off when the Agemo master lease was taken to a cash basis of revenue recognition in 2020. We believe it is not probable that we will collect the additional \$25.2 million of principal balance associated with the deferred rent under Agemo Replacement Loan B. As such, we added an additional allowance for credit losses of \$25.2 million related to Agemo Replacement Loan B concurrent with the increase in loan principal during the first quarter of 2023. There is no income statement impact as a result of this additional reserve due to the balance previously being written off.

Agemo exercised its option to defer the interest payment due on April 1, 2023 and resumed making interest payments in May 2023 in accordance with the restructuring terms discussed above. During the three months ended June 30, 2023, we received \$0.8 million of interest payments from Agemo that we applied against the outstanding principal of the loans and recognized a recovery for credit loss equal to the amount of payments applied against principal. As of June 30, 2023, the amortized cost basis of these loans was \$80.2 million, which represents 23.3% of the total amortized cost basis of all non-real estate loan receivables. The total reserve as of June 30, 2023 related to the Agemo Replacement Loans was \$74.3 million.

Notes due 2023-2029

During the second quarter of 2023, we entered into two \$15.0 million mezzanine loans with an existing operator and its affiliates in connection with the operator’s acquisition of 13 SNFs in West Virginia (discussed in Note 5 – Real Estate Loans Receivable). The first \$15.0 million mezzanine loan (the “2028 Mezz Loan”) matures on April 1, 2028 and bears interest at a variable rate based on the one month term SOFR plus 8.6% per annum. The 2028 Mezz Loan requires monthly principal payments commencing on May 1, 2023 and is secured by a pledge of the operator’s equity interest in its subsidiaries. The second \$15.0 million mezzanine loan (the “2029 Mezz Loan”) matures on April 13, 2029 and bears interest at a fixed rate of 12% per annum. The 2029 Mezz Loan also requires quarterly principal payments of \$0.3 million commencing on July 1, 2023 and additional payments contingent on the operator’s achievement of certain metrics. The 2029 Mezz Loan is secured by a pledge of the operator’s equity interest in subsidiaries of the operator. In connection with the two mezzanine loans, we also provided a \$3.3 million working capital loan to a new joint venture, WV Pharm Holdings, LLC, that we formed in April 2023 with the acquiring operator (see Note 9 – Investments in Joint Ventures for additional information on this joint venture).

Notes due 2036; interest at 2.00%

During the fourth quarter of 2022, we amended an \$8.3 million term loan and a \$25.0 million term loan with LaVie to, among other terms, extend the loan maturities to November 30, 2036 to align with the lease term, and starting in January 2023, reduce the interest rates to 2%, remove the requirement to make any principal payments until the maturity dates and convert from monthly cash interest payments to PIK interest. These amendments were treated as loan modifications provided to a borrower experiencing financial difficulty. Both of these loans are on non-accrual status, and we are utilizing the cost recovery method, under which any payments made by LaVie are applied against the principal amount outstanding. During the six months ended June 30, 2023, we applied an aggregate \$0.2 million of interest payments received to the \$25.0 million term loan principal balance and the \$8.3 million term loan principal balance outstanding. As of June 30, 2023, the amortized cost basis of these loans was \$32.3 million, which represents 9.4% of the total amortized cost basis of all non-real estate loan receivables. The total reserve as of June 30, 2023 related to the LaVie loans was \$24.8 million.

Note due 2024

On July 8, 2019, the Company entered into a \$15 million unsecured revolving credit facility agreement with a principal of an operator that bears interest at a fixed rate of 7.5% per annum and originally matured on July 8, 2022. During 2022, this revolving credit facility was amended multiple times to increase the maximum principal to \$48 million, extend the maturity date to December 31, 2024 and require monthly principal payments. During the second quarter of 2023, this revolving credit facility was further amended to increase the maximum principal to \$52 million and modify the principal payment schedule.

Other notes outstanding

\$10.0 million Mezzanine Loan and Working Capital Loan

On June 30, 2023, the Company entered into a \$10.0 million mezzanine loan and a revolving working capital loan with an existing operator in connection with the operator's acquisition of a portfolio of facilities in Pennsylvania. The \$10.0 million mezzanine loan matures on June 30, 2028 and bears interest at a fixed rate of 11% per annum. The \$10.0 million mezzanine loan also requires monthly amortizing payments of principal and interest in the amount of \$0.2 million. The \$10.0 million mezzanine loan is secured by an equity interest in a subsidiary of the operator. The working capital loan matures on June 30, 2026 and bears interest at a fixed rate of 10% per annum. The working capital loan has a maximum principal of \$34.0 million for the first year that decreases to \$20.0 million thereafter. The working capital loan is secured by the accounts receivable of the acquired facilities. As of June 30, 2023, the revolving working capital loan has not been drawn on.

NOTE 7 – ALLOWANCE FOR CREDIT LOSSES

A rollforward of our allowance for credit losses for the six months ended June 30, 2023 is as follows:

Rating	Financial Statement Line Item	Allowance for Credit Loss as of December 31, 2022	Provision (recovery) for Credit Loss for the six months ended June 30, 2023	Write-offs charged against allowance for the six months ended June 30, 2023	Other additions to the allowance for the six months ended June 30, 2023	Allowance for Credit Loss as of June 30, 2023
(in thousands)						
1	Real estate loan receivable	\$ 162	\$ 366	\$ —	\$ —	\$ 528
2	Real estate loans receivable	157	(88)	—	—	69
3	Real estate loans receivable	15,110	(9,465)	—	—	5,645
4	Real estate loans receivable	33,666	11,636	—	—	45,302
6	Real estate loans receivable	52,265	(3,860)	(36,955) ⁽¹⁾	—	11,450
	Sub-total	101,360	(1,411)	(36,955)	—	62,994
5	Investment in direct financing leases	2,816	(545)	—	—	2,271
	Sub-total	2,816	(545)	—	—	2,271
2	Non-real estate loans receivable	859	(507)	—	—	352
3	Non-real estate loans receivable	2,079	(1,016)	—	—	1,063
4	Non-real estate loans receivable	634	(430)	—	—	204
5	Non-real estate loans receivable	18,619	(439)	—	25,200 ⁽²⁾	43,380
6	Non-real estate loans receivable	61,677	9,003	—	—	70,680
	Sub-total	83,868	6,611	—	25,200	115,679
2	Off-balance sheet non-real estate loan commitments	207	177	—	—	384
3	Off-balance sheet non-real estate loan commitments	29	(27)	—	—	2
4	Off-balance sheet non-real estate loan commitments	—	8	—	—	8
4	Off-balance sheet real estate loan commitments	84	4,097	—	—	4,181
	Sub-total	320	4,255	—	—	4,575
	Total	\$ 188,364	\$ 8,910	\$ (36,955)	\$ 25,200	\$ 185,519

(1) This amount relates to the write-off of the allowance for the Guardian mortgage note in connection with the settlement and partial forgiveness of the note in the second quarter of 2023. See Note 5 – Real Estate Loans Receivable for additional details.

(2) This amount relates to the additional \$25.2 million allowance recorded during the first quarter of 2023 in order to reserve the aggregate deferred rent amount that is included within Agemo Replacement Loan B. See Note 6 – Non-Real Estate Loans Receivable for additional details.

[Table of Contents](#)

A rollforward of our allowance for credit losses for the six months ended June 30, 2022 is as follows:

Rating	Financial Statement Line Item	Allowance for Credit	Provision (recovery) for	Write-offs charged against	Allowance for Credit
		Loss at December 31, 2021	Credit Loss for the six months ended June 30, 2022	allowance for the six months ended June 30, 2022	Loss as of June 30, 2022
(in thousands)					
1	Real estate loans receivable	\$ —	\$ 246	\$ —	\$ 246
2	Real estate loans receivable	14	13	—	27
3	Real estate loans receivable	5,367	431	—	5,798
4	Real estate loans receivable	20,577	(2,814)	—	17,763
5	Real estate loans receivable	136	(67)	—	69
6	Real estate loans receivable	56,480	(6,584) ⁽¹⁾	—	49,896
	Sub-total	82,574	(8,775)	—	73,799
3	Investment in direct financing leases	530	(47)	—	483
	Sub-total	530	(47)	—	483
2	Non-real estate loans receivable	29	20	—	49
3	Non-real estate loans receivable	1,206	1,820 ⁽²⁾	—	3,026
4	Non-real estate loans receivable	56	596	—	652
5	Non-real estate loans receivable	7,861	5,993 ⁽³⁾	—	13,854
6	Non-real estate loans receivable	51,269	(1,479)	—	49,790
	Sub-total	60,421	6,950	—	67,371
2	Off-balance sheet non-real estate loan commitments	7	236	—	243
3	Off-balance sheet non-real estate loan commitments	207	12	—	219
3	Off-balance sheet real estate loan commitments	251	24	—	275
4	Off-balance sheet non-real estate loan commitments	216	(165)	—	51
4	Off-balance sheet real estate loan commitments	117	(106)	—	11
6	Off-balance sheet non-real estate loan commitments	143	2,132	—	2,275
		941	2,133	—	3,074
	Total	\$ 144,466	\$ 261	\$ —	\$ 144,727

(1) This amount relates to a recovery recorded on the Guardian mortgage loan during the first and second quarters of 2022.

(2) This provision includes an additional \$2.3 million allowance recorded on a \$20 million working capital loan during the second quarter of 2022.

(3) This provision includes an additional \$4.7 million allowance recorded on the Agemo WC Loan during the first quarter of 2022 and an additional \$1.3 million allowance recorded on the Agemo WC Loan during the second quarter of 2022.

A summary of our amortized cost basis by year of origination and credit quality indicator is as follows:

Rating	Financial Statement Line Item	2023	2022	2021	2020	2019	2018	2017 & older	Revolving Loans	Balance as of June 30, 2023
1	Real estate loans receivable	\$ —	\$ 20,000	\$ —	\$ —	\$ —	\$ —	\$ 62,921	\$ —	\$ 82,921
2	Real estate loans receivable	7,700	—	—	21,325	—	—	—	—	29,025
3	Real estate loans receivable	73,964	33,600	72,420	—	—	—	744	—	180,728
4	Real estate loans receivable	—	210	31,820	89,463	5,099	131,632	332,460	263,520	854,204
6	Real estate loans receivable	—	—	—	—	—	—	12,922	—	12,922
	Sub-total	81,664	53,810	104,240	110,788	5,099	131,632	409,047	263,520	1,159,800
5	Investment in direct financing leases	—	—	—	—	—	—	11,266	—	11,266
	Sub-total	—	—	—	—	—	—	11,266	—	11,266
2	Non-real estate loans receivable	1,300	—	—	—	—	—	—	100,249	101,549
3	Non-real estate loans receivable	40,080	22,151	—	—	3,883	10,800	—	9,550	86,464
4	Non-real estate loans receivable	—	—	—	—	1,630	—	1,000	21,400	24,030
5	Non-real estate loans receivable	—	—	—	—	2,288	49,269	—	—	51,557
6	Non-real estate loans receivable	7,936	24,457	7,851	—	—	4,092	30,938	4,721	79,995
	Sub-total	49,316	46,608	7,851	—	7,801	64,161	31,938	135,920	343,595
	Total	\$ 130,980	\$ 100,418	\$ 112,091	\$ 110,788	\$ 12,900	\$ 195,793	\$ 452,251	\$ 399,440	\$ 1,514,661
	Year to date gross write-offs	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ (36,955)	\$ —	\$ (36,955)

Interest Receivable on Real Estate Loans and Non-Real Estate Loans

We have elected the practical expedient to exclude interest receivable from our allowance for credit losses. As of June 30, 2023 and December 31, 2022, we have excluded \$8.8 million and \$8.2 million, respectively, of contractual interest receivables and \$4.6 million and \$5.7 million, respectively, of effective yield interest receivables from our allowance for credit losses. We write-off contractual interest receivables to provision for credit losses in the period we determine the interest is no longer considered collectible.

During the three months ended June 30, 2023 and 2022, we recognized \$0.1 million and \$4.9 million, respectively, of interest income related to loans on non-accrual status as of June 30, 2023. During the six months ended June 30, 2023 and 2022, we recognized \$1.6 million and \$9.0 million, respectively, of interest income related to loans on non-accrual status as of June 30, 2023.

NOTE 8 – VARIABLE INTEREST ENTITIES

Unconsolidated Variable Interest Entities

We hold variable interests in several VIEs through our investing and financing activities, which are not consolidated, as we have concluded that we are not the primary beneficiary of these entities as we do not have the power to direct activities that most significantly impact the VIE's economic performance and/or the variable interest we hold does not obligate us to absorb losses or provide us with the right to receive benefits from the VIE which could potentially be significant.

Below is a summary of our assets, liabilities, collateral and maximum exposure to loss associated with these unconsolidated VIEs as of June 30, 2023 and December 31, 2022:

	<u>June 30,</u> <u>2023</u>	<u>December 31,</u> <u>2022</u>
	(in thousands)	
Assets		
Real estate assets – net	\$ 1,047,319	\$ 982,721
Real estate loans receivable – net	302,816	270,500
Investments in unconsolidated joint ventures	8,150	—
Non-real estate loans receivable – net	9,095	5,929
Contractual receivables – net	194	114
Other assets	1,423	1,499
Total assets	<u>1,368,997</u>	<u>1,260,763</u>
Liabilities		
Accrued expenses and other liabilities	(51,464)	(50,522)
Total liabilities	<u>(51,464)</u>	<u>(50,522)</u>
Collateral		
Personal guarantee	(48,000)	(48,000)
Other collateral ⁽¹⁾	(1,060,019)	(982,721)
Total collateral	<u>(1,108,019)</u>	<u>(1,030,721)</u>
Maximum exposure to loss	<u>\$ 209,514</u>	<u>\$ 179,520</u>

(1) Amount excludes accounts receivable that Omega has a security interest in as collateral under the three loans with operators that are unconsolidated VIEs. The fair value of the accounts receivable available to Omega was \$8.7 million and \$5.9 million as of June 30, 2023 and December 31, 2022, respectively.

[Table of Contents](#)

In determining our maximum exposure to loss from the unconsolidated VIEs, we considered the underlying carrying value of the real estate subject to leases with the operator and other collateral, if any, supporting our other investments, which may include accounts receivable, security deposits, letters of credit or personal guarantees, if any, as well as other liabilities recognized with respect to these operators.

The table below reflects our total revenues from the operators that are considered unconsolidated VIEs for the three and six months ended June 30, 2023 and 2022:

	<u>Three Months Ended June 30,</u>		<u>Six Months Ended June 30,</u>	
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
	<u>(in thousands)</u>		<u>(in thousands)</u>	
Revenue				
Rental income	\$ 25,962	\$ 21,239	\$ 35,800	\$ 42,102
Interest income	979	4,335	3,085	8,101
Total	<u>\$ 26,941</u>	<u>\$ 25,574</u>	<u>\$ 38,885</u>	<u>\$ 50,203</u>

Consolidated VIEs

We own 52.4% of the outstanding equity of a joint venture, which owns two ALFs, that is a VIE. We have consolidated this VIE as a result of our conclusion that we are the primary beneficiary of this VIE based on a combination of our ability to direct the activities that most significantly impact the joint venture's economic performance and our rights to receive residual returns or the obligation to absorb losses arising from the joint venture. As of June 30, 2023 and December 31, 2022, this joint venture has \$26.7 million and \$25.8 million, respectively, of total assets and \$20.3 million and \$19.8 million, respectively, of total liabilities, which are included in our Consolidated Balance Sheets.

During the fourth quarter of 2022, we acquired seven facilities using a reverse like-kind exchange structure pursuant to Section 1031 of the Code (a "reverse 1031 exchange"). We completed the reverse 1031 exchange for three of the acquired facilities in the fourth quarter of 2022. During the second quarter of 2023, the remaining four facilities were released from the possession of the Exchange Accommodation Titleholders ("EATs"), as we did not identify any qualifying exchange transactions. The EATs were classified as VIEs as they did not have sufficient equity investment at risk to permit the entity to finance its activities. The Company consolidated the EATs because it had the ability to control the activities that most significantly impacted the economic performance of the EATs and was, therefore, the primary beneficiary of the EATs. The properties held by the EATs were reflected as real estate with a carrying value of \$55.2 million as of December 31, 2022. The EATs also held cash of \$23.9 million as of December 31, 2022.

NOTE 9 – INVESTMENTS IN JOINT VENTURES

Unconsolidated Joint Ventures

The following is a summary of our investments in unconsolidated joint ventures (dollars in thousands):

Entity	Ownership %	Initial Investment Date	Investment ⁽¹⁾	Facility Type	Facilities at June 30, 2023	Carrying Amount	
						June 30, 2023	December 31, 2022
Second Spring Healthcare Investments	15%	11/1/2016	\$ 50,032	SNF	—	\$ 10,440	\$ 10,975
Lakeway Realty, L.L.C.	51%	5/17/2019	73,834	Specialty facility	1	69,551	70,151
Cindat Joint Venture	49%	12/18/2019	105,688	ALF	63	103,024	97,382
OMG Senior Housing, LLC	50%	12/6/2019	—	Specialty facility	1	—	—
OH CHS SNP, Inc.	9%	12/20/2019	1,013	N/A	N/A	502	412
RCA NH Holdings RE Co., LLC ⁽²⁾⁽³⁾	20%	4/14/2023	3,400	SNF	5	3,400	—
WV Pharm Holdings, LLC ⁽²⁾⁽³⁾	20%	4/14/2023	3,000	N/A	N/A	3,000	—
OMG-Form Senior Holdings, LLC ⁽³⁾	49%	6/15/2023	1,794	ALF	1	1,750	—
			<u>\$ 238,761</u>			<u>\$ 191,667</u>	<u>\$ 178,920</u>

(1) Our investment includes our transaction costs, if any.

(2) These joint ventures were entered into in connection with an existing operator's acquisition of SNFs in West Virginia during the second quarter of 2023, as discussed in Note 5 and Note 6. The acquiring operator in the transaction is the majority owner of these joint ventures. As of June 30, 2023, we have an aggregate of \$8.5 million of loans outstanding with these joint ventures.

(3) These joint ventures are unconsolidated VIEs and therefore are included in the tables in Note 8 – Variable Interest Entities.

(4) During the second quarter of 2023, we funded \$7.7 million under a mortgage loan with this joint venture.

The following table reflects our income (loss) from unconsolidated joint ventures for the three and six months ended June 30, 2023 and 2022:

Entity	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
	(in thousands)			
Second Spring Healthcare Investments	\$ 292	\$ 297	\$ 581	\$ 582
Second Spring II LLC ⁽¹⁾	—	—	—	(2)
Lakeway Realty, L.L.C.	677	659	1,356	1,320
Cindat Joint Venture	96	898	97	1,633
OMG Senior Housing, LLC	41	(96)	(179)	(179)
OH CHS SNP, Inc.	8	24	90	51
OMG-Form Senior Holdings, LLC	(45)	—	(45)	—
Total	<u>\$ 1,069</u>	<u>\$ 1,782</u>	<u>\$ 1,900</u>	<u>\$ 3,405</u>

(1) The assets held by this joint venture have been liquidated, and we have no remaining operations related to this joint venture.

Asset Management Fees

We receive asset management fees from certain joint ventures for services provided. For the three months ended June 30, 2023 and 2022, we recognized approximately \$0.2 million of asset management fees. For the six months ended June 30, 2023 and 2022, we recognized approximately \$0.4 million of asset management fees. These fees are included in miscellaneous income in the accompanying Consolidated Statements of Operations.

NOTE 10 – GOODWILL AND OTHER INTANGIBLES

The following is a summary of our goodwill as of June 30, 2023 and December 31, 2022:

	(in thousands)
Balance as of December 31, 2022	\$ 643,151
Foreign currency translation	711
Balance as of June 30, 2023	<u>\$ 643,862</u>

The following is a summary of our intangibles as of June 30, 2023 and December 31, 2022:

	June 30, 2023	December 31, 2022
	(in thousands)	
Assets:		
Above market leases	\$ 4,214	\$ 5,929
Accumulated amortization	(3,503)	(4,484)
Net above market leases	<u>\$ 711</u>	<u>\$ 1,445</u>
Liabilities:		
Below market leases	\$ 55,183	\$ 66,433
Accumulated amortization	(40,187)	(44,595)
Net below market leases	<u>\$ 14,996</u>	<u>\$ 21,838</u>

Above market leases, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market leases, net of accumulated amortization, are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. The net amortization related to the above and below market leases is included in our Consolidated Statements of Operations as an adjustment to rental income.

For the three months ended June 30, 2023 and 2022, our net amortization related to intangibles was \$0.7 million and \$1.0 million, respectively. For the six months ended June 30, 2023 and 2022, our net amortization related to intangibles was \$6.8 million and \$2.6 million, respectively. The estimated net amortization related to these intangibles for the remainder of 2023 and the next four years is as follows: remainder of 2023 – \$1.2 million; 2024 – \$2.3 million; 2025 – \$2.3 million; 2026 – \$2.1 million and 2027 – \$1.8 million. As of June 30, 2023, the weighted average remaining amortization period of above market lease assets is approximately fourteen years and below market lease liabilities is approximately eight years.

NOTE 11 – CONCENTRATION OF RISK

As of June 30, 2023, our portfolio of real estate investments (including properties associated with mortgages, direct financing leases, assets held for sale and consolidated joint ventures) consisted of 923 healthcare facilities, located in 42 states and the U.K. and operated by 71 third-party operators. Our investment in these facilities, net of impairments and allowances, totaled approximately \$9.6 billion at June 30, 2023, with approximately 97% of our real estate investments related to long-term healthcare facilities. Our portfolio is made up of (i) 661 SNFs, 175 ALFs, 19 ILFs, 17 specialty facilities and one medical office building, (ii) fixed rate mortgages on 44 SNFs, three ALFs and two specialty facilities, and (iii) one facility that is held for sale. At June 30, 2023, we also held other real estate loans receivable (excluding mortgages) of \$466.6 million, non-real estate loans receivable of \$227.9 million and \$191.7 million of investments in eight unconsolidated joint ventures.

[Table of Contents](#)

As of June 30, 2023 and December 31, 2022, we had investments with one operator or manager that approximated or exceeded 10% of our total investments: Maplewood. Maplewood generated approximately 6.5% and 9.0% of our total revenues (excluding the impact of write-offs) for the three months ended June 30, 2023 and 2022, respectively, and 7.3% and 9.0% of our total revenues for the six months ended June 30, 2023 and 2022, respectively. During the three and six months ended June 30, 2023, we also have one operator with total revenues (excluding the impact of write-offs) that exceeded 10% of our total revenues: CommuniCare Health Services, Inc. (“CommuniCare”). CommuniCare generated approximately 11.4% and 7.4% of our total revenues (excluding the impact of write-offs) for the three months ended June 30, 2023 and 2022, respectively, and 10.3% and 7.4% of our total revenues for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, CommuniCare represented approximately 8.6% of our total investments.

As of June 30, 2023, the three states in which we had our highest concentration of investments were Florida (11.4%), Texas (10.2%) and Indiana (6.6%).

NOTE 12 – STOCKHOLDERS’ EQUITY**\$500 Million Stock Repurchase Program**

We had no share repurchases during the three and six months ended June 30, 2023. The following is a summary of the shares repurchased for the three and six months ended June 30, 2022 (in millions except average price per share):

	Period Ended	Shares Repurchased	Average Price Per Share ⁽¹⁾	Repurchase Cost ⁽¹⁾
Three Months Ended	June 30, 2022	4.2	\$ 27.19	\$ 114.9
Six Months Ended	June 30, 2022	5.2	27.32	142.3

(1) Average price per share and repurchase cost includes the cost of commissions.

Dividends

The following is a summary of our declared cash dividends on common stock:

Record Date	Payment Date	Dividend per Common Share
February 6, 2023	February 15, 2023	\$ 0.67
May 1, 2023	May 15, 2023	0.67
July 31, 2023	August 15, 2023	0.67

Dividend Reinvestment and Common Stock Purchase Plan

The following is a summary of the shares issued under the Dividend Reinvestment and Common Stock Purchase Plan for the three and six months ended June 30, 2023 and 2022 (in millions):

	Period Ended	Shares issued	Gross Proceeds
Three Months Ended	June 30, 2022	0.1	\$ 2.3
Three Months Ended	June 30, 2023	0.1	2.2
Six Months Ended	June 30, 2022	0.2	4.6
Six Months Ended	June 30, 2023	0.2	4.5

At-The-Market Offering Programs

The following is a summary of the shares issued under our \$1.0 billion At-The-Market Offering Program (“ATM Program”) for the three and six months ended June 30, 2023 and 2022 (in millions except average price per share):

	Period Ended	Shares issued	Average Net Price		Gross Proceeds	Commissions	Net Proceeds
			Per Share ⁽¹⁾				
Three and Six Months Ended	June 30, 2022	—	\$ —	\$ —	—	—	—
Three and Six Months Ended	June 30, 2023	6.5	30.20		199.4	2.2	197.2

(1) Represents the average price per share after commissions.

Accumulated Other Comprehensive Income (Loss)

The following is a summary of our accumulated other comprehensive income (loss), net of tax where applicable:

	As of and for the Three Months Ended June 30,		As of and for the Six Months Ended June 30,	
	2023	2022	2023	2022
	(in thousands)			
Foreign Currency Translation:				
Beginning balance	\$ (69,170)	\$ (38,668)	\$ (85,004)	\$ (24,012)
Translation gain (loss)	17,140	(39,750)	32,890	(54,380)
Realized gain (loss)	82	(1,252)	166	(1,278)
Ending balance	<u>(51,948)</u>	<u>(79,670)</u>	<u>(51,948)</u>	<u>(79,670)</u>
Derivative Instruments:				
Cash flow hedges:				
Beginning balance	76,806	49,985	86,356	30,407
Unrealized gain (loss)	6,125	18,370	(4,499)	36,982
Realized gain ⁽¹⁾	1,074	1,074	2,148	2,040
Ending balance	<u>84,005</u>	<u>69,429</u>	<u>84,005</u>	<u>69,429</u>
Net investment hedges:				
Beginning balance	13,593	(5,741)	18,634	(9,588)
Unrealized (loss) gain	(4,015)	18,661	(9,056)	22,508
Ending balance	<u>9,578</u>	<u>12,920</u>	<u>9,578</u>	<u>12,920</u>
Total accumulated other comprehensive income before noncontrolling interest	<u>41,635</u>	<u>2,679</u>	<u>41,635</u>	<u>2,679</u>
Add: portion included in noncontrolling interest	(282)	822	(282)	822
Total accumulated other comprehensive income for Omega	<u>\$ 41,353</u>	<u>\$ 3,501</u>	<u>\$ 41,353</u>	<u>\$ 3,501</u>

(1) Recorded in interest expense on the Consolidated Statements of Operations.

NOTE 13 – TAXES

Omega was organized, has operated and intends to continue to operate in a manner that enables Omega to qualify for taxation as a REIT under Sections 856 through 860 of the Code. On a quarterly and annual basis, we perform several analyses to test our compliance within the REIT taxation rules. If we fail to meet the requirements for qualification as a REIT in any tax year, we will be subject to federal income tax on our taxable income at regular corporate rates and may not be able to qualify as a REIT for the four subsequent years, unless we qualify for certain relief provisions that are available in the event we fail to satisfy any of the requirements.

[Table of Contents](#)

We are also subject to federal taxation of 100% of the net income derived from the sale or other disposition of property, other than foreclosure property, that we held primarily for sale to customers in the ordinary course of a trade or business. We believe that we do not hold assets for sale to customers in the ordinary course of business and that none of the assets currently held for sale or that have been sold would be considered a prohibited transaction within the REIT taxation rules.

As a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. In 2022, we distributed dividends in excess of our taxable income.

We currently own stock in certain subsidiary REITs. These subsidiaries are required to individually satisfy all of the rules for qualification as a REIT. If we fail to meet the requirements for qualification as a REIT for any of the subsidiary REITs, it may cause Omega to fail the requirements for qualification as a REIT also.

We have elected to treat certain of our active subsidiaries as taxable REIT subsidiaries (“TRSs”). Our domestic TRSs are subject to federal, state and local income taxes at the applicable corporate rates.

As of June 30, 2023, one of our TRSs that is subject to income taxes at the applicable corporate rates had a net operating loss (“NOL”) carry-forward of approximately \$10.2 million. Our NOL carry-forward was fully reserved as of June 30, 2023, with a valuation allowance due to uncertainties regarding realization. Under current law, NOL carry-forwards generated up through December 31, 2017, may be carried forward for no more than 20 years, and NOL carry-forwards generated in taxable years ended after December 31, 2017, may be carried forward indefinitely. We do not anticipate that such changes will materially impact the computation of Omega’s taxable income, or the taxable income of any Omega entity, including our TRSs.

Our foreign subsidiaries are subject to foreign income taxes and withholding taxes. As of June 30, 2023, one of our U.K. subsidiaries had a NOL carryforward of approximately \$42.2 million. The NOLs have no expiration date and may be available to offset future taxable income. We believe these foreign NOLs are realizable under a “more likely than not” measurement and have not recorded a valuation allowance against the deferred tax asset.

The majority of our U.K. portfolio elected to enter the U.K. REIT regime with an effective date of April 1, 2023. In connection with entering the U.K. REIT regime, we recognized several adjustments to our deferred tax balances in the first quarter of 2023 as summarized below.

The following is a summary of deferred tax assets and liabilities (which are recorded in other assets and accrued expenses and other liabilities in our Consolidated Balance Sheets):

	<u>June 30,</u> <u>2023</u>	<u>December 31,</u> <u>2022</u>
	(in thousands)	
U.S. Federal net operating loss carryforward	\$ 2,138	\$ 2,138
Valuation allowance on deferred tax asset	(2,138)	(2,138)
Foreign net operating loss carryforward	10,544	11,268
Foreign deferred tax liability ⁽¹⁾	—	(5,373)
Net deferred tax asset	<u>\$ 10,544</u>	<u>\$ 5,895</u>
Foreign deferred tax liability ⁽²⁾	<u>\$ 1,422</u>	<u>\$ —</u>
Net deferred tax liability	<u>\$ 1,422</u>	<u>\$ —</u>

(1) The deferred tax liability primarily resulted from inherited basis differences resulting from our acquisition of entities in the U.K. Subsequent adjustments to these accounts result from GAAP to tax differences related to depreciation, indexation and revenue recognition. The foreign deferred tax liabilities were eliminated upon the majority of our U.K. portfolio entering the U.K. REIT regime.

(2) The deferred tax liability resulted from book to tax differences recorded in the U.S. relating to depreciation and revenue recognition in the U.K. recognized upon the majority of our U.K. portfolio entering the U.K. REIT regime.

[Table of Contents](#)

The following is a summary of our provision for income taxes:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
	(in millions)			
Federal, state and local income tax expense	\$ 0.3	\$ 0.3	\$ 0.6	\$ 0.6
Foreign income tax expense (benefit) ⁽¹⁾	1.3	0.8	(0.3)	1.7
Total income tax expense ⁽²⁾	\$ 1.6	\$ 1.1	\$ 0.3	\$ 2.3

(1) The benefit for the six months ended June 30, 2023 primarily relates to adjustments made to our deferred tax assets and liabilities as a result of the majority of our U.K. portfolio electing to enter into the U.K. REIT regime effective April 1, 2023.

(2) The above amounts do not include gross income receipts or franchise taxes payable to certain states and municipalities.

NOTE 14 – STOCK-BASED COMPENSATION

The following is a summary of our stock-based compensation expense for the three and six months ended June 30, 2023 and 2022, respectively:

	Three Months Ended		Six Months Ended	
	June 30, 2023	June 30, 2022	June 30, 2023	June 30, 2022
	(in thousands)			
Stock-based compensation expense	\$ 8,806	\$ 6,846	\$ 17,550	\$ 13,706

Stock-based compensation expense is included within general and administrative expenses on our Consolidated Statements of Operations.

We granted 254,777 time-based profits interest units (“PIUs”) during the first quarter of 2023 to certain officers and employees, and those units vest on December 31, 2025 (three years after the grant date), subject to continued employment and vesting in certain other events.

We granted 2,049,878 performance-based PIUs during the first quarter of 2023 to certain officers and employees, which are earned based on the level of performance over the performance period (normally three years) and vest quarterly in the fourth year, subject to continued employment and vesting in certain other events. We also granted 59,684 performance-based restricted stock units (“RSUs”) during the first quarter of 2023 to certain employees, which are earned based on the level of performance over the performance period (normally three years) and vest on December 31, 2025, subject to continued employment.

We granted 26,254 time-based PIUs and 25,224 time-based RSUs to directors during the second quarter of 2023, and those units vest on Omega’s 2024 annual meeting date, subject to the director’s continued service and vesting in certain other events.

Time-based and performance-based grants made to named executive officers and key employees that meet certain conditions under the Company’s retirement policy (length of service, age, etc.) vest on an accelerated basis pursuant to the 2018 Stock Incentive Plan.

NOTE 15 – BORROWING ACTIVITIES AND ARRANGEMENTS

The following is a summary of our borrowings:

	<u>Maturity</u>	<u>Annual Interest Rate as of June 30, 2023</u>	<u>June 30, 2023</u>	<u>December 31, 2022</u>
(in thousands)				
Secured borrowings:				
HUD mortgages ⁽¹⁾⁽²⁾	2046-2052	3.01 % ⁽³⁾	\$ 340,869	\$ 344,708
2023 term loan ⁽⁴⁾	2023	N/A	—	2,161
2024 term loan ⁽⁵⁾	2024	10.67 %	19,906	19,727
Total secured borrowings			360,775	366,596
Unsecured borrowings:				
Revolving credit facility ⁽⁶⁾⁽⁷⁾	2025	6.42 %	20,342	19,246
			20,342	19,246
Senior notes and other unsecured borrowings:				
2023 notes ⁽⁶⁾⁽⁸⁾	2023	4.375 %	350,000	350,000
2024 notes ⁽⁶⁾	2024	4.950 %	400,000	400,000
2025 notes ⁽⁶⁾	2025	4.500 %	400,000	400,000
2026 notes ⁽⁶⁾	2026	5.250 %	600,000	600,000
2027 notes ⁽⁶⁾	2027	4.500 %	700,000	700,000
2028 notes ⁽⁶⁾	2028	4.750 %	550,000	550,000
2029 notes ⁽⁶⁾	2029	3.625 %	500,000	500,000
2031 notes ⁽⁶⁾	2031	3.375 %	700,000	700,000
2033 notes ⁽⁶⁾	2033	3.250 %	700,000	700,000
OP term loan ⁽⁹⁾⁽¹⁰⁾	2025	5.52 %	50,000	50,000
Deferred financing costs – net			(19,923)	(22,276)
Discount – net			(24,316)	(26,732)
Total senior notes and other unsecured borrowings – net			4,905,761	4,900,992
Total unsecured borrowings – net			4,926,103	4,920,238
Total secured and unsecured borrowings – net ⁽¹¹⁾⁽¹²⁾			\$ 5,286,878	\$ 5,286,834

- (1) Reflects the weighted average annual contractual interest rate on the mortgages at June 30, 2023. The mortgages are secured by real estate assets with a net carrying value of \$470.8 million as of June 30, 2023.
- (2) Wholly owned subsidiaries of Omega OP are the obligor on these borrowings.
- (3) Excludes fees of approximately 0.65% for mortgage insurance premiums.
- (4) Borrowing was the debt of a consolidated joint venture.
- (5) Borrowing is the debt of the consolidated joint venture discussed in Note 8 – Variable Interest Entities which was formed in the first quarter of 2022. The borrowing is secured by two ALFs, which are owned by the joint venture.
- (6) Guaranteed by Omega OP.
- (7) During the second quarter of 2023, the Company transitioned its benchmark interest rate for its \$1.45 billion senior unsecured multicurrency revolving credit facility from LIBOR to SOFR. As of June 30, 2023, borrowings under Omega's \$1.45 billion senior unsecured multicurrency revolving credit facility consisted of £16.0 million British Pounds Sterling ("GBP"). The applicable interest rate on the US Dollar tranche and on the GBP borrowings under the alternative currency tranche of the credit facility were 6.42% and 6.25% as of June 30, 2023, respectively.
- (8) On August 1, 2023, the Company repaid the \$350 million of 4.375% senior notes that matured on August 1, 2023 using available cash.
- (9) Omega OP is the obligor on this borrowing.
- (10) During the second quarter of 2023, the Company transitioned its benchmark interest rate for its \$50.0 million senior unsecured term loan facility from LIBOR to SOFR. The weighted average interest rate of the \$50 million OP term loan has been adjusted to reflect the impact of the interest rate swaps that effectively fix the SOFR based portion of the interest rate at 3.957%.
- (11) All borrowings are direct borrowings of Parent unless otherwise noted.
- (12) Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of June 30, 2023 and December 31, 2022, we were in compliance with all applicable covenants for our borrowings.

NOTE 16 – DERIVATIVES AND HEDGING

We are exposed to, among other risks, the impact of changes in foreign currency exchange rates as a result of our investments in the U.K. and interest rate risk related to our capital structure. As a matter of policy, we do not use derivatives for trading or speculative purposes. Our risk management program is designed to manage the exposure and volatility arising from these risks, and utilizes foreign currency forward contracts, interest rate swaps and debt issued in foreign currencies to offset a portion of these risks. As of June 30, 2023, we have one interest rate swap with \$50.0 million in notional value that was entered into during the second quarter of 2023 (discussed further below). The swap is designated as a cash flow hedge. Additionally, we have six foreign currency forward contracts with £250.0 million in notional value issued at a weighted average GBP-USD forward rate of 1.3641 that are designated as net investment hedges.

In June 2023, we entered into an interest rate swap with a notional amount of \$50.0 million. The swap is effective June 30, 2023 and terminates on April 30, 2027. This interest rate swap is designated as a hedge against our exposure to changes in interest payment cash flow fluctuations in the variable interest rates on the OP Term Loan. The interest rate swap contract effectively converts our \$50.0 million OP Term Loan to an aggregate fixed rate of approximately 5.52% through its maturity. The effective fixed rate achieved by the combination of the 2021 Omega OP Credit Agreement and the interest rate swaps could fluctuate up by 40 basis points or down by 60 basis points based on future changes to our credit ratings.

In March 2020, we entered into five forward starting swaps with \$400 million in notional value, indexed to 3-month LIBOR, that were issued at a weighted average fixed rate of 0.8675% and were subsequently designated as cash flow hedges. In conjunction with the October 2020 issuance of \$700 million of 3.375% Senior Notes due 2031 and the March 2021 issuance of \$700 million of 3.25% Senior Notes due 2033, we applied hedge accounting for these five forward starting swaps and began amortization. Simultaneously with these issuances, we re-designated these swaps in new cash flow hedging relationships of interest rate risk associated with interest payments for a future forecasted issuance of long-term debt. As a result of these transactions, the aggregate unrealized gain of \$41.2 million (\$9.5 million gain related to the October 2020 issuance and \$31.7 million gain related to the March 2021 issuance) included within accumulated other comprehensive income at the time of the bond issuances is being ratably reclassified as a reduction to interest expense, net over 10 years. On May 30, 2023, the five forward starting swaps were terminated, and Omega received a net cash settlement of \$92.6 million from the swap counterparties. The incremental \$51.4 million of gains related to the forward swaps, recorded in accumulated other comprehensive income, were frozen at the time of termination and will be recognized ratably over 10 years in earnings when the next qualifying debt issuance occurs. Consistent with our accounting policy and historical practice, the \$92.6 million net cash settlement from the forward swap termination is reflected within net cash used in financing activities in the Consolidated Statements of Cash Flows.

The location and fair value of derivative instruments designated as hedges, at the respective balance sheet dates, were as follows:

	<u>June 30,</u>		<u>December 31,</u>
	<u>2023</u>		<u>2022</u>
		(in thousands)	
Cash flow hedges:			
Other assets	\$	211	\$ 92,990
Net investment hedges:			
Other assets	\$	25,921	\$ 34,977

The fair value of the interest rate swap and foreign currency forwards is derived from observable market data such as yield curves and foreign exchange rates and represents a Level 2 measurement on the fair value hierarchy.

NOTE 17 – FINANCIAL INSTRUMENTS

The net carrying amount of cash and cash equivalents, restricted cash, contractual receivables, other assets and accrued expenses and other liabilities reported in the Consolidated Balance Sheets approximates fair value because of the short maturity of these instruments (Level 1).

At June 30, 2023 and December 31, 2022, the net carrying amounts and fair values of our other financial instruments were as follows:

	June 30, 2023		December 31, 2022	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
	(in thousands)			
Assets:				
Investments in direct financing leases – net	\$ 8,995	\$ 8,995	\$ 8,503	\$ 8,503
Real estate loans receivable – net	1,096,806	1,115,784	1,042,731	1,080,890
Non-real estate loans receivable – net	227,916	229,294	225,281	228,498
Total	<u>\$ 1,333,717</u>	<u>\$ 1,354,073</u>	<u>\$ 1,276,515</u>	<u>\$ 1,317,891</u>
Liabilities:				
Revolving credit facility	\$ 20,342	\$ 20,342	\$ 19,246	\$ 19,246
2023 term loan	—	—	2,161	2,275
2024 term loan	19,906	19,750	19,727	19,750
OP term loan	49,813	50,000	49,762	50,000
4.375% notes due 2023 – net	349,953	349,395	349,669	347,998
4.95% notes due 2024 – net	399,242	394,324	398,736	394,256
4.50% notes due 2025 – net	398,827	384,000	398,446	388,920
5.25% notes due 2026 – net	598,200	576,426	597,848	589,104
4.50% notes due 2027 – net	694,570	645,813	693,837	657,468
4.75% notes due 2028 – net	545,420	499,856	544,916	507,425
3.625% notes due 2029 – net	492,494	408,490	491,890	411,090
3.375% notes due 2031 – net	686,277	547,806	685,382	540,386
3.25% notes due 2033 – net	690,965	509,859	690,506	507,976
HUD mortgages – net	340,869	305,896	344,708	266,161
Total	<u>\$ 5,286,878</u>	<u>\$ 4,711,957</u>	<u>\$ 5,286,834</u>	<u>\$ 4,702,055</u>

Fair value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies in our Annual Report on [Form 10-K](#) for the year ended December 31, 2022). The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts.

The following methods and assumptions were used in estimating fair value disclosures for financial instruments.

- Real estate loans receivable: The fair value of the real estate loans receivables are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3).
- Non-real estate loans receivable: Non-real estate loans receivable are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3).

[Table of Contents](#)

- Revolving credit facility, OP term loan, 2023 term loan and 2024 term loan: The carrying amount of these approximate fair value because the borrowings are interest rate adjusted. Differences between carrying value and the fair value in the table above are due to the inclusion of deferred financing costs in the carrying value.
- Senior notes: The fair value of the senior unsecured notes payable was estimated based on (Level 1) publicly available trading prices.
- HUD mortgages: The fair value of our borrowings under HUD debt agreements are estimated using an expected present value technique based on quotes obtained by HUD debt brokers (Level 2).

NOTE 18 – COMMITMENTS AND CONTINGENCIES

Litigation

Shareholder Litigation

The Company and certain of its officers, *C. Taylor Pickett, Robert O. Stephenson, and Daniel J. Booth*, were named as defendants in a purported securities class action lawsuit in the U.S. District Court for the Southern District of New York (the “Securities Class Action”). Brought by lead plaintiff Royce Setzer and additional plaintiff Earl Holtzman, the Securities Class Action purported to assert claims for violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, as well as Section 20(a) of the Exchange Act, and sought monetary damages, interest, fees and expenses of attorneys and experts, and other relief. The Securities Class Action alleged that the defendants violated the Exchange Act by making materially false and/or misleading statements, and by failing to disclose material adverse facts about the Company’s business, operations, and prospects, including the financial and operating results of one of the Company’s operators, the ability of such operator to make timely rent payments, and the impairment of certain of the Company’s leases and the uncollectibility of certain receivables. The plaintiffs and defendants executed a stipulation of settlement dated December 9, 2022 (“Settlement”), which provided for dismissal and release of all claims against the defendants by a class of persons and/or entities who purchased or otherwise acquired Company securities from February 8, 2017 through October 31, 2017 without any admission of wrongdoing or liability on the part of the Company or the individual defendants. On April 25, 2023, following notice to class members and a hearing, the Court entered judgment approving the Settlement, which became effective May 25, 2023, upon the expiration of the period for appealing the Court’s judgment. Upon the effective date of the Settlement, the Settlement payment of \$30.75 million was permitted to be transmitted from an escrow account funded by the Company’s directors and officers insurers to a settlement fund to be distributed to class members by a third party administrator. In the second quarter of 2023, after the Company fulfilled all of its obligations pursuant to the Court-approved Settlement, the Company reversed the previously recorded \$31 million legal reserve, which was included within accrued expenses and other liabilities on the Consolidated Balance Sheets, and the related \$31 million receivable related to the insurance reimbursement, which was included within other assets on the Consolidated Balance Sheets.

Certain derivative actions have also been brought against the officers named in the Securities Class Action, and certain current and former directors of the Company, alleging claims relating to the matters at issue in the Securities Class Action.

In 2018, Stourbridge Investments LLC, a purported stockholder of the Company, filed a derivative action purportedly on behalf of the Company in the U.S. District Court for the Southern District of New York, alleging violations of Section 14(a) of the Exchange Act and state-law claims including breach of fiduciary duty. The complaint alleges, among other things, that the named defendants are responsible for the Company’s failure to disclose the financial condition of Orianna Health Systems, the alleged non-disclosures that were also the subject of the Securities Class Action described above. The plaintiff did not make a demand on the Company to bring the action prior to filing it, but rather alleges that demand would have been futile.

[Table of Contents](#)

In 2019, purported stockholder Phillip Swan by his counsel, and stockholders Tom Bradley and Sarah Smith by their counsel, filed derivative actions in the Baltimore City Circuit Court of Maryland, purportedly on behalf of the Company, asserting claims for breach of fiduciary duty, waste of corporate assets and unjust enrichment against the named defendants. Those actions were consolidated. Prior to filing suit, each of these stockholders had made demands on the Board of Directors in 2018 that the Company bring such lawsuits. After an investigation and due consideration, and in the exercise of its business judgment, the Board of Directors determined that it is not in the best interests of the Company to commence litigation against any current or former officers or directors based on the matters raised in the demands.

In addition, in late 2020, Robert Wojcik, a purported shareholder of the Company, filed a derivative action in the U.S. District Court for the District of Maryland, purportedly on behalf of the Company, asserting violations of Section 14(a) of the Exchange Act, Sections 10(b) and 21D of the Exchange Act, as well as claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. Wojcik also did not make a demand on the Company prior to filing suit.

Other

Gulf Coast Subordinated Debt

In August 2021, we filed suit in the Circuit Court for Baltimore County (the “Court”) against the holders of certain Subordinated Debt (the “Debt Holders”) associated with our Gulf Coast master lease agreement, following an assertion by the Debt Holders that our prior exercise of offset rights in connection with Gulf Coast’s non-payment of rent had resulted in defaults under the terms of the Subordinated Debt. The suit seeks a declaratory judgment to, among other items, declare that the aggregate amount of unpaid rent due from Gulf Coast under the master lease agreement exceeds all amounts which otherwise would be due and owing by an indirect subsidiary of Omega (“Omega Obligor”) under the Subordinated Debt, and that all principal and interest due and owing under the Subordinated Debt may be (and was) offset in full as of December 31, 2021. In October 2021, the Debt Holders filed a motion to dismiss for lack of personal jurisdiction. On November 3, 2022, the Court granted the Debt Holders’ motion to dismiss for lack of personal jurisdiction, and Omega filed a timely appeal of the ruling. While Omega believes Omega Obligor is entitled to the enforcement of the offset rights sought in the action, Omega cannot predict the outcome of the declaratory judgment action, irrespective of whether (a) it is ultimately litigated in the Court if Omega Obligor prevails in its appeal or (b) if the order granting the motion to dismiss for lack of personal jurisdiction is affirmed and the issues are litigated in the Delaware Court (as defined below).

On or about January 19, 2023, the Debt Holders served a lawsuit against the Omega Obligor in the Superior Court of the State of Delaware (the “Delaware Court”), asserting claims for (i) breach of the instruments evidencing the Subordinated Debt, (ii) declaratory judgment, and (iii) unjust enrichment, all claims that are factually based on the claims that are the subject of Omega Obligor’s suit in the Court and that are now on appeal. On February 8, 2023, Omega Obligor filed a motion to dismiss or, in the alternative, to stay this action pending the outcome of the above-referenced lawsuit in Maryland. On July 10, 2023, the Delaware state court case stayed the proceeding pending a hearing in September 2023. Omega believes that the claims are baseless and is evaluating procedural and substantive legal options in connection with this recently filed suit to the extent the stay is lifted.

Other

In addition to the matters above, we are subject to various other legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations.

Indemnification Agreements

In connection with certain facility transitions, we have agreed to indemnify certain operators in certain events. As of June 30, 2023, our maximum funding commitment under these indemnification agreements was approximately \$9.1 million. Claims under these indemnification agreements generally may be made within 18 months to 72 months of the transition date. These indemnification agreements were provided to certain operators in connection with facility transitions and generally would be applicable in the event that the prior operators do not perform under their transition agreements.

Commitments

We have committed to fund the construction of new leased and mortgaged facilities, capital improvements and other commitments. We expect the funding of these commitments to be completed over the next several years. Our remaining commitments at June 30, 2023, are outlined in the table below (in thousands):

Lessor construction and capital commitments under lease agreements	\$ 230,162
Non-real estate loan commitments	66,709
Other real estate loan commitments	48,803
Construction and capital expenditure mortgage loan commitments	8,036
Total remaining commitments ⁽¹⁾	\$ 353,710

(1) Includes finance costs.

NOTE 19 – EARNINGS PER SHARE

The following tables set forth the computation of basic and diluted earnings per share:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
	(in thousands, except per share amounts)			
Numerator:				
Net income available to common stockholders – basic	\$ 59,856	\$ 89,467	\$ 95,798	\$ 279,074
Add: net income attributable to OP Units	1,767	2,448	2,815	7,997
Net income available to common stockholders – diluted	<u>\$ 61,623</u>	<u>\$ 91,915</u>	<u>\$ 98,613</u>	<u>\$ 287,071</u>
Denominator:				
Denominator for basic earnings per share	236,233	235,847	235,594	237,687
Effect of dilutive securities:				
Common stock equivalents	2,893	707	2,139	835
Noncontrolling interest – Omega OP Units	6,974	6,772	6,912	6,919
Denominator for diluted earnings per share	<u>246,100</u>	<u>243,326</u>	<u>244,645</u>	<u>245,441</u>
Earnings per share – basic:				
Net income available to common stockholders	<u>\$ 0.25</u>	<u>\$ 0.38</u>	<u>\$ 0.41</u>	<u>\$ 1.17</u>
Earnings per share – diluted:				
Net income available to common stockholders	<u>\$ 0.25</u>	<u>\$ 0.38</u>	<u>\$ 0.40</u>	<u>\$ 1.17</u>

NOTE 20 – SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS

The following are supplemental disclosures to the Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022:

	<u>Six Months Ended June 30,</u>	
	<u>2023</u>	<u>2022</u>
	<u>(in thousands)</u>	
Reconciliation of cash and cash equivalents and restricted cash:		
Cash and cash equivalents	\$ 350,691	\$ 164,949
Restricted cash	5,820	3,515
Cash, cash equivalents and restricted cash at end of period	<u>\$ 356,511</u>	<u>\$ 168,464</u>
Supplemental information:		
Interest paid during the period, net of amounts capitalized	\$ 111,540	\$ 110,266
Taxes paid during the period	\$ 1,936	\$ 3,125
Non-cash investing activities:		
Non-cash acquisition of real estate	\$ —	\$ (9,818)
Non-cash financing activities:		
Non-cash contribution from noncontrolling member of consolidated joint venture	\$ —	\$ 2,903
Change in fair value of cash flow hedges	\$ (9,258)	\$ 63,668
Remeasurement of debt denominated in a foreign currency	\$ 1,096	\$ (6,128)

NOTE 21 – SUBSEQUENT EVENTS

On August 1, 2023, the Company repaid its \$350 million of 4.375% senior notes that matured on August 1, 2023 using available cash. The Company had \$350.7 million in cash and cash equivalents recorded on our Consolidated Balance Sheets as of June 30, 2023.

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements and Factors Affecting Future Results

Unless otherwise indicated or except where the context otherwise requires, the terms “we,” “us” and “our” and other similar terms in this Quarterly Report on Form 10-Q refer to Omega Healthcare Investors, Inc. and its consolidated subsidiaries.

The following discussion should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this document. This document contains “forward-looking statements” within the meaning of the federal securities laws. These statements relate to our expectations, beliefs, intentions, plans, objectives, goals, strategies, future events, performance and underlying assumptions and other statements other than statements of historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology including, but not limited to, terms such as “may,” “will,” “anticipates,” “expects,” “believes,” “intends,” “should” or comparable terms or the negative thereof. These statements are based on information available on the date of this filing and only speak as to the date hereof and no obligation to update such forward-looking statements should be assumed.

Our actual results may differ materially from those reflected in the forward-looking statements contained herein as a result of a variety of factors, including, among other things:

- (1) those items discussed under “Risk Factors” in Part I, Item 1A to our Annual Report on [Form 10-K](#) and Part II, Item 1A herein;
- (2) uncertainties relating to the business operations of the operators of our assets, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels;
- (3) the long-term impacts of the COVID-19 pandemic on our business and the business of our operators, including without limitation, the termination of the federally declared public health emergency and related government and regulatory support on May 11, 2023, the levels of staffing shortages, increased costs and decreased occupancy experienced by operators of skilled nursing facilities (“SNFs”) and assisted living facilities (“ALFs”) arising from the pandemic, the ability of our operators to comply with infection control and vaccine protocols and to manage facility infection rates or future infectious diseases, and the sufficiency of government support and reimbursement rates to offset such costs and the conditions related thereto;
- (4) the ability of our operators in bankruptcy to reject unexpired lease obligations, modify the terms of our mortgages and impede our ability to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor’s obligations, and other costs and uncertainties associated with operator bankruptcies;
- (5) our ability to re-lease, otherwise transition, or sell underperforming assets or assets held for sale on a timely basis and on terms that allow us to realize the carrying value of these assets;
- (6) the availability and cost of capital to us;
- (7) changes in our credit ratings and the ratings of our debt securities;
- (8) competition in the financing of healthcare facilities;
- (9) competition in the long-term healthcare industry and shifts in the perception of various types of long-term care facilities, including SNFs and ALFs;
- (10) additional regulatory and other changes in the healthcare sector;
- (11) changes in the financial position of our operators;
- (12) the effect of economic and market conditions generally and, particularly, in the healthcare industry;
- (13) changes in interest rates and the impact of inflation;
- (14) the timing, amount and yield of any additional investments;
- (15) changes in tax laws and regulations affecting real estate investment trusts (“REITs”);
- (16) the potential impact of changes in the SNF and ALF markets or local real estate conditions on our ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms;
- (17) our ability to maintain our status as a REIT; and
- (18) the effect of other factors affecting our business or the businesses of our operators that are beyond our or their control, including natural disasters, other health crises or pandemics and governmental action; particularly in the healthcare industry.

Summary

Our Management's Discussion and Analysis of Financial Condition and Results of Operations is organized as follows:

- Business Overview
- Outlook, Trends and Other Conditions
- Government Regulation and Reimbursement
- Second Quarter of 2023 and Recent Highlights
- Results of Operations
- Funds from Operations
- Liquidity and Capital Resources
- Critical Accounting Policies and Estimates

Business Overview

Omega Healthcare Investors, Inc. ("Parent") is a Maryland corporation that, together with its consolidated subsidiaries (collectively, "Omega" or "Company") has elected to be taxed as a REIT for federal income tax purposes. Omega is structured as an umbrella partnership REIT ("UPREIT") under which all of Omega's assets are owned directly or indirectly by, and all of Omega's operations are conducted directly or indirectly through, its operating partnership subsidiary, OHI Healthcare Properties Limited Partnership (collectively with its subsidiaries, "Omega OP"). As of June 30, 2023, Parent owned approximately 97% of the issued and outstanding units of partnership interest in Omega OP ("Omega OP Units"), and other investors owned approximately 3% of the outstanding Omega OP Units.

Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States ("U.S.") and the United Kingdom ("U.K."). Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on SNFs, ALFs, and to a lesser extent, independent living facilities ("ILFs"), rehabilitation and acute care facilities ("specialty facilities") and medical office buildings. Our core portfolio consists of our long-term leases and real estate loans with healthcare operating companies and affiliates (collectively, our "operators"). Real estate loans consist of mortgage loans and other real estate loans which are primarily collateralized by a first, second or third mortgage lien or a leasehold mortgage on, or an assignment of the partnership interest in the related properties. In addition to our core investments, we make loans to operators and/or their principals. These loans, which may be either unsecured or secured by the collateral of the borrower, are classified as non-real estate loans. From time to time, we also acquire equity interests in joint ventures or entities that support the long-term healthcare industry and our operators.

Outlook, Trends and Other Conditions

The COVID-19 pandemic significantly and adversely impacted SNFs and long-term care providers during the height of the pandemic due to the higher rates of virus transmission and fatality among the elderly and frail populations that these facilities serve; in addition, the pandemic contributed to occupancy declines, labor shortages and cost increases which continue to significantly impact our operators post-pandemic. As discussed further in "Collectibility Issues" below, during the year we have had several operators that have failed to make contractual payments under their lease and loan agreements, and we have agreed to short-term deferrals, lease and portfolio restructurings and/or allowed the application of security deposits or letters of credit to pay rent for several operators.

[Table of Contents](#)

We believe these operators were impacted by, among other things, reduced revenue as a result of lower occupancy, increased expenses, uncertainties regarding adequate reimbursement levels, and changes to government and regulatory support. The expense increases were offset to some extent by enhanced reimbursement due to skilling in place, which was permitted via waiver during the pandemic, but which was discontinued when the federally declared public health emergency expired on May 11, 2023. We believe the expense increases primarily stem from elevated labor costs, including increased use of overtime and bonus pay and reliance on agency staffing due to staffing shortages, as well as a significant increase in both the cost and usage of personal protective equipment, testing equipment and processes and supplies, as well as implementation of new infection control protocols and vaccination programs. In addition, operators who do not achieve full compliance with applicable infection control requirements may face potential survey issues and penalties. At this time, there is uncertainty regarding the ultimate impact of such developments.

We remain cautious as some of these factors may continue to have a significant impact on our operators and their financial conditions, particularly given the staffing shortages that continue to impact our operators' occupancy levels and profitability, uncertainty as to whether Medicare and Medicaid reimbursement rates will be sufficient to address longer-term cost increases faced by operators, uncertainty regarding pending U.S. federal minimum staffing rules for our industry, factors that may impact future virus transmission in our facilities, including vaccination rates and efficacy of the vaccine for staff members and residents at our facilities and the risk of future infectious diseases or pandemics.

Our facilities, on average, experienced declines, in some cases that are material, in occupancy levels as a result of the pandemic. Occupancy in our facilities has generally improved on average since early 2021; however, average occupancy has not returned to pre-pandemic levels. It remains unclear when and the extent to which demand and occupancy levels will return to pre-COVID-19 levels. We believe these challenges to occupancy recovery may be in part due to staffing shortages, which in some cases have required operators to limit admissions, as well as COVID-19 related fatalities at the facilities, the delay of SNF placement and/or utilization of alternative care settings for those with lower level of care needs, the suspension and/or postponement of elective hospital procedures, fewer discharges from hospitals to SNFs and higher hospital readmittances from SNFs.

While substantial government support was allocated to SNFs and to a lesser extent to ALFs in 2020, U.S. federal relief efforts have been limited since 2021 as have been relief efforts in certain states. The additional 6.2% Medicaid Federal Medical Assistance Percentage (the "FMAP") reimbursement enacted in connection with the pandemic is being phased out in 2023 pursuant to the Consolidated Appropriations Act of 2023. The additional 6.2% FMAP provided some of our operators with significant support, based on the state, and the phase-out of such support may adversely affect their operations to the extent that normal rate setting has not or does not adjust for this phase-out or expenses are not reduced. We believe further government support will be needed to continue to offset these impacts on operators, which could be in the form of direct support or reimbursement rate adjustments to reflect sustained cost changes experienced by operators. It is unclear whether and to what extent such government support or reimbursements will continue to be sufficient and timely to offset these impacts or whether pending U.S. federal minimum staffing rules, if not accompanied by additional government funding, will further increase expenses for our operators.

While certain states have provided pandemic-related relief measures, we expect such state relief measures to be limited going forward. Likewise, while certain states have in the course of routine rate-setting of Medicaid rates addressed inflationary factors and other expense-related items, there can be no assurance that these changes will be sufficient to offset existing increased inflation and expenses or that all states will address these items. See the "Government Regulation and Reimbursement" section for additional information. Further, to the extent the cost and occupancy impacts on our operators do not recover or are not offset by continued government relief or reimbursement rates that are sufficient and timely, we anticipate that the operating results of additional operators may be materially and adversely affected, some may be unwilling or unable to pay their contractual obligations to us in full or on a timely basis and we may be unable to restructure such obligations on terms as favorable to us as those currently in place.

There are a number of uncertainties we face as we consider the effects of the industry's recovery on our business, including how long census disruption and elevated costs will last, the continued management of infectious diseases in our facilities, and the extent to which reimbursement increases from the federal government, the states and the U.K. will continue to offset these incremental costs as well as lost revenues.

While we continue to believe that longer term demographics will drive increasing demand for needs-based skilled nursing care, we expect the uncertainties to our business described above to persist at least for the near term until we can gain more information as to the level of costs our operators will continue to experience, the duration of such increased costs, the adequacy of government reimbursement increases to cover such costs, the potential support our operators may request from us and the future demand for needs-based skilled nursing care and senior living facilities. We continue to monitor the rate of occupancy recovery at many of our operators, and it remains uncertain whether and when demand, staffing availability and occupancy levels will return to pre-COVID-19 levels.

In addition to the impacts of COVID-19 discussed above, our operators have been and are likely to continue to be adversely affected by labor shortages and increased labor costs, as well as other inflation-related cost increases.

We continue to monitor the impacts of other regulatory changes, as discussed below, including any significant limits on the scope of services reimbursed and on reimbursement rates and fees, which could have a material adverse effect on an operator's results of operations and financial condition, which could adversely affect the operator's ability to meet its obligations to us.

Government Regulation and Reimbursement

The following information supplements and updates, and should be read in conjunction with, the information contained under the caption Item 1. Business – Government Regulation and Reimbursement in our Annual Report on [Form 10-K](#) for the year ended December 31, 2022.

The healthcare industry is heavily regulated. Our operators, which are primarily based in the U.S., are subject to extensive and complex federal, state and local healthcare laws and regulations; we also have several U.K.-based operators that are subject to a variety of laws and regulations in their jurisdiction. These laws and regulations are subject to frequent and substantial changes resulting from the adoption of new legislation, rules and regulations, and administrative and judicial interpretations of existing law. The ultimate timing or effect of these changes, which may be applied retroactively, cannot be predicted. Changes in laws and regulations impacting our operators, in addition to regulatory non-compliance by our operators, can have a significant effect on the operations and financial condition of our operators, which in turn may adversely impact us. There is the potential that we may be subject directly to healthcare laws and regulations because of the broad nature of some of these regulations, such as the Anti-kickback Statute and False Claims Act, among others.

The U.S. Department of Health and Human Services (“HHS”) declared a public health emergency on January 31, 2020, following the World Health Organization's decision to declare COVID-19 a public health emergency of international concern. This declaration, which expired on May 11, 2023, allowed HHS to provide temporary regulatory waivers and new reimbursement rules, such as a temporary increase in the FMAP and other rules designed to equip providers with flexibility to respond to the COVID-19 pandemic by suspending various Medicare patient coverage criteria and documentation and care requirements, including, for example, suspension of the three-day prior hospital stay coverage requirement and expanding the list of approved services which may be provided via telehealth. The three-day prior hospital stay waiver was a significant benefit to the skilled nursing industry during the height of the pandemic, as the reimbursement associated with the ability to skill in place helped to offset some of the increased costs connected with managing the pandemic. These regulatory actions contributed to a change in census volumes and skilled nursing mix that may not otherwise have occurred. Following termination of the public health emergency declaration on May 11, 2023, we believe federal and state regulators have resumed enforcement of those regulations which have been waived or otherwise not been enforced during the public health emergency.

[Table of Contents](#)

These temporary changes to regulations and reimbursement, as well as emergency legislation, including the CARES Act enacted on March 27, 2020 and discussed below, have had a significant impact on the operations and financial condition of our operators. The extent of the COVID-19 pandemic's continued effect, including through prolonged labor shortages, slow occupancy recovery, and expense increases, on the Company's and our operators' operational and financial performance will depend on future developments, including the recovery in occupancy and availability of labor, the ability of our operators to manage the impact of the termination of public health emergency and temporary relief thereunder, the sufficiency and timeliness of additional governmental relief and reimbursement rate setting in offsetting cost increases, and the continued efficacy of infection control measures, all of which developments and impacts are uncertain and difficult to predict and may continue to adversely impact our business, results of operations, financial condition and cash flows.

A significant portion of our operators' revenue is derived from government-funded reimbursement programs, consisting primarily of Medicare and Medicaid. As federal and state governments continue to focus on healthcare reform initiatives, efforts to reduce costs by government payors will likely continue. Significant limits on the scope of services reimbursed and/or reductions of reimbursement rates could therefore have a material adverse effect on our operators' results of operations and financial condition. Additionally, new and evolving payor and provider programs that are tied to quality and efficiency could adversely impact our tenants' and operators' liquidity, financial condition or results of operations, and there can be no assurance that payments under any of these government healthcare programs are currently, or will be in the future, sufficient to fully reimburse the property operators for their operating and capital expenses. In addition to quality and value-based reimbursement reforms, the U.S. Centers for Medicare and Medicaid Services ("CMS") has implemented a number of initiatives focused on the reporting of certain facility specific quality of care indicators that could affect our operators, including publicly released quality ratings for all of the nursing homes that participate in Medicare or Medicaid under the CMS "Five Star Quality Rating System." Facility rankings, ranging from five stars ("much above average") to one star ("much below average") are updated on a monthly basis. SNFs are required to provide information for the CMS Nursing Home Compare website regarding staffing and quality measures. These rating changes have impacted referrals to SNFs, and it is possible that changes to this system or other ranking systems could lead to future reimbursement policies that reward or penalize facilities on the basis of the reported quality of care parameters.

The following is a discussion of certain U.S. laws and regulations generally applicable to our operators, and in certain cases, to us.

Reimbursement Changes Related to COVID-19:

U.S. Federal Stimulus Funds and Financial Assistance for Healthcare Providers. In response to the pandemic, Congress enacted a series of economic stimulus and relief measures. On March 18, 2020, the Families First Coronavirus Response Act ("FFCRA") was enacted in the U.S., providing a temporary 6.2% increase to each qualifying state and territory's FMAP effective January 1, 2020, which expired on May 11, 2023 in connection with the expiration of the public health emergency. In exchange for receiving the enhanced federal funding, the FFCRA included a requirement that Medicaid programs keep beneficiaries enrolled through the end of the month in which the public health emergency terminates. However, as part of the Consolidated Appropriations Act of 2023 signed into law on December 29, 2022, Congress decoupled the Medicaid continuous enrollment from the public health emergency and terminated this provision effective March 31, 2023. Additionally, starting April 1, 2023, states that complied with federal rules regarding conducting renewals were eligible to begin the phase-down of the enhanced federal funding according to the following schedule: 6.2 percentage points through March 2023; 5 percentage points through June 2023; 2.5 percentage points through September 2023 and 1.5 percentage points through December 2023. States cannot restrict eligibility standards, methodologies, and procedures and states cannot increase premiums as required in FFCRA. Primarily due to the continuous enrollment provision, Medicaid enrollment has grown substantially compared to before the pandemic and the uninsured rate has dropped. The extent to which this increase in Medicaid enrollment is sustained following the discontinuation of the continuous enrollment provision is uncertain.

In further response to the pandemic, the CARES Act authorized approximately \$178 billion to be distributed through the Provider Relief Fund to reimburse eligible healthcare providers for healthcare related expenses or lost revenues that were attributable to coronavirus; in addition, the American Rescue Plan Act authorized \$8.5 billion for rural providers with Medicaid and Medicare patients. Funds were generally allocated beginning in 2020 in targeted and general distributions, the latter over four phases. The Provider Relief Fund was administered under the broad authority and discretion of HHS and recipients were not required to repay distributions received to the extent they were used in compliance with applicable requirements. We do not expect our operators will receive additional funding from HHS in connection with the pandemic.

The CARES Act and related legislation also made other forms of financial assistance available to healthcare providers, which impacted our operators to varying degrees. This assistance included Medicare and Medicaid payment adjustments and an expansion of the Medicare Accelerated and Advance Payment Program, which made available accelerated payments of Medicare funds in order to increase cash flow to providers. These payments were loans that providers were scheduled to repay over a period of several years beginning one year from the issuance date of each provider's or supplier's accelerated or advance payment. We believe these repayments commenced for many of our operators in April 2021 and impacted operating cash flows of these operators in 2021 and 2022. While not limited to healthcare providers, the CARES Act additionally provided payroll tax relief for employers, allowing them to defer payment of employer Social Security taxes that were otherwise owed for wage payments made after March 27, 2020 through December 31, 2020 to December 31, 2021 with respect to 50% of the payroll taxes owed, with the remaining 50% deferred until December 31, 2022.

The Budget Control Act of 2011 established a Medicare Sequestration of 2%, which is an automatic reduction of certain federal spending as a budget enforcement tool. Originally, the sequester was supposed to be in effect from FY 2013 to FY 2021. However, most recently, the Infrastructure Investment and Jobs Act extended the sequester through FY 2031. Additional legislation, including the CARES Act and the Protecting Medicare and American Farmers Act, suspended the application of the sequester to Medicare from May 1, 2020 through March 30, 2022. It also limited Medicare reductions to 1% from April 1, 2022 through June 30, 2022. The full 2% Medicare sequestration went into effect as of July 1, 2022. The sequestration is currently extended through fiscal year 2031, and gradually increases to 4% from 2030 through 2031.

Quality of Care Initiatives and Additional Requirements Related to COVID-19. In addition to COVID-19 reimbursement changes, several regulatory initiatives announced from 2020 to 2022 focused on addressing quality of care in long-term care facilities, including those related to COVID-19 testing and infection control protocols, vaccine protocols, staffing levels, reporting requirements, and visitation policies, as well as increased inspection of nursing homes. In addition, the Nursing Home Care website and the Five Star Quality Rating System were updated to include revisions to the inspection process, adjustment of staffing rating thresholds, the implementation of new quality measures and the inclusion of a staff turnover percentage (over a 12-month period). Although the American Rescue Plan Act did not allocate specific funds directly to SNF or ALF providers, certain funds were allocated to states who then distributed a portion of these funds to SNF and ALF providers.

Additionally, in March 2022, the Biden Administration announced a focus on implementing minimum staffing requirements and increased inspections at nursing homes, and in July 2022, CMS announced it was evaluating a proposed federal staffing mandate for SNFs. It is uncertain when such a mandate will be announced or become effective, what level of staffing would be required thereunder, and whether any such mandate would be accompanied by additional funding to offset any increased staffing requirements for our operators. Depending on the level of staffing required, an unfunded mandate to increase staff in SNFs may have a material and adverse impact on the financial condition of our operators. Of note, the Biden Administration issued an executive order on April 18, 2023 that directed HHS to consider issuing several regulations and guidance documents to build on the minimum staffing standards for nursing homes and condition a portion of Medicare payments on how well a nursing home retains workers. Many questions surrounding the potential execution of these proposed actions, such as how Medicare rates will exactly be impacted if nursing homes fail to retain a certain level of workers, remained unanswered, particularly in light of CMS still considering the above-referenced federal minimum staffing standard.

[Table of Contents](#)

On June 16, 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis announced the launch of an investigation into the COVID-19 response of nursing homes and the use of federal funds by nursing homes during the pandemic. The Select Subcommittee continued to be active throughout the remainder of 2020, 2021 and 2022. In March 2021, the Oversight Subcommittee of the House Ways and Means Committee held a hearing on examining the impact of private equity in the U.S. healthcare system, including the impact on quality of care provided within the skilled nursing industry. The Biden Administration additionally announced in March 2022 a focus on reviewing private equity investment specifically in the skilled nursing sector. Further, on February 13, 2023, CMS issued a proposed rule that would require SNFs participating in the Medicare or Medicaid programs to disclose certain information regarding entities such as REITs that lease real estate to SNFs. The CMS announcement noted concerns regarding the quality of care provided at SNFs owned by private equity firms, REITs and other investment firms. These initiatives, as well as additional calls for government review of the role of private equity in the U.S. healthcare industry, could result in additional requirements on our operators.

Reimbursement Generally:

Medicaid. Most of our SNF operators derive a substantial portion of their revenue from state Medicaid programs. Whether and to what extent the level of Medicaid reimbursement covers the actual cost to care for a Medicaid eligible resident varies by state. While periodic rate setting occurs and, in most cases, has an inflationary component, the state rate setting process does not always keep pace with inflation or, even if it does, there is a risk that it may still not be sufficient to cover all or a substantial portion of the cost to care for Medicaid eligible residents. Additionally, rate setting is also subject to changes based on state budgetary constraints and political factors, both of which could result in decreased or insufficient reimbursement to the industry even in an environment where costs are rising. Since our operators' profit margins on Medicaid patients are generally relatively low, more than modest reductions in Medicaid reimbursement or an increase in the percentage of Medicaid patients has in the past, and may in the future, adversely affect our operators' results of operations and financial condition, which in turn could adversely impact us.

The CARES Act and American Rescue Plan Act contained several provisions designed to increase coverage, expand benefits, and adjust federal financing for state Medicaid programs. While the CARES Act provided for a 6.2% FMAP add-on to the Medicaid program during the public health emergency, only certain states passed any of that specifically on to SNF operators either via an enhanced rate or lump sum payments. Additionally, the American Rescue Plan Act provided for a 10% FMAP add-on for state home and community-based service expenditures from April 1, 2021 through March 30, 2022 in an effort to assist seniors and people with disabilities to receive services safely in the community rather than in nursing homes and other congregate care settings. Both of these programs came with conditions that states had to meet to be eligible for the FMAP add-on. There may be future initiatives proposed to allocate funding available for reimbursement away from SNFs in favor of home health agencies and community-based care.

The risks of insufficient Medicaid reimbursement rates along with possible initiatives to push residents historically cared for in SNFs to alternative settings may impact us more acutely in states where we have a larger presence, including Florida and Texas, our states with the largest concentration of investments. In Texas several of our operators have historically experienced lower operating margins on their SNFs, as compared to other states, as a result of lower Medicaid reimbursement rates and higher labor costs. The state did provide for a sizeable increase in rate during the public health emergency based on the FMAP add-on. The Medicaid reimbursement rate has been approved to be increased effective September 1, 2023 by at least that same amount. In Florida, added support to our operators during the pandemic was generally limited, with approximately \$100 million in additional FMAP funds announced in November 2021, payable over a three-month period through increased Medicaid rates. A revised state budget for 2023-2024 has been approved, which increases Medicaid reimbursement rates, effective October 1, 2023, by up to 5%, with a portion of such rate relating to a quality care add-on. This comes after a 7.8% increase effective October 1, 2022, which was somewhat offset by required increased wages for certain nursing home staff. In addition, on April 6, 2022, the State of Florida enacted staffing reforms for SNFs that may provide additional flexibility to our operators in meeting minimum staffing requirements by using supplemental staff. We continue to monitor rate adjustment activity in other states in which we have a meaningful presence; however, it is difficult to assess whether rates will generally keep pace with increased operator costs.

Medicare. On July 31, 2023, CMS issued a final rule regarding the government fiscal year 2024 Medicare payment rates and quality payment programs for SNFs, with aggregate Medicare Part A payments projected to increase by \$1.4 billion, or 4.0%, for fiscal year 2024 compared to fiscal year 2023. This estimated reimbursement increase is attributable to a 6.4% net market basket update to the payment rates, which is based on a 3.0% SNF market basket increase plus a 3.6% market basket forecast error adjustment and less a 0.2% productivity adjustment, as well as a negative 2.3%, or approximately \$789 million, decrease in the fiscal year 2024 SNF Medicare payment rates as a result of the second phase of the Patient Driven Payment Model (“PDPM”) parity adjustment recalibration described below, which was being phased in over two years. The annual update is reduced by two percentage points for SNFs that fail to submit required quality data to CMS under the SNF Quality Reporting Program. CMS has indicated that these impact figures did not incorporate the SNF Value-Based Program reductions that are estimated to be \$185 million in fiscal year 2024. While Medicare reimbursement rate setting, which takes effect annually each October, has historically included forecasted inflationary adjustments, the degree to which those forecasts accurately reflect current inflation rates remains uncertain. Additionally, it remains uncertain whether these adjustments will ultimately be offset by non-inflationary factors, including any adjustments related to the impact of various payment models, such as those described below.

Payments to providers continue to be increasingly tied to quality and efficiency. The PDPM, which was designed by CMS to improve the incentives to treat the needs of the whole patient, became effective October 1, 2019. CMS has stated that it intended PDPM to be revenue-neutral to operators, with future Medicare reimbursement reductions possible if that was not the case. In April 2022, CMS issued a proposal for comment, which included an adjustment to obtain that revenue neutrality as early as the 2023 rate setting period. After considering the feedback received in the rulemaking cycle, CMS finalized recalibration of the PDPM parity adjustment factor of 4.6% with a two-year phase-in period that would reduce SNF spending by 2.3%, or approximately \$780 million, in each of fiscal years 2023 and 2024. Prior to COVID-19, we believed that certain of our operators could realize efficiencies and cost savings from increased concurrent and group therapy under PDPM and some had reported early positive results. During the COVID-19 pandemic, many operators were restricted from pursuing concurrent and group therapy and unable to realize these benefits. Additionally, our operators continue to adapt to the reimbursement changes and other payment reforms resulting from the value-based purchasing programs applicable to SNFs under the 2014 Protecting Access to Medicare Act. These reimbursement changes have had and may, together with any further reimbursement changes to PDPM or value-based purchasing models, in the future have an adverse effect on the operations and financial condition of some operators and could adversely impact the ability of operators to meet their obligations to us.

On May 27, 2020, CMS added physical therapy, occupational therapy and speech-language pathology to the list of approved telehealth Providers for the Medicare Part B programs provided by a SNF as a part of the COVID-19 1135 waiver provisions. The COVID-19 1135 waiver provisions also allowed for the facility to bill an originating site fee to CMS for telehealth services provided to Medicare Part B beneficiary residents of the facility when the services were provided by a physician from an alternate location, effective March 6, 2020 through May 11, 2023, the expiration of the public health emergency.

On March 30, 2023, CMS issued a memorandum revising and enhancing enforcement efforts for infection control deficiencies found in nursing homes that are targeted at higher-level infection control deficiencies that result in actual harm or immediate jeopardy to residents. Penalties for the most serious deficiencies include civil monetary penalties and discretionary payment denials for new resident admissions.

Other Regulation:

Office of the Inspector General Activities. The Office of Inspector General (“OIG”) of HHS has provided long-standing guidance for SNFs regarding compliance with federal fraud and abuse laws. More recently, the OIG has conducted increased oversight activities and issued additional guidance regarding its findings related to identified problems with the quality of care and the reporting and investigation of potential abuse or neglect at group homes, nursing homes and SNFs. The OIG has additionally reviewed the staffing levels reported by SNFs as part of its August 2018 and February 2019 Work Plan updates, and included a review of involuntary transfers and discharges from nursing homes in the June 2019 Work Plan updates. In August 2020, the OIG released its findings regarding its review of staffing levels in SNFs from 2018. The OIG recommended that CMS enhance efforts to ensure nursing homes meet daily staffing requirements and explore ways to provide consumers with additional information on nursing homes’ daily staffing levels and variability. The OIG indicated that while the review was initiated before the COVID-19 pandemic emerged, the pandemic reinforces the importance of sufficient staffing for nursing homes, as inadequate staffing can make it more difficult for nursing homes to respond to infectious disease outbreaks like COVID-19. It is unknown what impact, if any, enhanced scrutiny of staffing levels by OIG and CMS will have on our operators.

Department of Justice and Other Enforcement Actions. SNFs are under intense scrutiny for ensuring the quality of care being rendered to residents and appropriate billing practices conducted by the facility. The Department of Justice (“DOJ”) has historically used the False Claims Act to civilly pursue nursing homes that bill the federal government for services not rendered or care that is grossly substandard. For example, California prosecutors announced in March 2021 an investigation into a skilled nursing provider that is affiliated with one of our operators, alleging the chain manipulated the submission of staffing level data in order to improve its Five Star rating. In 2020, the DOJ launched a National Nursing Home Initiative to coordinate and enhance civil and criminal enforcement actions against nursing homes with grossly substandard deficiencies. Such enforcement activities are unpredictable and may develop over lengthy periods of time. An adverse resolution of any of these enforcement activities or investigations incurred by our operators may involve injunctive relief and/or substantial monetary penalties, either or both of which could have a material adverse effect on their reputation, business, results of operations and cash flows.

Second Quarter of 2023 and Recent Highlights

Investments

- During the three and six months ended June 30, 2023, we acquired five facilities and 11 facilities for an aggregate consideration of \$128.6 million and \$155.0 million, respectively. The initial cash yield (the initial annual contractual cash rent divided by the purchase price) on these asset acquisitions was between 8.0% and 10.0%.
- We invested \$17.8 million and \$27.9 million under our construction in progress and capital improvement programs during the three and six months ended June 30, 2023, respectively.
- We financed \$78.9 million and \$83.9 million of new real estate loans with a weighted average interest rate of 11.8% and 11.6% during the three and six months ended June 30, 2023, respectively. We also advanced \$5.5 million and \$16.2 million under existing real estate loans during the three and six months ended June 30, 2023, respectively.

Dispositions and Impairments

- During the three and six months ended June 30, 2023, we sold ten facilities (nine SNFs and one ILF) and twelve facilities (ten SNFs, one ILF and one medical office building) for approximately \$44.7 million and \$62.3 million in net cash proceeds, recognizing net gains of approximately \$12.2 million and \$25.9 million, respectively.

[Table of Contents](#)

- During the three and six months ended June 30, 2023, we recorded impairments on four facilities and six facilities of approximately \$21.1 million and \$60.1 million, respectively. Of the \$60.1 million recorded impairment, \$57.5 million related to four facilities that were classified as held-for-use for which the carrying values exceeded the estimated fair values, and \$2.6 million related to two held for sale facilities for which it was determined that the carrying value exceeded the fair value less costs to sell.

Financing Activities

- During the three and six months ended June 30, 2023, we sold 6.6 million and 6.7 million shares of common stock under our \$1.0 billion At-The-Market Offering Program (“ATM Program”) and Dividend Reinvestment and Common Stock Purchase Plan (“DRSPP”), generating aggregate gross proceeds of \$201.6 million and \$203.9 million, respectively.
- During the second quarter of 2023, we terminated our five forward starting swaps with \$400 million in notional value that were designated cash flow hedges of interest rate risk associated with interest payments on a forecasted issuance of fixed rate long-term debt, and we received a \$92.6 million net cash settlement from the swap counterparties.
- During the second quarter of 2023, we entered into an interest rate swap with a notional amount of \$50.0 million. The swap is effective June 30, 2023 and terminates on April 30, 2027. This interest rate swap is designated as a hedge against our exposure to changes in interest payment cash flow fluctuations in the variable interest rates on the OP term loan. The interest rate swap contract effectively converts our \$50.0 million OP term loan to an aggregate fixed rate of approximately 5.52% through its maturity.
- On August 1, 2023, the Company repaid its \$350 million of 4.375% senior notes that matured on August 1, 2023 using available cash.

Other Highlights

- We made \$62.0 million and \$72.4 million of new non-real estate loans with a weighted average interest rate of 11.4% and 10.6% during the three and six months ended June 30, 2023, respectively. We also advanced \$5.0 million under existing non-real estate loans during the three and six months ended June 30, 2023.

Collectibility Issues

- During the three and six months ended June 30, 2023, we placed two new operators, which Omega has not previously had relationships with prior to the second quarter of 2023, on a cash basis of revenue recognition as collection of substantially all contractual lease payments due from them was not deemed probable. The new lease agreements with each of these operators were executed in the second quarter of 2023 as part of transitions of facilities from other operators, and we placed them on a cash basis concurrent with the respective lease commencement dates, so there were no straight-line rent write-offs associated with moving these operators to cash basis. During the three and six months ended June 30, 2023, we transitioned the portfolios of one and four cash basis operators, respectively, with an aggregate of five facilities and 48 facilities, respectively, to leases with operators on a straight-line basis of revenue recognition. As of June 30, 2023, 18 operators are on a cash basis. These operators represent an aggregate 25.8% and 32.3% of our total revenues (excluding the impact of write-offs) for the six months ended June 30, 2023 and 2022, respectively.

[Table of Contents](#)

- During the six months ended June 30, 2023, we allowed nine operators to defer \$33.6 million in aggregate of contractual rent and interest. The deferrals primarily related to the following operators: LaVie Care Centers, LLC (“LaVie,” f/k/a Consulate Health Care) (\$19.0 million), Healthcare Homes Limited (\$8.2 million), Agemo Holdings, LLC (“Agemo”) (\$1.9 million) and Maplewood Senior Living (along with affiliates, “Maplewood”) (\$0.7 million). Additionally, we allowed four operators to apply collateral, such as security deposits or letters of credit, to contractual rent and interest during the six months ended June 30, 2023. The total collateral applied to contractual rent and interest was \$5.5 million for the six months ended June 30, 2023.
- In the first quarter of 2023, Omega and Agemo, a cash basis operator, entered into a restructuring agreement, an amended and restated master lease and a new loan agreement for two replacement loans. As part of the restructuring agreement and related agreements, Omega agreed to, among other things, forgive and release Agemo from previously written off past due rent and interest obligations, with contractual rent and interest scheduled to resume on April 1, 2023, reduce monthly contractual base rent from \$4.8 million to \$1.9 million, extend the initial Agemo lease term to December 31, 2036 and modify the existing Agemo loans into two replacement loans. Agemo resumed making contractual rent payments during the second quarter of 2023 in accordance with the restructuring terms discussed above. Agemo is on a cash basis of revenue recognition for lease purposes, and we recorded rental income of \$5.8 million for the three and six months ended June 30, 2023 for the contractual rent payments that were received. Additionally, Agemo’s loans are on non-accrual status and are being accounted for under the cost recovery method, so the \$0.8 million of interest payments that we received during the three and six months ended June 30, 2023 were applied directly against the principal balance outstanding.
- In the first quarter of 2023, Omega continued the process of restructuring our portfolio with LaVie and agreed to a partial rent deferral for the first four months of 2023. In doing so, we agreed to allow LaVie to defer up to \$19.1 million of contractual rent from January 2023 through April 2023 under our lease agreements. As a result, during the three and six months ended June 30, 2023, LaVie paid \$16.9 million and \$24.3 million, respectively, of contractual rent due under the leases and elected to defer the remaining \$4.7 million and \$19.0 million, respectively, of the full contractual payment due of \$21.6 million and \$43.4 million, respectively. In July 2023, LaVie paid \$2.5 million of contractual rent, a short pay of \$4.7 million of the \$7.2 million due under its lease agreement.
- In the first quarter of 2023, we entered into a restructuring agreement, master lease amendments and loan amendments with Maplewood, a cash basis operator. As part of the restructuring agreement and related agreements, Omega agreed to, among other things, extend the maturity date of the master lease to December 2037, fix contractual rent at \$69.3 million per annum and defer the 2.5% annual escalators under our lease agreement through December 31, 2035, pay a \$12.5 million option termination fee to Maplewood, extend the maturity date of the secured revolving credit facility to June 2035, increase the capacity of the secured revolving credit facility to \$320.0 million and convert the 7% per annum cash interest due on the secured revolving credit facility to all PIK interest in 2023, 1% cash interest and 6% PIK interest in 2024, and 4% cash interest and 3% PIK interest in 2025 and through the maturity date. Additionally, we agreed to reduce Maplewood’s share of any future potential sales proceeds (in excess of our gross investment) by the unpaid deferred rent balance, the \$22.5 million of capital expenditures granted through the restructuring agreement and the \$12.5 million option termination fee payment. Maplewood short-paid the contractual rent amount due under its lease agreement in June 2023 and July 2023 by \$1.0 million each. We are taking actions to preserve our rights and are in discussions with Maplewood to address the deficiency. We have recorded \$16.3 million and \$35.1 million of revenue related to Maplewood for the three and six months ended June 30, 2023, respectively, for the contractual rent and interest payments that we received. During the third quarter of 2023, we applied \$2.0 million of Maplewood’s security deposit toward the unpaid portion of June 2023 rent and July 2023 rent. Following the application of the security deposit, we have a \$2.8 million security deposit remaining.

[Table of Contents](#)

Dividends

- On July 20, 2023, the Board of Directors declared a cash dividend of \$0.67 per share. The dividend will be paid on August 15, 2023 to stockholders of record as of the close of business on July 31, 2023.

Results of Operations

The following is our discussion of the consolidated results of operations, financial position and liquidity and capital resources, which should be read in conjunction with our unaudited consolidated financial statements and accompanying notes.

Comparison of results of operations for the three and six months ended June 30, 2023 and 2022 (dollars in thousands):

	Three Months Ended			Six Months Ended		
	June 30,		Increase/ (Decrease)	June 30,		Increase/ (Decrease)
	2023	2022		2023	2022	
Revenues:						
Rental income	\$ 219,101	\$ 211,428	\$ 7,673	\$ 408,178	\$ 428,311	\$ (20,133)
Income from direct financing leases	254	256	(2)	508	512	(4)
Interest income	29,232	31,374	(2,142)	57,652	62,517	(4,865)
Miscellaneous income	1,600	1,591	9	2,051	2,624	(573)
Expenses:						
Depreciation and amortization	82,018	83,207	(1,189)	163,210	165,959	(2,749)
General and administrative	22,158	18,775	3,383	42,684	35,160	7,524
Real estate taxes	3,925	3,717	208	7,922	7,320	602
Acquisition, merger and transition related costs	423	3,960	(3,537)	1,062	5,473	(4,411)
Impairment on real estate properties	21,114	7,695	13,419	60,102	11,206	48,896
Provision (recovery) for credit losses	12,967	(1,563)	14,530	8,910	261	8,649
Interest expense	58,776	58,372	404	117,322	116,517	805
Other income (expense):						
Other income (expense) – net	1,029	(4,407)	5,436	3,749	(4,862)	8,611
Loss on debt extinguishment	—	(7)	7	(6)	(13)	7
Gain on assets sold – net	12,243	25,180	(12,937)	25,880	138,817	(112,937)
Income tax (expense) benefit	(1,626)	(1,119)	(507)	(334)	(2,344)	2,010
Income from unconsolidated joint ventures	1,069	1,782	(713)	1,900	3,405	(1,505)

Three Months Ended June 30, 2023 and 2022

Revenues

The following is a description of certain of the changes in revenues for the three months ended June 30, 2023 compared to the same period in 2022:

- The increase in rental income was primarily the result of (i) a \$9.5 million increase as a result of a net decrease in straight-line rent receivable write-offs in the second quarter of 2023, (ii) a \$7.1 million increase related to facility acquisitions made throughout 2022 and in the first and second quarters of 2023, (iii) a \$2.3 million increase due to higher capital expenditure rent and the impact of lease extensions with existing operators and (iv) a \$1.0 million net increase related to impact of facility transitions and sale, partially offset by a \$12.0 million net decrease in rental income from cash basis operators, including Maplewood and LaVie, as a result of not recording straight-line lease revenue and/or receiving lower cash rent payments period over period from these operators

[Table of Contents](#)

- The decrease in interest income was primarily due to (i) a \$4.9 million decrease related to loans placed on non-accrual status, primarily the LaVie loans and the Maplewood loan, during 2022 and (ii) a \$4.0 million decrease related to early principal payments on our mortgage loans with Ciena Healthcare during 2022 and the pay-off of other loans during 2022 and the first and second quarters of 2023, partially offset by a \$6.8 million increase related to new and refinanced loans and additional funding to existing operators made throughout 2022 and the first and second quarters of 2023. As noted above, during the three months ended June 30, 2023, we funded \$84.4 million in new or existing real estate loans and \$67.0 million in new or existing non-real estate loans.

Expenses

The following is a description of certain of the changes in our expenses for the three months ended June 30, 2023 compared to the same period in 2022:

- The decrease in depreciation and amortization expense primarily relates to facility sales and facilities reclassified to assets held-for-sale, partially offset by facility acquisitions and capital additions.
- The increase in general and administrative (“G&A”) expense primarily relates to a \$2.0 million increase in stock-based compensation expense.
- The decrease in acquisition, merger and transition related costs primarily relates to costs incurred related to the transition of facilities with troubled operators in 2022.
- The 2023 impairments were recognized in connection with one facility that was classified as held for sale for which the carrying values exceeded the estimated fair values less costs to sell and three held-for-use facilities for which it was determined that the carrying value exceeded the fair value. The 2022 impairments were recognized in connection with four held-for-use facilities for which the carrying values exceeded the fair value. The 2023 and 2022 impairments were primarily the result of the closure of certain facilities and decisions to exit certain non-strategic facilities and/or terminate our relationships with certain non-strategic operators.
- The change in provision for credit losses primarily relates to increases in the general reserve recorded primarily resulting from increases in loan balances and movements in other inputs utilized in our model, partially offset by (i) a net decrease in aggregate specific provisions recorded during the second quarter of 2023 compared to specific provisions recorded during the same period in 2022 and (ii) decreases in loss rates utilized in the estimate of expected credit losses for loans.

Other Income (Expense)

The change in total other income (expense) was primarily due to a \$12.9 million decrease in gain on assets sold related to the sale of ten facilities in the second quarter of 2023 compared to the sale of 13 facilities during the same period in 2022.

[Table of Contents](#)

Six Months Ended June 30, 2023 and 2022

Revenues

The following is a description of certain of the changes in revenues for the six months ended June 30, 2023 compared to the same period in 2022:

- The decrease in rental income was primarily the result of a \$46.3 million net decrease in rental income from cash basis operators, including Maplewood and LaVie, as a result of not recording straight-line lease revenue and/or receiving lower cash rent payments period over period from these operators, along with a one-time option termination payment of \$12.5 million to Maplewood that was recorded as a reduction to rental income during the second quarter of 2023. The overall decrease in rental income was partially offset by (i) a \$12.7 million increase as a result of fewer straight-line rent receivable write-offs in the first and second quarters of 2023, (ii) a \$11.6 million increase related to facility acquisitions made throughout 2022 and in the first and second quarters of 2023 and (iii) a \$1.2 million net increase due to higher capital expenditure rent and the impact of lease extensions with existing operators, along with other movements.
- The decrease in interest income was primarily due to (i) a \$9.4 million decrease related to early principal payments on our mortgage loans with Ciena Healthcare during 2022 and the pay-off of other loans during 2022 and the first and second quarters of 2023 and (ii) a \$7.5 million decrease related to loans placed on non-accrual status, primarily the LaVie loans and Maplewood loan, during 2022, partially offset by a \$12.2 million increase related to new and refinanced loans and additional funding to existing operators made throughout 2022 and the first and second quarters of 2023. As noted above, during the six months ended June 30, 2023, we funded \$100.1 million in new or existing real estate loans and \$77.4 million in new or existing non-real estate loans.

Expenses

The following is a description of certain of the changes in our expenses for the six months ended June 30, 2023 compared to the same period in 2022:

- The decrease in depreciation and amortization expense primarily relates to facility sales and facilities reclassified to assets held for sale, partially offset by facility acquisitions and capital additions.
- The increase in G&A expense primarily relates to (i) a \$3.8 million increase in stock-based compensation expense, (ii) a \$1.3 million increase in payroll and benefits and (iii) a \$0.9 million increase in outside services primarily related to professional fees.
- The decrease in acquisition, merger and transition related costs primarily relates to costs incurred related to the transition of facilities with troubled operators.
- The 2023 impairments were recognized in connection with two facilities that were classified as held for sale for which the carrying values exceeded the estimated fair values less costs to sell and four held-for-use facilities for which it was determined that the carrying value exceeded the fair value. The 2022 impairments were recognized in connection with two facilities that were classified as held for sale for which the carrying values exceeded the estimated fair values less costs to sell and four held-for-use facilities for which the carrying value exceeded the fair value. The 2023 and 2022 impairments were primarily the result of decisions to exit certain non-strategic facilities and/or terminate our relationships with certain non-strategic operators.
- The change in provision for credit losses primarily relates to (i) increases in the general reserve recorded primarily resulting from increases in loan balances and movements in other inputs utilized in our model and (ii) a net increase in aggregate specific provisions recorded during the second quarter of 2023 compared to specific provisions recorded during the same period in 2022, partially offset by decreases in loss rates utilized in the estimate of expected credit losses for loans.

[Table of Contents](#)

Other Income (Expense)

The change in total other income (expense) was primarily due to a \$112.9 million decrease in gain on assets sold related to the sale of 12 facilities in the six months ended June 30, 2023 compared to the sale of 40 facilities, primarily associated with our exit of the facilities associated with Gulf Coast Health Care LLC (together with certain affiliates “Gulf Coast”), during the same period in 2022.

Income Tax (Expense) Benefit

The change in income tax (expense) benefit was primarily due to adjustments made to our deferred tax assets and liabilities in the second quarter of 2023 as a result of the majority of our U.K. portfolio entering into the U.K. REIT regime effective April 1, 2023.

Funds from Operations

We use funds from operations (“Nareit FFO”), a non-GAAP financial measure, as one of several criteria to measure the operating performance of our business. We calculate and report Nareit FFO in accordance with the definition of Funds from Operations and interpretive guidelines issued by the National Association of Real Estate Investment Trusts (“Nareit”). Nareit FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairment on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures and changes in the fair value of warrants. Adjustments for unconsolidated partnerships and joint ventures are calculated to reflect funds from operations on the same basis. Revenue recognized based on the application of security deposits and letters of credit or based on the ability to offset against other financial instruments is included within Nareit FFO. We believe that Nareit FFO is an important supplemental measure of our operating performance. As real estate assets (except land) are depreciated under GAAP, such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. Nareit FFO was designed by the real estate industry to address this issue. Nareit FFO herein is not necessarily comparable to Nareit FFO of other REITs that do not use the same definition or implementation guidelines or interpret the standards differently from us.

We further believe that by excluding the effect of depreciation, amortization, impairment on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, Nareit FFO can facilitate comparisons of operating performance between periods. We offer this measure to assist the users of our financial statements in evaluating our financial performance under GAAP, and Nareit FFO should not be considered a measure of liquidity or cash flow, an alternative to net income or an indicator of any other performance measure determined in accordance with GAAP. Investors and potential investors in our securities should not rely on this measure as a substitute for any GAAP measure, including net income.

[Table of Contents](#)

The following table presents our Nareit FFO results for the three and six months ended June 30, 2023 and 2022:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
	(in thousands)		(in thousands)	
Net income ⁽¹⁾	\$ 61,521	\$ 91,915	\$ 98,366	\$ 287,071
Deduct gain from real estate dispositions	(12,243)	(25,180)	(25,880)	(138,817)
Add back loss from real estate dispositions - unconsolidated joint ventures	—	253	—	253
	49,278	66,988	72,486	148,507
Elimination of non-cash items included in net income:				
Depreciation and amortization	82,018	83,207	163,210	165,959
Depreciation – unconsolidated joint ventures	2,743	2,735	5,427	5,631
Add back impairments on real estate properties	21,114	7,695	60,102	11,206
Nareit FFO	\$ 155,153	\$ 160,625	\$ 301,225	\$ 331,303

(1) The three and six months ended June 30, 2023 includes the application of \$0.3 million and \$5.5 million, respectively, of security deposits (letter of credit and cash deposits) in revenue. The three and six months ended June 30, 2022 includes the application of \$1.4 million and \$4.7 million, respectively, of security deposits (letter of credit and cash deposits) in revenue.

Liquidity and Capital Resources

Sources and Uses

Our primary sources of cash include rental income and interest receipts, existing availability under our revolving credit facility, proceeds from our DRSP and the ATM Program, facility sales, and proceeds from real estate loan and non-real estate loan payoffs. We anticipate that these sources will be adequate to fund our cash flow needs through the next twelve months, which include common stock dividends, debt service payments (including principal and interest), real estate investments (including facility acquisitions, capital improvement programs and other capital expenditures), real estate loan and non-real estate loan advances and normal recurring G&A expenses (primarily consisting of employee payroll and benefits and expenses relating to third parties for legal, consulting and audit services).

Capital Structure

At June 30, 2023, we had total assets of \$9.4 billion, total equity of \$3.8 billion and total debt of \$5.3 billion in our consolidated financial statements, with such debt representing approximately 58.3% of total capitalization.

Debt

At June 30, 2023 and December 31, 2022, the weighted average annual interest rate of our debt was 4.2%. Additionally, as of June 30, 2023, 99% of our debt with outstanding principal balances has fixed interest payments. Our high percentage of fixed interest debt has kept our interest expense relatively flat year over year despite rising interest rates. As of June 30, 2023, we had long-term credit ratings of Baa3 from Moody's and BBB- from S&P Global and Fitch. Credit ratings impact our ability to access capital and directly impact our cost of capital as well. For example, our revolving credit facility accrues interest and fees at a rate per annum equal to LIBOR plus a margin that depends upon our credit rating. A downgrade in credit ratings by Moody's, S&P Global and/or Fitch may have a negative impact on the interest rates and fees for our revolving credit facility.

On August 1, 2023, the Company repaid its \$350 million of 4.375% senior notes that matured on August 1, 2023 using available cash. As of June 30, 2023, we had approximately \$350.7 million of cash and cash equivalents on our Consolidated Balance Sheets. As of June 30, 2023, we have \$400 million of 4.95% senior notes due April 2024. As of June 30, 2023, we had \$1.43 billion of availability under our revolving credit facility. As discussed below, we also have \$730.5 million of potential sales remaining under the ATM Program. This combination of liquidity sources, along with cash from operating activities, provides us with flexibility to repay the senior notes due in April 2024.

[Table of Contents](#)

Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of June 30, 2023 and December 31, 2022, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings.

Supplemental Guarantor Information

Parent has issued approximately \$4.9 billion aggregate principal of senior notes outstanding at June 30, 2023 that were registered under the Securities Act of 1933, as amended. The senior notes are guaranteed by Omega OP.

The U.S. Securities and Exchange Commission (“SEC”) adopted amendments to Rule 3-10 of Regulation S-X and created Rule 13-01 to simplify disclosure requirements related to certain registered securities, such as our senior notes. As a result of these amendments, registrants are permitted to provide certain alternative financial and non-financial disclosures, to the extent material, in lieu of separate financial statements for subsidiary issuers and guarantors of registered debt securities. Accordingly, separate consolidated financial statements of Omega OP have not been presented. Parent and Omega OP, on a combined basis, have no material assets, liabilities or operations other than financing activities (including borrowings under the outstanding senior notes, the revolving credit facility and the OP term loan) and their investments in non-guarantor subsidiaries.

Omega OP is currently the sole guarantor of our senior notes. The guarantees by Omega OP of our senior notes are full and unconditional and joint and several with respect to the payment of the principal and premium and interest on our senior notes. The guarantees of Omega OP are senior unsecured obligations of Omega OP that rank equal with all existing and future senior debt of Omega OP and are senior to all subordinated debt. However, the guarantees are effectively subordinated to any secured debt of Omega OP. As of June 30, 2023, there were no significant restrictions on the ability of Omega OP to make distributions to Omega.

Equity

At June 30, 2023, we had approximately 241.0 million shares of common stock outstanding, and our shares had a market value of \$7.4 billion. The following is a summary of activity under our equity programs during the three and six months ended June 30, 2023:

- We issued 6.5 million shares of common stock under our ATM Program for aggregate gross proceeds of \$199.4 million. We did not utilize the forward provisions under the ATM Program. We have \$730.5 million of potential sales remaining under the ATM Program as of June 30, 2023.
- We issued 0.1 million and 0.2 million shares of common stock under the DRSPP during the three and six months ended June 30, 2023, respectively. Aggregate gross proceeds from these sales were \$2.2 million and \$4.5 million during the three and six months ended June 30, 2023, respectively.
- We did not repurchase any shares of our outstanding common stock under the \$500 Million Stock Repurchase Program. We have \$357.8 million remaining authorized for repurchases under the \$500 Million Stock Repurchase Program as of June 30, 2023.

[Table of Contents](#)

Dividends

As a REIT, we are required to distribute dividends (other than capital gain dividends) to our stockholders in an amount at least equal to (A) the sum of (i) 90% of our “REIT taxable income” (computed without regard to the dividends paid deduction and our net capital gain), and (ii) 90% of the net income (after tax), if any, from foreclosure property, minus (B) the sum of certain items of non-cash income. In addition, if we dispose of any built-in gain asset during a recognition period, we will be required to distribute at least 90% of the built-in gain (after tax), if any, recognized on the disposition of such asset. Such distributions must be paid in the taxable year to which they relate, or in the following taxable year if declared before we timely file our tax return for such year and paid on or before the first regular dividend payment after such declaration. In addition, such distributions are required to be made pro rata, with no preference to any share of stock as compared with other shares of the same class, and with no preference to one class of stock as compared with another class except to the extent that such class is entitled to such a preference. To the extent that we do not distribute all of our net capital gain or distribute at least 90%, but less than 100% of our “REIT taxable income” as adjusted, we will be subject to tax thereon at regular corporate rates.

For the six months ended June 30, 2023, we paid dividends of approximately \$314.8 million to our common stockholders. On February 15, 2023, we paid dividends of \$0.67 per outstanding common share to the common stockholders of record as of the close of business on February 6, 2023. On May 15, 2023, we paid dividends of \$0.67 per outstanding common share to the common stockholders of record as of the close of business on May 1, 2023.

Material Cash Requirements

During the six months ended June 30, 2023, there were no significant changes to our material cash requirements from those disclosed in the section “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on [Form 10-K](#) for the year ended December 31, 2022.

As of June 30, 2023, we had \$238.2 million of commitments to fund the construction of new leased and mortgaged facilities, capital improvements and other commitments. Additionally, we have commitments to fund \$48.8 million of advancements under existing other real estate loans and \$66.7 million of advancements under existing non-real estate loans. These commitments are expected to be funded over the next several years and are dependent upon the operators’ election to use the commitments.

Other Arrangements

We own interests in certain unconsolidated joint ventures as described in Note 9 to the Consolidated Financial Statements – Investments in Joint Ventures. Our risk of loss is generally limited to our investment in the joint venture and any outstanding loans receivable. We use derivative instruments to hedge interest rate and foreign currency exchange rate exposure as discussed in Note 15 – Derivatives and Hedging in our Annual Report on [Form 10-K](#) for the year ended December 31, 2022.

Cash Flow Summary

Cash, cash equivalents and restricted cash totaled \$356.5 million as of June 30, 2023, an increase of \$55.9 million as compared to the balance at December 31, 2022. The following is a summary of our sources and uses of cash flows for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022 (dollars in thousands):

	Six Months Ended June 30,		Increase/(Decrease)
	2023	2022	
Net cash provided by (used in):			
Operating activities	\$ 281,736	\$ 305,196	\$ (23,460)
Investing activities	(184,669)	277,166	(461,835)
Financing activities	(41,685)	(436,756)	395,071

[Table of Contents](#)

The following is a discussion of changes in cash, cash equivalents and restricted cash for the six months ended June 30, 2023 compared to the six months ended June 30, 2022.

Operating Activities – The decrease in net cash provided by operating activities is driven primarily by a decrease of \$6.0 million of net income, net of \$182.7 million of non-cash items, primarily due to a year over year reduction in rental income and interest income, as discussed in our material changes analysis under Results of Operations above. A \$17.5 million change in the net movements of the operating assets and liabilities also contributed to the overall decrease in cash provided by operating activities.

Investing Activities – The change in cash used in investing activities primarily related to (i) a \$324.6 million decrease in proceeds from the sales of real estate investments driven by the sale of the Gulf Coast facilities in the first quarter of 2022, (ii) a \$96.9 million decrease in loan repayments, net of placements due to significant paydowns on the Ciena Healthcare mortgage loans and other loans during 2022, (iii) a \$41.8 million increase in real estate acquisitions and (iv) an \$8.1 million increase in investments in unconsolidated joint ventures primarily related to the three new joint venture investments in the second quarter of 2023, partially offset by (i) a \$6.4 million decrease in capital improvements to real estate investments and construction in progress and (ii) a \$3.2 million increase in receipts from insurance proceeds.

Financing Activities – The decrease in cash used in financing activities primarily related to (i) a \$198.1 million increase in net proceeds from issuance of common stock, (ii) a \$142.3 million decrease in repurchases of shares of common stock, (iii) a \$92.6 million increase in proceeds from derivative instruments as a result of the termination of our forward starting swaps in the second quarter of 2023, (iv) a \$9.6 million decrease in redemptions of Omega OP units and (v) a \$3.5 million decrease in dividends paid primarily related to share repurchases during 2022, partially offset by (i) a \$46.3 million decrease in proceeds from long-term borrowings, net of repayments due to higher cash balances in the second quarter of 2023 as a result of common stock issuances, the termination of the forward starting swaps and significant facility sale proceeds received in 2022 and 2023 and (ii) a \$4.4 million increase in distributions to Omega OP Unit holders.

Critical Accounting Policies and Estimates

Our financial statements are prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. Our preparation of the financial statements requires us to make estimates and assumptions about future events that affect the amounts reported in our financial statements and accompanying footnotes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment. Actual results inevitably will differ from those estimates, and such differences may be material to the consolidated financial statements. We have described our accounting policies in Note 2 – Summary of Significant Accounting Policies to our Annual Report on [Form 10-K](#) for the year ended December 31, 2022. There have been no material changes to our critical accounting policies or estimates since December 31, 2022.

Item 3 – Quantitative and Qualitative Disclosures about Market Risk

During the quarter ended June 30, 2023, there were no material changes in our primary market risk exposures or how those exposures are managed from the information disclosed under Item 7A of our Annual Report on [Form 10-K](#) for the year ended December 31, 2022.

Item 4 – Controls and Procedures

Disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

[Table of Contents](#)

In connection with the preparation of our Form 10-Q as of and for the quarter ended June 30, 2023, management evaluated the effectiveness of the design and operation of the disclosure controls and procedures of the Company as of June 30, 2023. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures of the Company were effective at a reasonable assurance level as of June 30, 2023.

Internal Control Over Financial Reporting

There were no changes in the Company's internal control over financial reporting during the quarter ended June 30, 2023 identified in connection with the evaluation of our disclosure controls and procedures described above that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1 – Legal Proceedings

See Note 18 – Commitments and Contingencies to the Consolidated Financial Statements - Part I, Item 1 hereto, which is hereby incorporated by reference in response to this Item.

Item 1A – Risk Factors

There have been no material changes to our risk factors as previously disclosed in Item 1A contained in Part I of our Annual Report on [Form 10-K](#) for the year ended December 31, 2022.

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds

From time to time, the Company issues shares of common stock in reliance on the private placement exemption under Section 4(a) (2) of the Securities Act of 1933, as amended, in exchange for Omega OP Units. During the quarter ended June 30, 2023, Omega issued an aggregate of 17,839 shares of our common stock in exchange for an equivalent number of Omega OP Units.

Issuer Purchases of Equity Securities

On January 27, 2022, the Board of Directors authorized the Company to repurchase of up to \$500 million of our outstanding common stock from time to time through March 2025. The Company is authorized to repurchase shares of its common stock in open market and privately negotiated transactions or in any other manner as determined by the Company's management and in accordance with applicable law. The timing and amount of stock repurchases will be determined, in management's discretion, based on a variety of factors, including but not limited to market conditions, other capital management needs and opportunities, and corporate and regulatory considerations. The Company has no obligation to repurchase any amount of its common stock, and such repurchases, if any, may be discontinued at any time.

During the second quarter of 2023, we did not repurchase any shares of our outstanding common stock.

Item 6–Exhibits

Exhibit No.	
3.1	Amendment to Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan, effective June 5, 2023 (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed June 5, 2023).
10.1	Conforming Changes Amendment to Credit Agreement, dated as of June 7, 2023, between the Company and Bank of America, N.A., as administrative agent.*
10.2	Conforming Changes Amendment to Credit Agreement, dated as of June 7, 2023, between OHI Healthcare Properties Limited Partnership and Bank of America, N.A., as administrative agent.*
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer of Omega Healthcare Investors, Inc.*
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer of Omega Healthcare Investors, Inc.*
32.1	Section 1350 Certification of the Chief Executive Officer of Omega Healthcare Investors, Inc.*
32.2	Section 1350 Certification of the Chief Financial Officer of Omega Healthcare Investors, Inc.*
101	The following financial statements (unaudited) from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
104	Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101).

* Exhibits that are filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

OMEGA HEALTHCARE INVESTORS, INC.
Registrant

Date: August 3, 2023

By: /S/ C. TAYLOR PICKETT

C. Taylor Pickett
Chief Executive Officer

Date: August 3, 2023

By: /S/ ROBERT O. STEPHENSON

Robert O. Stephenson
Chief Financial Officer

CONFORMING CHANGES AMENDMENT

THIS CONFORMING CHANGES AMENDMENT (this "Agreement"), dated as of June 7, 2023, is entered into by BANK OF AMERICA, N.A., as administrative agent ("Administrative Agent"), and OMEGA HEALTHCARE INVESTORS, INC., a Maryland corporation, as borrower ("Borrower").

RECITALS

WHEREAS, Borrower, the Guarantors party thereto, the lenders from time to time party thereto (the "Lenders"), and Bank of America, N.A., as Administrative Agent, have entered into that certain Credit Agreement dated as of April 30, 2021 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the "Credit Agreement");

WHEREAS, certain loans and/or other extensions of credit (the "Loans") under the Credit Agreement denominated in Dollars incur or are permitted to incur interest, fees, commissions or other amounts based on the London Interbank Offered Rate as administered by the ICE Benchmark Administration ("LIBOR") in accordance with the terms of the Credit Agreement; and

WHEREAS, applicable parties under the Credit Agreement have determined in accordance with the Credit Agreement that LIBOR for Loans denominated in Dollars should be replaced with a successor rate in accordance with the Credit Agreement and, in connection therewith, Administrative Agent has determined that certain conforming changes are necessary or advisable.

NOW, THEREFORE, in accordance with the terms of the Credit Agreement, the parties hereto agree as follows:

1. Defined Terms. Capitalized terms used herein but not otherwise defined herein (including on any Appendix attached hereto) shall have the meanings provided to such terms in the Credit Agreement, as amended by this Agreement.

2. Agreement. Notwithstanding any provision of the Credit Agreement or any other Loan Documents to the contrary, the terms set forth on Appendix A shall apply to Loans denominated in Dollars that bear interest at the Eurocurrency Rate (as defined in Appendix A) and the terms set forth on Appendix B shall apply to Loans denominated in Dollars that bear interest at the LIBOR Daily Floating Rate (as defined in Appendix B). For the avoidance of doubt, to the extent provisions in the Credit Agreement apply to Loans denominated in Dollars and such provisions are not specifically addressed by Appendix A and Appendix B, the provisions in the Credit Agreement shall continue to apply to such Loans denominated in Dollars.

3. Conflict with Loan Documents. In the event of any conflict between the terms of this Agreement and the terms of the Credit Agreement or the other Loan Documents, the terms hereof shall control.

4. Conditions Precedent. This Agreement shall become effective on upon proper execution by Administrative Agent and Borrower of a counterpart of this Agreement (such date, the "Amendment Effective Date").

5. Payment of Expenses. Borrower agrees to reimburse Administrative Agent for all reasonable and documented fees, charges and disbursements of Administrative Agent in connection with the preparation, execution and delivery of this Agreement, including all reasonable and documented fees,

charges and disbursements of counsel to Administrative Agent (paid directly to such counsel if requested by Administrative Agent).

6. Miscellaneous.

(a) The Loan Documents, and the obligations of Borrower under the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect according to their terms. This Agreement is a Loan Document.

(b) Borrower (i) acknowledges and consents to all of the terms and conditions of this Agreement, (ii) affirms all of its obligations under the Loan Documents and (iii) agrees that this Agreement and all documents executed in connection herewith do not operate to reduce or discharge its obligations under the Loan Documents.

(c) Borrower represents and warrants that:

(i) The execution, delivery and performance by it of this Agreement is within its corporate powers and has been duly authorized by all necessary corporate action, and do not and will not (A) contravene the terms of its Organization Documents; (B) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be made under (x) any Contractual Obligation to which Borrower is party or affecting Borrower or the properties of Borrower or any of its Consolidated Subsidiaries (other than the Loan Documents) or (y) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which Borrower or the properties of Borrower or any of its Consolidated Subsidiaries are subject; or (C) violate any Law.

(ii) This Agreement has been duly executed and delivered by it. This Agreement constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as enforceability may be limited by applicable Debtor Relief Laws and equitable principles relating to enforceability.

(iii) Before and after giving effect to this Agreement, (A) all representations and warranties of Borrower contained in Article V of the Credit Agreement or any other Loan Document, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects (*provided*, that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified by materiality in the text thereof) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct (*provided*, that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified by materiality in the text thereof) as of such earlier date, and except that for purposes of this clause (iii)(A), the representations and warranties contained in clauses (a) and (b) of Section 5.05 of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 of the Credit Agreement; and (B) no Event of Default exists.

(d) This Agreement may be in the form of an electronic record (in “.pdf” form or otherwise) and may be executed using electronic signatures, which shall be considered as originals and shall have the same legal effect, validity and enforceability as a paper record. This Agreement may be executed in as many counterparts as necessary or convenient, including both paper and electronic counterparts, but all such counterparts shall be one and the same Agreement. For the

avoidance of doubt, the authorization under this paragraph may include, without limitation, use or acceptance by Administrative Agent of a manually signed Agreement which has been converted into electronic form (such as scanned into “.pdf” format), or an electronically signed Agreement converted into another format, for transmission, delivery and/or retention.

(e) Any provision of this Agreement held to be illegal, invalid or unenforceable in any jurisdiction, shall, as to such jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability without affecting the legality, validity or enforceability of the remaining provisions hereof and the illegality, invalidity or unenforceability of a particular provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

(f) The terms of the Credit Agreement with respect to governing law, submission to jurisdiction, waiver of venue and waiver of jury trial are incorporated herein by reference, *mutatis mutandis*.

[SIGNATURE PAGE FOLLOWS]

Administrative Agent has caused a counterpart of this Agreement to be duly executed and delivered as of the date first above written.

ADMINISTRATIVE AGENT:

BANK OF AMERICA, N.A.,
as Administrative Agent

By: /s/ Michelle D. Diggs

Name: Michelle D.
Diggs
Title: Officer

BORROWER:

OMEGA HEALTHCARE INVESTORS, INC.

By: /s/ Daniel J. Booth

Name: Daniel J. Booth
Title: Chief Operating
Officer

APPENDIX A

TERMS APPLICABLE TO TERM SOFR LOANS

1. Defined Terms. The following terms shall have the meanings set forth below:

“Administrative Agent’s Office” means, with respect to Dollars, Administrative Agent’s address and, as appropriate, account specified in the Credit Agreement with respect to Dollars, or such other address or account with respect to Dollars as Administrative Agent may from time to time notify Borrower and the Lenders.

“Applicable Rate” means the Applicable Rate, Applicable Margin or any similar or analogous definition in the Credit Agreement.

“Base Rate” means the Base Rate, Alternative Base Rate, ABR, Prime Rate or any similar or analogous definition in the Credit Agreement.

“Base Rate Loans” means a Loan that bears interest at a rate based on the Base Rate.

“Borrowing” means a Committed Borrowing, Borrowing, or any similar or analogous definition in the Credit Agreement.

“Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the laws of, or are in fact closed in, the state where Administrative Agent’s Office is located.

“CME” means CME Group Benchmark Administration Limited.

“Committed Loan Notice” means a Committed Loan Notice, Loan Notice, Borrowing Notice, Continuation/Conversion Notice, or any similar or analogous definition in the Credit Agreement, and such term shall be deemed to include the Committed Loan Notice attached hereto as Exhibit A.

“Dollar” and “\$” mean lawful money of the United States.

“Eurocurrency Rate” means Eurocurrency Rate, LIBOR, Adjusted LIBOR Rate, LIBOR Rate or any similar or analogous definition in the Credit Agreement.

“Eurocurrency Rate Loans” means a Loan that bears interest at a rate based on the Eurocurrency Rate.

“Interest Payment Date” means, as to any Term SOFR Loan, the last day of each Interest Period applicable to such Loan and the applicable maturity date set forth in the Credit Agreement; provided, however, that if any Interest Period for a Term SOFR Loan exceeds three months, the respective dates that fall every three months after the beginning of such Interest Period shall also be Interest Payment Dates.

“Interest Period” means as to each Term SOFR Loan, the period commencing on the date such Term SOFR Loan is disbursed or converted to or continued as a Term SOFR Loan and ending on the date one, three or six months thereafter, as selected by Borrower in its Committed Loan Notice (in the case of each requested Interest Period, subject to availability); provided that:

(a) any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless, in the case of a Term SOFR Loan, such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day;

(b) any Interest Period pertaining to a Term SOFR Loan that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; and

(c) no Interest Period shall extend beyond the applicable maturity date set forth in the Credit Agreement.

“Notice of Loan Prepayment” means a Notice of Loan Prepayment, Prepayment Notice, or any similar or analogous definition in the Credit Agreement.

“Required Lenders” means the Required Lenders, Requisite Lenders, Majority Lenders or any similar or analogous definition in the Credit Agreement.

“Responsible Officer” means Responsible Officer, Authorized Officer or any similar or analogous definition in the Credit Agreement.

“SOFR” means the Secured Overnight Financing Rate as administered by the Federal Reserve Bank of New York (or a successor administrator).

“SOFR Adjustment” with respect to Term SOFR means 0.11448% (11.448 basis points) for an Interest Period of one-month’s duration, 0.26161% (26.161 basis points) for an Interest Period of three-month’s duration, and 0.42826% (42.826 basis points) for an Interest Period of six-months’ duration.

“Successor Rate” means the Successor Rate, LIBOR Successor Rate or any similar or analogous definition in the Credit Agreement.

“Term SOFR” means:

(a) for any Interest Period with respect to a Term SOFR Loan, the rate per annum equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to the commencement of such Interest Period with a term equivalent to such Interest Period; provided that if the rate is not published prior to 11:00 a.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto, in each case, plus the SOFR Adjustment for such Interest Period; and

(b) for any interest calculation with respect to a Base Rate Loan on any date, the rate per annum equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to such date with a term of one month commencing that day; provided that if the rate is not published prior to 11:00 a.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto, in each case, plus the SOFR Adjustment for such term;

provided that if Term SOFR determined in accordance with either of the foregoing provisions (a) or (b) of this definition would otherwise be less than zero, Term SOFR shall be deemed zero for purposes of this Agreement.

“Term SOFR Loan” means a Loan that bears interest at a rate based on clause (a) of the definition of Term SOFR.

“Term SOFR Screen Rate” means the forward-looking SOFR term rate administered by CME (or any successor administrator satisfactory to Administrative Agent) and published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by Administrative Agent from time to time).

“Type” means, with respect to a Loan, its character as a Base Rate Loan or a Term SOFR Loan.

“U.S. Government Securities Business Day” means any Business Day, except any Business Day on which any of the Securities Industry and Financial Markets Association, the New York Stock Exchange or the Federal Reserve Bank of New York is not open for business because such day is a legal holiday under the federal laws of the United States or the laws of the State of New York, as applicable.

2. Terms Applicable to Term SOFR Loans. From and after the Amendment Effective Date, the following terms shall apply to Term SOFR Loans:

(a) LIBOR. (i) Dollars shall not be considered a currency for which there is a published LIBOR rate and (ii) any request for a new Eurocurrency Rate Loan denominated in Dollars, or to continue an existing Eurocurrency Rate Loan denominated in Dollars, shall be deemed to be a request for a new Loan bearing interest at Term SOFR.

To the extent any Loan bearing interest at the Eurocurrency Rate is outstanding on the Amendment Effective Date, such Loan shall continue to bear interest at the Eurocurrency Rate until the end of the current Interest Period or payment period applicable to such Loan.

(b) References to Eurocurrency Rate and Eurocurrency Rate Loans in the Credit Agreement and Loan Documents.

(i) References to the Eurocurrency Rate and Eurocurrency Rate Loans in provisions of the Credit Agreement and the other Loan Documents that are not specifically addressed herein (other than the definitions of Eurocurrency Rate and Eurocurrency Rate Loan) shall be deemed to include Term SOFR and Term SOFR Loans, as applicable. In addition, to the extent the definition of Base Rate in the Credit Agreement refers to the Eurocurrency Rate, such reference shall be deemed to refer to Term SOFR.

(ii) For purposes of any requirement for Borrower to compensate Lenders for losses in the Credit Agreement resulting from any continuation, conversion, payment or prepayment of any Loan on a day other than the last day of any Interest Period (as defined in the Credit Agreement), references to the Interest Period (as defined in the Credit Agreement) shall be deemed to include any relevant interest payment date or payment period for a Term SOFR Loan.

(c) Borrowings, Conversions, Continuations and Prepayments of Term SOFR Loans. In addition to any other borrowing or prepayment requirements set forth in the Credit Agreement or any other Loan Document:

(i) Term SOFR Loans. Each Borrowing, each conversion of Loans from one Type to the other, and each continuation of Term SOFR Loans shall be made upon Borrower's irrevocable notice to Administrative Agent, which may be given by (A) telephone or (B) a Committed Loan Notice; provided that any telephonic notice must be confirmed immediately by delivery to Administrative Agent of a Committed Loan Notice. Each such Committed Loan Notice must be received by Administrative Agent not later than 11:00 a.m. (Eastern time) two Business Days prior to the requested date of any Borrowing of, conversion to or continuation of Term SOFR Loans or of any conversion of Term SOFR Loans to Base Rate Loans. Each Borrowing of, conversion to or continuation of Term SOFR Loans shall be in a principal amount of \$1,000,000 or a whole multiple of \$1,000,000 in excess thereof. Each Committed Loan Notice shall specify (i) whether Borrower is requesting a Borrowing, a conversion of Loans from one Type to the other, or a continuation of Term SOFR Loans, (ii) the requested date of the Borrowing, conversion or continuation, as the case may be (which shall be a Business Day), (iii) the principal amount of Loans to be borrowed, converted or continued, (iv) the Type of Loans to be borrowed or to which existing Loans are to be converted, and (v) if applicable, the duration of the Interest Period with respect thereto. If Borrower fails to specify a Type of Loan in a Committed Loan Notice or if Borrower fails to give a timely notice requesting a conversion or continuation, then the applicable Loans shall be made as, or converted to, Base Rate Loans. Any such automatic conversion to Base Rate Loans shall be effective as of the last day of the Interest Period then in effect with respect to the applicable Term SOFR Loans. If Borrower requests a Borrowing of, conversion to, or continuation of Term SOFR Loans in any such Committed Loan Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one month.

(ii) Committed Loan Notice. For purposes of a Borrowing of Term SOFR Loans, or a continuation of a Term SOFR Loan, Borrower shall use the Committed Loan Notice attached hereto as Exhibit A.

(iii) Voluntary Prepayments of Term SOFR Loans. Borrower may, upon notice to Administrative Agent pursuant to delivery to Administrative Agent of a Notice of Loan Prepayment, at any time or from time to time voluntarily prepay the Term SOFR Loans in whole or in part without premium or penalty (except as otherwise specified in the Credit Agreement); provided that such notice must be received by Administrative Agent not later than 11:00 a.m. (Eastern time) two Business Days prior to any date of prepayment of Term SOFR Loans.

(d) Interest.

(i) Subject to the provisions of the Credit Agreement with respect to default interest, each Term SOFR Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the sum of Term SOFR for such Interest Period plus the Applicable Rate.

(ii) Interest on each Term SOFR Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as may be specified in the Credit Agreement; provided, that any prepayment of any Term SOFR Loan shall be

accompanied by all accrued interest on the amount prepaid, together with any additional amounts required pursuant to Section 3.05. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any debtor relief law.

(e) Computations. All computations of interest for Base Rate Loans (including Base Rate Loans determined by reference to Term SOFR) shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed. All other computations of fees and interest with respect to Term SOFR Loans shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year). Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, provided that any Loan that is repaid on the same day on which it is made shall, subject to the provisions in the Credit Agreement addressing payments generally, bear interest for one day. Each determination by Administrative Agent of an interest rate or fee hereunder shall be conclusive and binding for all purposes, absent manifest error.

(f) Successor Rates. The provisions in the Credit Agreement addressing the replacement of a current Successor Rate for Dollars shall be deemed to apply to Term SOFR Loans and Term SOFR, as applicable, and the related defined terms shall be deemed to include Dollars and Term SOFR, as applicable.

APPENDIX B

TERMS APPLICABLE TO SOFR DAILY FLOATING RATE LOANS

1. Defined Terms. The following terms shall have the meanings set forth below:

“Administrative Agent’s Office” means, with respect to Dollars, Administrative Agent’s address and, as appropriate, account specified in the Credit Agreement with respect to Dollars, or such other address or account with respect to Dollars as Administrative Agent may from time to time notify Borrower and the Lenders.

“Applicable Rate” means the Applicable Rate, Applicable Margin or any similar or analogous definition in the Credit Agreement.

“Base Rate” means the Base Rate, Alternative Base Rate, ABR, Prime Rate or any similar or analogous definition in the Credit Agreement.

“Base Rate Loans” means a Loan that bears interest at a rate based on the Base Rate.

“Borrowing” means a Committed Borrowing, Borrowing, or any similar or analogous definition in the Credit Agreement.

“Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the laws of, or are in fact closed in, the state where Administrative Agent’s Office is located.

“CME” means CME Group Benchmark Administration Limited.

“Committed Loan Notice” means a Committed Loan Notice, Loan Notice, Borrowing Notice, Continuation/Conversion Notice, or any similar or analogous definition in the Credit Agreement, and such term shall be deemed to include the Committed Loan Notice attached hereto as Exhibit A.

“Dollar” and “\$” mean lawful money of the United States.

“Interest Payment Date” means, as to any SOFR Daily Floating Rate Loan, the last Business Day of each calendar month and the applicable maturity date set forth in the Credit Agreement.

“LIBOR Daily Floating Rate” means the LIBOR Daily Floating Rate, Daily LIBOR Floating Rate or any similar or analogous definition in the Credit Agreement.

“LIBOR Daily Floating Rate Loan” means a Loan that bears interest at the LIBOR Daily Floating Rate.

“Notice of Loan Prepayment” means a Notice of Loan Prepayment, Prepayment Notice, or any similar or analogous definition in the Credit Agreement.

“Required Lenders” means the Required Lenders, Requisite Lenders, Majority Lenders or any similar or analogous definition in the Credit Agreement.

“Responsible Officer” means Responsible Officer, Authorized Officer or any similar or analogous definition in the Credit Agreement.

“SOFR” means the Secured Overnight Financing Rate as administered by the Federal Reserve Bank of New York (or a successor administrator).

“SOFR Adjustment” with respect to the SOFR Daily Floating Rate means 0.11448% (11.448 basis points).

“SOFR Daily Floating Rate” means, for any day, a fluctuating rate of interest, which can change on each Business Day, equal to the Term SOFR Screen Rate two (2) U.S. Government Securities Business Days prior to such day, with a term equivalent to one (1) month beginning on that date; provided, that, if the rate is not published prior to 11:00 a.m. on such determination date then the SOFR Daily Floating Rate means such Term SOFR Screen Rate on the first (1st) U.S. Government Securities Business Day immediately prior thereto, in each case, plus the SOFR Adjustment; provided, further, that, if the SOFR Daily Floating Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement.

“SOFR Daily Floating Rate Loan” means a Loan that bears interest at a rate based on the definition of SOFR Daily Floating Rate.

“Successor Rate” means the Successor Rate, LIBOR Successor Rate or any similar or analogous definition in the Credit Agreement.

“Term SOFR Screen Rate” means the forward-looking SOFR term rate administered by CME (or any successor administrator satisfactory to Administrative Agent) and published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by Administrative Agent from time to time).

“Type” means, with respect to a Loan, its character as a Base Rate Loan or a SOFR Daily Floating Rate Loan.

“U.S. Government Securities Business Day” means any Business Day, except any Business Day on which any of the Securities Industry and Financial Markets Association, the New York Stock Exchange or the Federal Reserve Bank of New York is not open for business because such day is a legal holiday under the federal laws of the United States or the laws of the State of New York, as applicable.

2. Terms Applicable to SOFR Daily Floating Rate Loans. From and after the Amendment Effective Date, the following terms shall apply to SOFR Daily Floating Rate Loans:

(a) LIBOR. (i) Dollars shall not be considered a currency for which there is a published LIBOR rate and (ii) any request for a new LIBOR Daily Floating Rate Loan shall be deemed to be a request for a new Loan bearing interest at the SOFR Daily Floating Rate.

To the extent any Loan bearing interest at the LIBOR Daily Floating Rate is outstanding on the Amendment Effective Date, such Loan shall bear interest at the LIBOR Daily Floating Rate until the end of the payment period applicable to such Loan.

(b) References to LIBOR Daily Floating Rate and LIBOR Daily Floating Rate Loans in the Credit Agreement and Loan Documents. References to the LIBOR Daily Floating Rate and

LIBOR Daily Floating Rate Loans in provisions of the Credit Agreement and the other Loan Documents that are not specifically addressed herein (other than the definitions of LIBOR Daily Floating Rate and LIBOR Daily Floating Rate Loan) shall be deemed to include the SOFR Daily Floating Rate and SOFR Daily Floating Rate Loans, as applicable. In addition, to the extent the definition of Base Rate in the Credit Agreement refers to the LIBOR Daily Floating Rate, such reference shall be deemed to refer to the SOFR Daily Floating Rate.

(c) Borrowings, Conversions and Prepayments of SOFR Daily Floating Rate Loans. In addition to any other borrowing or prepayment requirements set forth in the Credit Agreement or any other Loan Document:

(i) SOFR Daily Floating Rate Loans. Each Borrowing and each conversion of Loans from one Type to the other shall be made upon Borrower's irrevocable notice to Administrative Agent, which may be given by (A) telephone or (B) a Committed Loan Notice; provided that any telephonic notice must be confirmed immediately by delivery to Administrative Agent of a Committed Loan Notice. Each such Committed Loan Notice must be received by Administrative Agent not later than 11:00 a.m. (Eastern time) on the requested date of any Borrowing of or conversion to SOFR Daily Floating Rate Loans. Each Borrowing of or conversion to SOFR Daily Floating Rate Loans shall be in a principal amount of \$500,000 or a whole multiple of \$100,000 in excess thereof. Each Committed Loan Notice shall specify (i) whether Borrower is requesting a Borrowing or a conversion of Loans from one Type to the other, (ii) the requested date of the Borrowing or conversion, as the case may be (which shall be a Business Day), (iii) the principal amount of Loans to be borrowed or converted, and (iv) the Type of Loans to be borrowed or to which existing Loans are to be converted. If Borrower fails to specify a Type of Loan in a Committed Loan Notice, then the applicable Loans shall be made as, or converted to, Base Rate Loans.

(ii) Committed Loan Notice. For purposes of a Borrowing of or conversion to SOFR Daily Floating Rate Loans, Borrower shall use the Committed Loan Notice attached hereto as Exhibit B.

(iii) Voluntary Prepayments of SOFR Daily Floating Rate Loans. Borrower may, upon notice to Administrative Agent pursuant to delivery to Administrative Agent of a Notice of Loan Prepayment, at any time or from time to time voluntarily prepay the SOFR Daily Floating Rate Loans in whole or in part without premium or penalty (except as otherwise specified in the Credit Agreement); provided that such notice must be received by Administrative Agent not later than 11:00 a.m. (Eastern time) one Business Day prior any date of prepayment of SOFR Daily Floating Rate Loans.

(d) Interest.

(i) Subject to the provisions of the Credit Agreement with respect to default interest, each SOFR Daily Floating Rate Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the sum of the SOFR Daily Floating Rate plus the Applicable Rate.

(ii) Interest on each SOFR Daily Floating Rate Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as may be specified in the Credit Agreement. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any debtor relief law.

(e) Computations. All computations of fees and interest with respect to SOFR Daily Floating Rate Loans shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year). Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, provided that any Loan that is repaid on the same day on which it is made shall, subject to the provisions in the Credit Agreement addressing payments generally, bear interest for one day. Each determination by Administrative Agent of an interest rate or fee hereunder shall be conclusive and binding for all purposes, absent manifest error.

(f) Successor Rates. The provisions in the Credit Agreement addressing the replacement of a current Successor Rate for Dollars shall be deemed to apply to SOFR Daily Floating Rate Loans and SOFR Daily Floating Rate, as applicable, and the related defined terms shall be deemed to include Dollars and the SOFR Daily Floating Rate, as applicable.

EXHIBIT A

FORM OF COMMITTED LOAN NOTICE
(Term SOFR Loans)

Date: _____, ____¹

To: Bank of America, N.A., as Administrative Agent

Ladies and Gentlemen:

Reference is made to that certain Credit Agreement, dated as of April 30, 2021 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the "Credit Agreement," the terms defined therein being used herein as therein defined), among OMEGA HEALTHCARE INVESTORS, INC., a Maryland corporation (the "Borrower"), the Guarantors party thereto, the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent.

The undersigned hereby requests (select one)²:

Indicate: Borrowing, Conversion or Continuation	Indicate: Borrower Name	Indicate: Requested Amount	Indicate: Currency	Indicate: Term SOFR Loans	For Term SOFR Rate Loans Indicate: Interest Period (e.g., 1, 3 or 6 month interest period)

The Borrowing, if any, requested herein complies with the requirements set forth in the Credit Agreement.

OMEGA HEALTHCARE INVESTORS, INC.

By: _____

Name:

Title:

¹ Note to Borrower. All requests submitted under a single Committed Loan Notice must be effective on the same date. If multiple effective dates are needed, multiple Committed Loan Notices will need to be prepared and signed.

² Note to Borrower. For multiple borrowings, conversions and/or continuations for a particular facility, fill out a new row for each borrowing/conversion and/or continuation.

EXHIBIT B

FORM OF COMMITTED LOAN NOTICE
(SOFR Daily Floating Rate Loans)

Date: _____, ____³

To: Bank of America, N.A., as Administrative Agent

Ladies and Gentlemen:

Reference is made to that certain Credit Agreement, dated as of April 30, 2021 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the "Credit Agreement," the terms defined therein being used herein as therein defined), among OMEGA HEALTHCARE INVESTORS, INC., a Maryland corporation (the "Borrower"), the Guarantors party thereto, the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent.

The undersigned hereby requests (select one)⁴:

Indicate: Borrowing or Conversion	Indicate: Borrower Name	Indicate: Requested Amount	Indicate: Currency	Indicate: SOFR Daily Floating Rate Loans

The Borrowing, if any, requested herein complies with the requirements set forth in the Credit Agreement.

OMEGA HEALTHCARE INVESTORS, INC.

By: _____

Name:

Title:

³ Note to Borrower. All requests submitted under a single Committed Loan Notice must be effective on the same date. If multiple effective dates are needed, multiple Committed Loan Notices will need to be prepared and signed.

⁴ Note to Borrower. For multiple borrowings, conversions and/or continuations for a particular facility, fill out a new row for each borrowing/conversion and/or continuation.

CONFORMING CHANGES AMENDMENT

THIS CONFORMING CHANGES AMENDMENT (this "Agreement"), dated as of June 7, 2023, is entered into by BANK OF AMERICA, N.A., as administrative agent ("Administrative Agent"), and OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP, a Delaware limited partnership, as borrower ("Borrower").

RECITALS

WHEREAS, Borrower, the Guarantors party thereto, the lenders from time to time party thereto (the "Lenders"), and Bank of America, N.A., as Administrative Agent, have entered into that certain Credit Agreement dated as of Note to Borrower. All requests submitted under a single Committed Loan Notice must be effective on the same date. If multiple effective dates are needed, multiple Committed Loan Notices will need to be prepared and signed.

2 Note to Borrower. For multiple conversions and/or continuations for a particular facility, fill out a new row for each conversion and/or continuation. April 30, 2021 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the "Credit Agreement");

WHEREAS, certain loans and/or other extensions of credit (the "Loans") under the Credit Agreement denominated in Dollars incur or are permitted to incur interest, fees, commissions or other amounts based on the London Interbank Offered Rate as administered by the ICE Benchmark Administration ("LIBOR") in accordance with the terms of the Credit Agreement; and

WHEREAS, applicable parties under the Credit Agreement have determined in accordance with the Credit Agreement that LIBOR for Loans denominated in Dollars should be replaced with a successor rate in accordance with the Credit Agreement and, in connection therewith, Administrative Agent has determined that certain conforming changes are necessary or advisable.

NOW, THEREFORE, in accordance with the terms of the Credit Agreement, the parties hereto agree as follows:

1. Defined Terms. Capitalized terms used herein but not otherwise defined herein (including on any Appendix attached hereto) shall have the meanings provided to such terms in the Credit Agreement, as amended by this Agreement.

2. Agreement. Notwithstanding any provision of the Credit Agreement or any other Loan Documents to the contrary, the terms set forth on Appendix A shall apply to Loans denominated in Dollars that bear interest at the Eurocurrency Rate (as defined in Appendix A). For the avoidance of doubt, to the extent provisions in the Credit Agreement apply to Loans denominated in Dollars and such provisions are not specifically addressed by Appendix A, the provisions in the Credit Agreement shall continue to apply to such Loans denominated in Dollars.

3. Conflict with Loan Documents. In the event of any conflict between the terms of this Agreement and the terms of the Credit Agreement or the other Loan Documents, the terms hereof shall control.

4. Conditions Precedent. This Agreement shall become effective on upon proper execution by Administrative Agent and Borrower of a counterpart of this Agreement (such date, the "Amendment Effective Date").

5. Payment of Expenses. Borrower agrees to reimburse Administrative Agent for all reasonable and documented fees, charges and disbursements of Administrative Agent in connection with the preparation, execution and delivery of this Agreement, including all reasonable and documented fees,

charges and disbursements of counsel to Administrative Agent (paid directly to such counsel if requested by Administrative Agent).

6. Miscellaneous.

(a) The Loan Documents, and the obligations of Borrower under the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect according to their terms. This Agreement is a Loan Document.

(b) Borrower (i) acknowledges and consents to all of the terms and conditions of this Agreement, (ii) affirms all of its obligations under the Loan Documents and (iii) agrees that this Agreement and all documents executed in connection herewith do not operate to reduce or discharge its obligations under the Loan Documents.

(c) Borrower represents and warrants that:

(i) The execution, delivery and performance by it of this Agreement is within its corporate powers and has been duly authorized by all necessary corporate action, and do not and will not (A) contravene the terms of its Organization Documents; (B) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be made under (x) any Contractual Obligation to which Borrower is party or affecting Borrower or the properties of Borrower or any of its Consolidated Subsidiaries (other than the Loan Documents) or (y) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which Borrower or the properties of Borrower or any of its Consolidated Subsidiaries are subject; or (C) violate any Law.

(ii) This Agreement has been duly executed and delivered by it. This Agreement constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as enforceability may be limited by applicable Debtor Relief Laws and equitable principles relating to enforceability.

(iii) Before and after giving effect to this Agreement, (A) all representations and warranties of Borrower contained in Article V of the Credit Agreement or any other Loan Document, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects (*provided*, that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified by materiality in the text thereof) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct (*provided*, that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified by materiality in the text thereof) as of such earlier date, and except that for purposes of this clause (iii)(A), the representations and warranties contained in clauses (a) and (b) of Section 5.05 of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 of the Credit Agreement; and (B) no Event of Default exists.

(d) This Agreement may be in the form of an electronic record (in “.pdf” form or otherwise) and may be executed using electronic signatures, which shall be considered as originals and shall have the same legal effect, validity and enforceability as a paper record. This Agreement may be executed in as many counterparts as necessary or convenient, including both paper and electronic counterparts, but all such counterparts shall be one and the same Agreement. For the

avoidance of doubt, the authorization under this paragraph may include, without limitation, use or acceptance by Administrative Agent of a manually signed Agreement which has been converted into electronic form (such as scanned into “.pdf” format), or an electronically signed Agreement converted into another format, for transmission, delivery and/or retention.

(e) Any provision of this Agreement held to be illegal, invalid or unenforceable in any jurisdiction, shall, as to such jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability without affecting the legality, validity or enforceability of the remaining provisions hereof and the illegality, invalidity or unenforceability of a particular provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

(f) The terms of the Credit Agreement with respect to governing law, submission to jurisdiction, waiver of venue and waiver of jury trial are incorporated herein by reference, *mutatis mutandis*.

[SIGNATURE PAGE FOLLOWS]

Administrative Agent has caused a counterpart of this Agreement to be duly executed and delivered as of the date first above written.

ADMINISTRATIVE AGENT:

BANK OF AMERICA, N.A.,
as Administrative Agent

By: /s/ Michelle D. Diggs

Name: Michelle D.
Diggs
Title: Officer

BORROWER:

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

By: Omega Healthcare Investors, Inc.,
the General Partner of such limited partnership

By: /s/ Daniel J. Booth

Name: Daniel J. Booth
Title: Chief Operating
Officer

APPENDIX A

TERMS APPLICABLE TO TERM SOFR LOANS

1. Defined Terms. The following terms shall have the meanings set forth below:

“Administrative Agent’s Office” means, with respect to Dollars, Administrative Agent’s address and, as appropriate, account specified in the Credit Agreement with respect to Dollars, or such other address or account with respect to Dollars as Administrative Agent may from time to time notify Borrower and the Lenders.

“Applicable Rate” means the Applicable Rate, Applicable Margin or any similar or analogous definition in the Credit Agreement.

“Base Rate” means the Base Rate, Alternative Base Rate, ABR, Prime Rate or any similar or analogous definition in the Credit Agreement.

“Base Rate Loans” means a Loan that bears interest at a rate based on the Base Rate.

“Borrowing” means a Committed Borrowing, Borrowing, or any similar or analogous definition in the Credit Agreement.

“Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the laws of, or are in fact closed in, the state where Administrative Agent’s Office is located.

“CME” means CME Group Benchmark Administration Limited.

“Committed Loan Notice” means a Committed Loan Notice, Loan Notice, Borrowing Notice, Continuation/Conversion Notice, or any similar or analogous definition in the Credit Agreement, and such term shall be deemed to include the Committed Loan Notice attached hereto as Exhibit A.

“Dollar” and “\$” mean lawful money of the United States.

“Eurocurrency Rate” means Eurocurrency Rate, LIBOR, Adjusted LIBOR Rate, LIBOR Rate or any similar or analogous definition in the Credit Agreement.

“Eurocurrency Rate Loans” means a Loan that bears interest at a rate based on the Eurocurrency Rate.

“Interest Payment Date” means, as to any Term SOFR Loan, the last day of each Interest Period applicable to such Loan and the applicable maturity date set forth in the Credit Agreement; provided, however, that if any Interest Period for a Term SOFR Loan exceeds three months, the respective dates that fall every three months after the beginning of such Interest Period shall also be Interest Payment Dates.

“Interest Period” means as to each Term SOFR Loan, the period commencing on the date such Term SOFR Loan is disbursed or converted to or continued as a Term SOFR Loan and ending on the date one, three or six months thereafter, as selected by Borrower in its Committed Loan Notice (in the case of each requested Interest Period, subject to availability); provided that:

(a) any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless, in the case of a Term SOFR Loan, such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day;

(b) any Interest Period pertaining to a Term SOFR Loan that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; and

(c) no Interest Period shall extend beyond the applicable maturity date set forth in the Credit Agreement.

“Notice of Loan Prepayment” means a Notice of Loan Prepayment, Prepayment Notice, or any similar or analogous definition in the Credit Agreement.

“Required Lenders” means the Required Lenders, Requisite Lenders, Majority Lenders or any similar or analogous definition in the Credit Agreement.

“Responsible Officer” means Responsible Officer, Authorized Officer or any similar or analogous definition in the Credit Agreement.

“SOFR” means the Secured Overnight Financing Rate as administered by the Federal Reserve Bank of New York (or a successor administrator).

“SOFR Adjustment” with respect to Term SOFR means 0.11448% (11.448 basis points) for an Interest Period of one-month’s duration, 0.26161% (26.161 basis points) for an Interest Period of three-month’s duration, and 0.42826% (42.826 basis points) for an Interest Period of six-months’ duration.

“Successor Rate” means the Successor Rate, LIBOR Successor Rate or any similar or analogous definition in the Credit Agreement.

“Term SOFR” means:

(a) for any Interest Period with respect to a Term SOFR Loan, the rate per annum equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to the commencement of such Interest Period with a term equivalent to such Interest Period; provided that if the rate is not published prior to 11:00 a.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto, in each case, plus the SOFR Adjustment for such Interest Period; and

(b) for any interest calculation with respect to a Base Rate Loan on any date, the rate per annum equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to such date with a term of one month commencing that day; provided that if the rate is not published prior to 11:00 a.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto, in each case, plus the SOFR Adjustment for such term;

provided that if Term SOFR determined in accordance with either of the foregoing provisions (a) or (b) of this definition would otherwise be less than zero, Term SOFR shall be deemed zero for purposes of this Agreement.

“Term SOFR Loan” means a Loan that bears interest at a rate based on clause (a) of the definition of Term SOFR.

“Term SOFR Screen Rate” means the forward-looking SOFR term rate administered by CME (or any successor administrator satisfactory to Administrative Agent) and published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by Administrative Agent from time to time).

“Type” means, with respect to a Loan, its character as a Base Rate Loan or a Term SOFR Loan.

“U.S. Government Securities Business Day” means any Business Day, except any Business Day on which any of the Securities Industry and Financial Markets Association, the New York Stock Exchange or the Federal Reserve Bank of New York is not open for business because such day is a legal holiday under the federal laws of the United States or the laws of the State of New York, as applicable.

2. Terms Applicable to Term SOFR Loans. From and after the Amendment Effective Date, the following terms shall apply to Term SOFR Loans:

(a) LIBOR. (i) Any request to continue an existing Eurocurrency Rate Loan denominated in Dollars, shall be deemed to be a request for a new Loan bearing interest at Term SOFR.

To the extent any Loan bearing interest at the Eurocurrency Rate is outstanding on the Amendment Effective Date, such Loan shall continue to bear interest at the Eurocurrency Rate until the end of the current Interest Period or payment period applicable to such Loan.

(b) References to Eurocurrency Rate and Eurocurrency Rate Loans in the Credit Agreement and Loan Documents.

(i) References to the Eurocurrency Rate and Eurocurrency Rate Loans in provisions of the Credit Agreement and the other Loan Documents that are not specifically addressed herein (other than the definitions of Eurocurrency Rate and Eurocurrency Rate Loan) shall be deemed to include Term SOFR and Term SOFR Loans, as applicable. In addition, to the extent the definition of Base Rate in the Credit Agreement refers to the Eurocurrency Rate, such reference shall be deemed to refer to Term SOFR.

(ii) For purposes of any requirement for Borrower to compensate Lenders for losses in the Credit Agreement resulting from any continuation, conversion, payment or prepayment of any Loan on a day other than the last day of any Interest Period (as defined in the Credit Agreement), references to the Interest Period (as defined in the Credit Agreement) shall be deemed to include any relevant interest payment date or payment period for a Term SOFR Loan.

(c) Conversions, Continuations and Prepayments of Term SOFR Loans. In addition to any other borrowing or prepayment requirements set forth in the Credit Agreement or any other Loan Document:

(i) Term SOFR Loans. Each conversion of Loans from one Type to the other, and each continuation of Term SOFR Loans shall be made upon Borrower's irrevocable notice to Administrative Agent, which may be given by (A) telephone or (B) a Committed Loan Notice; provided that any telephonic notice must be confirmed immediately by delivery to Administrative Agent of a Committed Loan Notice. Each such Committed Loan Notice must be received by Administrative Agent not later than 11:00 a.m. (Eastern time) two Business Days prior to the requested date of any conversion to or continuation of Term SOFR Loans or of any conversion of Term SOFR Loans to Base Rate Loans. Each conversion to or continuation of Term SOFR Loans shall be in a principal amount of \$1,000,000 or a whole multiple of \$1,000,000 in excess thereof. Each Committed Loan Notice shall specify (i) whether Borrower is requesting a conversion of Loans from one Type to the other, or a continuation of Term SOFR Loans, (ii) the requested date of the conversion or continuation, as the case may be (which shall be a Business Day), (iii) the principal amount of Loans to be converted or continued, (iv) the Type of Loans to which existing Loans are to be converted, and (v) if applicable, the duration of the Interest Period with respect thereto. If Borrower fails to specify a Type of Loan in a Committed Loan Notice or if Borrower fails to give a timely notice requesting a conversion or continuation, then the applicable Loans shall be converted to Base Rate Loans. Any such automatic conversion to Base Rate Loans shall be effective as of the last day of the Interest Period then in effect with respect to the applicable Term SOFR Loans. If Borrower requests a conversion to, or continuation of Term SOFR Loans in any such Committed Loan Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one month.

(ii) Committed Loan Notice. For purposes of a continuation of a Term SOFR Loan, Borrower shall use the Committed Loan Notice attached hereto as Exhibit A.

(iii) Voluntary Prepayments of Term SOFR Loans. Borrower may, upon notice to Administrative Agent pursuant to delivery to Administrative Agent of a Notice of Loan Prepayment, at any time or from time to time voluntarily prepay the Term SOFR Loans in whole or in part without premium or penalty (except as otherwise specified in the Credit Agreement); provided that such notice must be received by Administrative Agent not later than 11:00 a.m. (Eastern time) two Business Days prior to any date of prepayment of Term SOFR Loans.

(d) Interest.

(i) Subject to the provisions of the Credit Agreement with respect to default interest, each Term SOFR Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the sum of Term SOFR for such Interest Period plus the Applicable Rate.

(ii) Interest on each Term SOFR Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as may be specified in the Credit Agreement; provided, that any prepayment of any Term SOFR Loan shall be accompanied by all accrued interest on the amount prepaid, together with any additional amounts required pursuant to Section 3.05. Interest hereunder shall be due and payable in

accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any debtor relief law.

(e) Computations. All computations of interest for Base Rate Loans (including Base Rate Loans determined by reference to Term SOFR) shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed. All other computations of fees and interest with respect to Term SOFR Loans shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year). Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, provided that any Loan that is repaid on the same day on which it is made shall, subject to the provisions in the Credit Agreement addressing payments generally, bear interest for one day. Each determination by Administrative Agent of an interest rate or fee hereunder shall be conclusive and binding for all purposes, absent manifest error.

(f) Successor Rates. The provisions in the Credit Agreement addressing the replacement of a current Successor Rate for Dollars shall be deemed to apply to Term SOFR Loans and Term SOFR, as applicable, and the related defined terms shall be deemed to include Dollars and Term SOFR, as applicable.

EXHIBIT A

FORM OF COMMITTED LOAN NOTICE
(Term SOFR Loans)

Date: _____, ____¹

To: Bank of America, N.A., as Administrative Agent

Ladies and Gentlemen:

Reference is made to that certain Credit Agreement, dated as of April 30, 2021 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the "Credit Agreement," the terms defined therein being used herein as therein defined), among OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP, a Delaware limited partnership (the "Borrower"), the Guarantors party thereto, the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent.

The undersigned hereby requests (select one)²:

<u>Indicate:</u> Conversion or Continuation	<u>Indicate:</u> Borrower Name	<u>Indicate:</u> Requested Amount	<u>Indicate:</u> Term SOFR Loans	<u>For Term SOFR Rate Loans</u> <u>Indicate:</u> Interest Period (e.g., 1, 3 or 6 month interest period)

The request herein complies with the requirements set forth in the Credit Agreement.

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

By: Omega Healthcare Investors, Inc.,
the General Partner of such limited partnership

By: _____
Name:
Title:

¹ Note to Borrower. All requests submitted under a single Committed Loan Notice must be effective on the same date. If multiple effective dates are needed, multiple Committed Loan Notices will need to be prepared and signed.

² Note to Borrower. For multiple conversions and/or continuations for a particular facility, fill out a new row for each conversion and/or continuation.

RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF EXECUTIVE OFFICER**Certification**

I, C. Taylor Pickett, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Omega Healthcare Investors, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 3, 2023

/s/ C. TAYLOR PICKETT
C. Taylor Pickett
Chief Executive Officer

RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF FINANCIAL OFFICER**Certification**

I, Robert O. Stephenson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Omega Healthcare Investors, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 3, 2023

/s/ ROBERT O. STEPHENSON
Robert O. Stephenson
Chief Financial Officer

**SECTION 1350 CERTIFICATION
OF THE CHIEF EXECUTIVE OFFICER**

I, C. Taylor Pickett, Chief Executive Officer of Omega Healthcare Investors, Inc. (the "Company"), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of my knowledge:

- (1) the Quarterly Report on Form 10-Q of the Company for the three months ended June 30, 2023 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 3, 2023

/s/ C. TAYLOR PICKETT

C. Taylor Pickett
Chief Executive Officer

**SECTION 1350 CERTIFICATION
OF THE CHIEF FINANCIAL OFFICER**

I, Robert O. Stephenson, Chief Financial Officer of Omega Healthcare Investors, Inc. (the “Company”), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:

- (1) the Quarterly Report on Form 10-Q of the Company for the three months ended June 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 3, 2023

/s/ ROBERT O. STEPHENSON
Robert O. Stephenson
Chief Financial Officer
